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Abstract 
 
The calcium-dependent phospholipid-binding protein annexin A11 was discovered over 25 
years ago, however little is known about its function. This thesis supports a role for 
annexin A11 in the cell cycle and suggests an association with the microtubule network. 
Recent studies have implicated annexin A11 in the autoimmune disease sarcoidosis, 
which is further investigated in this study. 
 
A single nucleotide polymorphism within annexin A11 (R230C) was identified as a highly 
associated susceptibility locus for sarcoidosis. Over-expression of annexin A11
WT and 
annexin A11
R230C showed no difference in their distribution. Stimulation with ionomycin, 
which induces a rise in intracellular calcium, resulted in the translocation of both variants to 
the plasma membrane and nuclear envelope with approximately the same time course. 
The calcium-dependent translocation of annexin A11 is therefore unaffected by the R230C 
mutation. In this one aspect there appears to be no difference between the two variants, 
however much still remains to be investigated such as the potential extracellular roles of 
these variants and their function in immune cells. 
 
Much of the work in this thesis has focused on elucidating the function of wild type annexin 
A11, particularly during the cell cycle. During mitosis the distribution of annexin A11 is 
highly dynamic and localises to the mitotic spindle at metaphase and anaphase, as well as 
the midbody at cytokinesis. The use of methanol fixation highlighted the co-localisation of 
annexin A11 with the microtubule network throughout mitosis, as well as at interphase. 
Furthermore annexin A11 was shown to concentrate at the centrosome, again during both 
mitosis and interphase. Several centrosomal proteins also localise to the midbody and are 
key regulators of mitotic progression, supporting a similar role for annexin A11. 
Furthermore the centrosomal localisation of annexin A11 may serve as an ideal docking 
site from which it can be easily targeted throughout the cell.  
 
This study highlights the novel localisation of annexin A11 to the centrosome and the 
microtubule network. Furthermore these findings contribute to a growing picture for the 
role of annexin A11 in the cell cycle, particularly with regards to its use of the microtubule 
network – a feature which may also have a role in interphase cells.  
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1. Introduction 
 
1.1 The Annexin Family 
The annexins are a family of calcium-dependent phospholipid-binding proteins, which are 
present in all eukaryotes but have not yet been described in prokaryotes. They were first 
discovered  in  the  1970s  and  80s  and  were  named  at  the  time  according  to  their 
biochemical  properties,  for  example  annexin  A7  was  originally  named  synexin  [1]  and 
annexin  A1  named  lipocortin  [2].  They  remained  a  disparate  set  of  proteins  for  some 
years, until sequence homology and unique domain structures were identified, resulting in 
the term annexins being coined in 1990. 
 
1.1.1 Annexin Nomenclature and Molecular Phylogeny 
Formal classification of the annexins in 1990 led to the current alphabetical nomenclature 
[3], with vertebrate annexins classified as the A family, invertebrate annexins the B family, 
fungal  and  mold  annexins  as  C, plant  annexins  as  D  and  protist  annexins  as  E.  This 
illustrates  the  highly  conserved  nature  of  the  annexins  through  evolution.  The  oldest 
members are the protist annexins, originating approximately 1,200 Mya, followed by the 
divergence of the plant annexins, fungal, invertebrate and lastly vertebrate annexins [4] 
(Figure 1). 
 
There  are  12  mammalian  annexins  (ANXA1-ANXA11,  ANXA13),  usually  with 
corresponding orthologues within the vertebrate family. However it should be noted that 
some annexins have been lost or duplicated in certain species like fish [5]. The duplication 
of annexin genes is also seen in humans, exemplified by annexin A6. This annexin was 
first thought to have emerged by the tandem duplication and fusion of a distinct annexin 
[6]. However subsequent sequence analysis showed the two halves of annexin A6 to be 
most  similar  to  annexin  A5  and  annexin  A10,  supporting  the  idea  of  chromosomal 
duplication of these regions resulting in the formation of annexin A6 [7].  
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Figure 1 Phylogenetic Tree of the Annexins 
Taken from [5]. The annexins originated approximately 1200 Mya (million years ago). The first annexins to 
diverge  from  the  ancient protist  annexins  (ANXE)  were  the  plant  annexins  (ANXD).  These annexins  were 
followed by the evolution of the fungal (ANXC), the invertebrate (ANXB) and finally the vertebrate (ANXA) 
annexins. The largest of these groups are the plant annexins with currently 20 known members, followed by 
the  invertebrate,  the  vertebrate,  the  fungal  and  lastly  the  protist  annexins.  The  vertebrate  family  currently 
consist of 12 annexins, named annexin A1 – A11 and annexin A13. Annexin A12 has yet to be ascribed. 
 
Vertebrate annexins best exemplify the stereotypical annexin structure. This comprises a 
unique  N  terminal  domain,  followed  by  a  C  terminal  domain  containing  four  highly 
conserved regions called annexin repeats, or eight in the case of annexin A6 [8], which 
can bind calcium. The plant annexins (annexin Ds) tend to lack the N terminal domains as 
well as functional calcium binding sites in two of the four annexin repeats [9]. The annexin  
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C  family  members,  which  range  from  species  as  simple  as  the  unicellular  protozoan 
Giardia lamblia to the more complex multicellular fungus Neurospora crassa, do contain 
variable N terminal domains. As yet amongst these more primitive annexins, no clear front 
runner has been identified as a putative ancestor to the annexin A family members. It is 
however known, from gene structure analysis, that annexin A11 is the common ancestor to 
all but two of the vertebrate annexins, preceded in evolution only by annexin A13 and 
annexin A7.  
 
1.1.2 Annexin Structure 
 
The  annexins  are  composed  of  two  domains;  the  conserved  C  terminal  domain,  often 
referred to as the annexin core and the divergent N terminal effector domain or head. 
 
Annexin Core Domain 
This domain contains the highly conserved annexin repeats, of which there are usually 
four, of about 70 amino acids in length. Each repeat contains the 17 amino acid consensus 
sequence, referred to as the endonexin fold. Though primary sequence homology of this 
domain between the different annexins ranges only between 45-55%, the secondary and 
tertiary structures are almost superimposable, as shown through x-ray crystallography [5]. 
The first annexin core domain to be crystallised was that of human annexin A5 [10].  
 
This study showed that each repeat was folded into five alpha helices that are wound into 
a right handed super helix (Figure 2). The five helices, designated A to E, are arranged 
such that A and B, and D and E form two parallel helix-loop-helix structures.  Helix C is 
situated perpendicular to these two structures and connects the C terminus of helix B to 
the  N  terminus  of  helix  D  [11].  The  annexin  core  itself  is  formed  into  a  planar,  cyclic 
structure, giving it a slightly curved form with the convex side believed to be the membrane 
binding surface and the concave side facing the cytoplasm. The convex side was shown to 
house unique calcium binding sites [12], different to the type I calcium binding sites of EF 
hand proteins.  
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Figure 2 Ribbon Drawing of the Crystal Structure of Human Annexin A5 
Taken from [13]. The crystal structure of annexin A5 depicted here is representative of all vertebrate annexins. 
The N terminal domain (shown here as unstructured) lies along the concave side of the protein. The C terminal 
core  comprises  four  annexin  repeats,  shown  in  yellow  (1
st  repeat),  dark  blue  (2
nd  repeat),  violet/cyan  (3
rd 
repeat) and green (4
th repeat). The structure of the 3
rd repeat in low calcium conditions is depicted in violet. 
High calcium conditions cause a structural change in this repeat, depicted in cyan, such that a tryptophan 
residue is exposed. This conformational change is unique to annexin A5, as most other annexins do not show 
a significant conformational change upon binding calcium. Calcium (shown in red) binds to the exposed loops 
of the annexin repeats.  
 
Crystallisation of other annexins led to further characterisation of these calcium binding 
sites, which are divided into high affinity type II sites, made of a „GxGT-[38 residues]-D/E‟ 
motif and low affinity type III sites [11].  These calcium binding sites are formed by loops 
from different parts of the core domain converging and have different structures in addition 
to their different affinities. Type II sites localise to the loop between helix A and helix B, a 
region commonly known as the endonexin fold, whereas type III sites are located to the 
loop between helix D and helix E. The sites themselves interact with calcium ions via three 
or  two  peptide  oxygen  groups,  for  type  II  and  III  sites  respectively,  and  a  bidentate 
carboxylate head group.  
 
The number and precise location of calcium binding sites between the annexins varies, for 
example annexin A1 was shown to have six calcium binding sites [11], but annexin A5 only 
five [12]. More dramatically annexin A9 has lost the calcium binding sites in all four of its 
annexin repeats [5]. These structural differences account for variation in calcium affinity 
between family members and so also affect phospholipid binding. 
 
The  ability  of  the  annexins  to  bind  membranes  is  generally  regulated  by  calcium  and 
occurs via the convex side of the protein. In the presence of calcium, annexin A2 has been 
shown  using  cryoelectron  microscopy  to  assemble  at  lipid  bilayers  [14].  Further  
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investigation demonstrated that annexin A2 is capable of binding phospholipid membranes 
in  both  a  calcium  dependent  and  calcium  independent  manner  [15].  Binding  to  these 
membranes is facilitated by slight changes in conformation, as illustrated by annexin A5 
which  alters  the  position  of  the  annexin  repeats  such  that  the  calcium  binding  sites 
become coplanar with the membrane [16]. This coplanar arrangement usually induces only 
subtle  changes  in  conformation,  except  in  the  case  of  annexin  A6  whose  two  halves 
undergo approximately 90° rotations to reach this configuration [17].  
 
Annexin N Terminal Head 
The N terminal domain shows the greatest variability amongst the annexins and can vary 
in length from less than 20 amino acids, for example in annexin A3 with 13 residues and 
annexin A5 with 16 residues, to just over 200 amino acids for annexin A11. Unlike the 
annexin core which has been crystallised for several of the annexins, much less is known 
about the tertiary structure of the N terminal head. A few crystal structures have been 
compiled for the shorter annexins, including annexin A1 [18], annexin A3 [19] and A5 [16]. 
In these cases where the N terminal domains are relatively short, they tend to extend 
along the inner, concave surface of the protein and often have hydrophobic interactions 
with this surface.  
 
This is true of annexin A5, whose N terminal domain is buried between the first and fourth 
annexin repeats to which it is anchored [16]. The 3D conformation of the N terminus is 
suggested to exert functional effects on the annexin core, as in the case of annexin A3. A 
tryptophan residue within the N terminus of annexin A3 is known to interact with the first, 
second and fourth annexin repeats via hydrogen bonds and Van der Waals interactions. 
The side chain of this residue points into a hinge region between the annexin repeats and 
it is suggested that this positioning could alter the flexibility of the protein and so affect its 
calcium and phospholipid binding properties [19]. 
 
The longer the N terminal head, the more complex the interactions appear to become, as 
illustrated by annexin A1, which though short in comparison to annexin A11, is more than 
twice the length of annexin A5. The crystal structure of annexin  A1 in the absence of 
calcium revealed the ability of the N terminus to form an alpha helix containing both polar 
and  non-polar  regions.  This  amphipathic  helix  substituted  for  helix  D  within  the  third 
annexin repeat, which under these conditions was unwound and protruded out from the  
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protein surface. In the presence of calcium the N terminus was more exposed and not 
packaged into the annexin core. Given that this domain is known to bind S100A11, it is 
possible that this interaction is facilitated by the conformational change induced in the N 
terminus in the presence of calcium [18]. 
  
Although the N terminal heads of the longer annexins have not been crystallised, much 
has been written about their functions, as they are known to contain a range of domains 
and binding sites which lend these annexins to more complex regulation (Figure 3). As 
mentioned above, annexin A1 can bind the S100 protein S100A11, this is a characteristic 
of several of the annexins including annexin A11 which binds S100A6 [20] and annexin A2 
which binds S100A10 [21], both via their N terminal domains.  
 
 
 
Figure 3 Schematic of Vertebrate Annexin N and C Terminal Domains 
The  vertebrate  annexins  show  a  high  degree  of homology  in  their  C terminal cores, each containing  four 
annexin repeats, with the exception of annexin A6 which contains eight. The N terminal domains however are 
more variable between the annexins and contain a variety of different sub-domains. Annexins A1 and A2 
contain  amphipathic  alpha  helices  in  their  N  terminal  domains  which  facilitate  binding  to  S100  proteins, 
allowing the formation of heterotetramers of two annexin proteins and two S100 proteins. Annexins A7 and 
A11 contain glycine, tyrosine and proline rich N terminal domains, with annexin A11 having the longest N 
terminal domain of all the vertebrate annexins. Annexin A13 is unique in containing a myristoylation signal in its 
N terminal domain.  
 
The N terminal domains are also targets for phosphorylation by several kinases, including  
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protein  kinase  C  which  phosphorylates  annexin  A2  [22]  and  the  EGF  receptor  kinase 
which targets annexin A1 [23]. Such events can result in functional consequences and in 
the case of annexin A1 its phosphorylation on tyrosine residues is implicated in late stage 
inward  vesiculation  of  multivesicular  bodies  [24],  whereas  phosphorylation  on  serine 
residues is essential for translocation to the plasma membrane [25]. 
 
Proteases, as well kinases, target the N terminal domains and several of the annexins 
contain  sequences  marking  them  out  for  proteolysis  [26],  adding  another  layer  of 
enzymatic regulation. In addition to these motifs, are signals for nuclear localisation [27], 
myristoylation [28] and transglutaminase crosslinking [29].  
 
1.1.3 Annexin Interacting Proteins 
S100 Proteins 
S100 proteins are a group of low molecular weight proteins belonging to the superfamily of 
EF  hand  proteins.  The  EF  hand  motif  comprises  a  helix-loop-helix  motif  which  binds 
calcium with a high affinity. S100 proteins contain two of these motifs connected by a 
hinge region and are capable of forming both hetero- and homodimers. These proteins are 
present only within vertebrate lineages. Their functions are diverse and include modulating 
both  actin  and  microtubule  networks,  promoting  cell  survival  and  proliferation,  calcium 
homeostasis and mediating muscle contraction (reviewed in [30]). The functions of these 
proteins are highly intertwined with those of the annexins, which they are known to bind.  
 
Annexin A2 binds S100A10 via its N terminal domain [21], in a heterotetrameric complex 
of two annexin A2 molecules and two S100A10 molecules [31]. This interaction is unique 
amongst the annexin-S100 complexes, as S100A10 does not contain functional calcium 
binding  sites.  Therefore  its  interaction  with  annexin  A2  is  calcium  independent  and  is 
instead dependent on the interaction of hydrophobic side chains of both proteins and post-
translational modifications of annexin A2, such as N-acetylation [32].  
 
This complex has been shown to interact with several membrane ion channels such as  
TRPV5 and TRPV6 (transient receptor like potential vanalloid type 5 and 6 channels) and 
is  suggested  to  regulate  their  distribution  and  functionality  [33].  Similarly  this  complex  
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interacts with the CFTR (cystic fibrosis conductance regulator protein channel) channel 
and is also implicated in regulating its channel currents [34]. In addition, the annexin A2-
S100A10  complex  plays  a  role  in  membrane  trafficking,  for  example  in  exocytosis  of 
secretory  vesicles  [35]  and  polarised  vesicular  transport  [36].  It  is  also  implicated  in 
junctional formation, in both the formation of adherens junctions [37] and the reassembly 
of tight junctions following breakdown [38].  
 
The binding of annexin A1 to S100A11 is thought to lead to heterotetramer formation in a 
similar manner to that of the annexin A2-S100A10 complex, although this has never been 
formally  proven.  This  interaction  is  also  mediated  by  the  annexin  N  terminal  domain, 
however  it  is  calcium  dependent  [39].  S100A11  has  also  been  shown  to  interact  with 
annexin  A6  [40],  though  the  functional  role  of  this  interaction  is  currently  unknown. 
Although little is also known about the function of the annexin A1-S100A11 complex, it has 
been  speculated  to  have  a  role  at  the  plasma  membrane  in  epidermal  keratinocyte 
differentiation [41] and has been shown to diminish phospholipid vesicle aggregation in 
vitro [42].  
 
Other annexin S100 interactions include those of annexin A11 with S100A6, discussed in 
Section  1.2.8  and  annexin  A6  with  both  S100A1  and  S100B.  Unlike  the  interactions 
discussed so far, the interaction of annexin A6 with S100 proteins occurs via both its N 
terminal domain and its C terminal core [43]. It also forms a heterotetramer with S100 
proteins and this formation appears to block the ability of S100A1 and S100B to inhibit 
intermediate filament formation. 
 
Cytoskeletal Proteins 
Several annexins are known to bind cytoskeletal components, in particular actin. These 
include annexin A1 [44], A2 [45], A5 [46] and A6 [47]. The best characterised of these 
interactions is that of annexin A2 with F-actin. Annexin A2 induces actin microfilament 
bundling in vitro [45] in a calcium dependent manner and binds F-actin via its C terminal 
domain [48]. Tyrosine phosphorylation of annexin A2 modulates its effects on the actin 
cytoskeleton and has been shown to regulate actin branching [49] and the formation of 
insulin-induced  actin  domes  [50].  Annexin  A2  is  located  at  the  interface  between 
phosphatidylinositol-4,5-bisphosphate  (PtdIns4,5P2)  enriched  membranes  and  F-actin,  
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where it is involved in membrane-associated actin assembly [51,52]. The annexin A2-actin 
interaction  is  involved  in  physiological  processes  such  as  membrane  ruffling  and 
protrusion  [53],  and  is also  implicated  in  pathophysiological  processes  such  as  wound 
healing [54] and tumour invasion [55,56].  
 
Annexin A1, like annexin A2 [55], is suggested as a potential drug target for anti-cancer 
therapies due to its actin binding properties [57,58]. In the presence of calcium annexin A1 
induces actin microfilament bundling in vitro [59]. It has also been shown to bind the actin 
regulator profilin, in a calcium independent manner [60], though the physiological role of 
this interaction is not yet known. The interaction of annexin A6 and actin is believed to play 
a role in the contractile tissues of the heart [61] and smooth muscle [47]. In cardiac muscle 
annexin  A6  co-purified  with  the  sarcolemma  and  bound  actin  in  a  calcium  dependent 
manner. This interaction is hypothesised to stabilise the sarcolemma during contraction. In 
smooth muscle cells annexin A6 relocalised to the plasmalemma in response to elevated 
calcium levels and co-precipitated with actomyosin. This interaction is suggested to be 
important in smooth muscle contraction. Plasma membrane targeting of annexin A6 has 
also  been  shown  to  stimulate  F-actin  accumulation  at  the  plasma  membrane.  This  is 
suggested  to  be  a  mechanism  by  which  plasma  membrane  targeted  annexin  A6 
diminishes store-operated calcium entry into the cell [62]. An interaction between annexin 
A5  and  actin  has  also  been  shown,  however  the  function  of  the  annexin  A5-actin 
interaction  is  less  clear.  It  is  known  to  be  calcium  dependent  and  is  suggested  to  be 
specific to gamma actin [46].  
 
Other Ligands  
A wide range of other proteins have been reported to interact with annexins. Annexin A6 
binds the GTPase (guanosine triphosphatase) activating protein p120 [63]. p120GAP is 
involved in inactivating the small Ras family of GTPases, which are known to have a key 
role in oncogenesis. Annexin A6 was shown to directly bind the calcium dependent lipid 
binding  domain  (known  as  the  C2  domain)  of  p120GAP  in  vitro.  The  binding  site  for 
p120GAP within annexin A6 was later mapped to the linker region between the two lobes 
of annexin A6 [64]. Annexin A6 is suggested to regulate Ras activity via its ability to target 
p120GAP to the plasma membrane in a calcium dependent manner [65].  
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The use of recombinant annexin A7 has identified the penta EF hand protein sorcin as a 
calcium-dependent interactor [66]. This interaction occurs between the N terminal domain 
of annexin A7 [66] and the N terminal domain of sorcin [67]. Annexin A7 was shown to 
enhance  the  binding  of  sorcin  to  phospholipid  membranes,  as  tested  using  purified 
chromaffin granules. The physiological function of this interaction is unknown, however it 
may be involved in membrane dynamics as sorcin binding of annexin A7 has been shown 
to  inhibit  annexin  A7  stimulated  aggregation  of  chromaffin  granules  [66].  Annexin  A11 
interacts with the penta EF hand protein ALG2 (Apoptosis Linked Gene 2), which belongs 
to the group I PEF family, as opposed to the group II PEF family of which sorcin is a 
member [68]. Annexin A11 has also been shown to interact with the motor protein CHO1 
(Chinese Hamster Ovary 1). These interactions are discussed further in 1.2.8 Annexin A11 
Interacting Proteins.  
 
In addition to the various protein interactions of the annexins, several of the annexins are 
known  to  bind  ribonucleic  acids  (RNA).  Annexin  A2  specifically  binds  polyguanosine 
residues  in  the  presence  of  calcium  in  vitro  [69].  The  investigation  of  annexin  A2 
ribonucleoprotein complexes led to the identification of c-myc mRNA as a direct binding 
target of annexin A2. The overexpression of annexin A2 resulted in the up-regulation of c-
myc protein. It is therefore suggested that this interaction, through the regulation of c-myc 
translation, could modulate cellular transformation. Annexin A1 also has been shown to 
bind RNA as well as DNA [70] and in complex with S100A6 to anneal to and unwind 
double stranded DNA [71].  
  
1.1.4 Annexins in Membrane Trafficking 
The annexins are known to bind membranes in a calcium dependent manner, however 
several of the annexins can bind membrane phospholipids in the absence of calcium. A 
fraction of the annexin A1 protein population identified in human placenta, was shown to 
bind membranes without the need for calcium [72]. Further analysis of this isolated pool of 
protein  demonstrated  that  it  can  be  phosphorylated  by  the  EGF  receptor  kinase.  
Subsequently  a  calcium  independent  membrane  binding  pool  of  annexin  A1  has  been 
detected in association with the plasma membrane and in isolated multivesicular bodies 
[23].  The  ability  of  this  pool  of  annexin  A1  to  bind  membranes  independently  of  the 
presence  of  calcium,  was  found  to  be  dependent  on  its  phosphorylation  state.  
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Phosphorylation by the EGF receptor kinase resulted in the loss of its calcium independent 
membrane binding properties. A pool of calcium independent membrane binding annexin 
A5  has  also  been  detected,  in  cultured  chick  embryo  fibroblasts  [73].  Although  these 
annexins do not require calcium to bind membranes, the calcium dependent phospholipid 
binding properties of the annexins still dominate their functionality.  
 
Annexins in Exocytosis 
The  role  of  annexins  in  exocytosis  began  with  initial  observations  of  the  membrane 
aggregation properties of annexin A7 [1]. Annexin A7 was shown to aggregate isolated 
adrenal  chromaffin  granules  in  the  presence  of  calcium  in  vitro.  Electron  microscopy 
showed individual granules in close apposition to each other. However fusion of these 
granules was only stimulated upon the addition of low concentrations of arachidonic acid, 
suggesting that annexin A7 mediates the contact between membranes but does not initiate 
fusion  [74].    Annexin  A2  has  similarly  been  shown  to  promote  chromaffin  granule 
aggregation in vitro in the presence of calcium [75], with fusion again only occurring upon 
addition  of  arachidonic  acid.  Furthermore,  studies  in  permeabilised  adrenal  chromaffin 
cells  demonstrated  that  the  gradual  failure  of  secretory  activity  due  to  the  loss  of 
intracellular proteins was partially inhibited in the presence of purified annexin A2 [76]. The 
rescue of calcium stimulated secretory activity was lost when annexin A2 antibodies were 
added [76] and appears to be dependent on the phosphorylation state of annexin A2 [77]. 
Inhibition of protein kinase C (PKC) in these cells prevents the reconstitution of secretion 
by purified annexin A2. However the addition of PKC-prephosphorylated annexin A2 over-
rides  the  inhibition  of  PKC,  restoring  secretory  function.  Taken  together  these  studies 
support a phosphorylation dependent role for annexin A2 in exocytosis.  
 
Studies  in  vivo  in  different  cell  lines  however  have  produced  conflicting  results  for  a 
universal role of annexin A2 in exocytosis. The up-regulation of annexin A2 protein levels 
or the down-regulation of annexin A2 function in adrenal pheochromocytoma cells, has 
shown no effect on calcium dependent dopamine release [78]. A mutant clone of this cell 
line  is  known  to  express  higher  levels  of  annexin  A2  and  is  rich  in  small  cytoplasmic 
vesicular  structures  called  enlargeosomes.  Annexin  A2  was  shown  to  localise  to  the 
surface  of  these  structures  and  following  siRNA-mediated  depletion  of  annexin  A2 
enlargeosome exocytosis was significantly decreased [79]. siRNA-mediated depletion of 
the annexin A2-S100A10 complex in endothelial cells, decreased the calcium dependent  
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secretion of von Willebrand factor, but not tissue plasminogen activator [35]. Therefore the 
role of annexin A2 in exocytosis is cell type specific and moreover is highly dependent on 
the specific secretory granule pathway examined. However one must also question the 
significance of these studies in cell lines, given that the annexin A2 knock out mouse is 
essentially normal.  
 
Annexin A13b has also been implicated in exocytosis in canine polarised epithelial cells. 
Permeabilised cells showed deficient membrane trafficking from the trans-Golgi network 
(TGN)  to  the  apical  membrane  in  the  presence  of  antibodies  targeting  annexin  A13b, 
though trafficking to the basolateral membrane was not affected [80]. The myristoylation of 
annexin A13b stimulates this apical transport [81], as does the myristoylation of annexin 
A13a.  However  annexin  A13a  in  addition  to  stimulating  apical  transport,  inhibits 
basolateral transport from the TGN, exhibiting a dual role in both positively and negatively 
regulating exocytosis [82]. 
 
The  mechanistic  workings  of  the  annexins  in  exocytosis  is  not  well  understood  and 
warrants further investigation, particularly with regard to how these proteins would fit into 
the well-established SNARE model (reviewed in [83]). This is especially of interest given 
the  work  carried  out  on  synaptotagmins  -  a  family  of  membrane  trafficking  proteins 
characteristically  containing  two  C2  domains,  responsible  for  calcium  dependent  lipid 
binding. Like the annexins, they have also been shown to aggregate chromaffin granules 
in vitro and promote fusion upon addition of arachidonic acid [84]. They have now been 
shown to enhance the calcium- and SNARE-dependent fusion of membranes in vitro [85].  
 
Annexins in Endocytosis 
The main annexins implicated in endocytosis are annexins A1, A2 and A6, all of which 
localise  to  endosomes  [23,86,87].  Annexin  A1  is  associated  with  multivesicular  bodies 
(MVBs) containing internalised epidermal growth factor (EGF) receptors and EGF receptor 
kinase  [23].  Following EGF stimulation, the EGF receptor  is internalised and sorted to 
early endosomes for recycling or degradation. During this process they are processed in 
MVBs prior to targeting to recycling endosomes or the lysosome. MVBs, as the name 
implies,  contain  multiple  internal  vesicles  in  which  cargo  is  stored. These  vesicles  are 
formed through inward vesiculation. The role of annexin A1 in this process was examined 
in a mouse lung fibroblast cell line derived from the annexin A1 knock out mouse [24].  
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EGF stimulation increased inward vesiculation of EGF receptor containing MVBs and this 
effect was abolished in annexin A1 knock out cells. This effect was then rescued upon 
expression of wildtype annexin A1 in knock out cells. However no rescue was achieved 
when an EGF phosphorylation mutant of annexin A1 was expressed. Therefore annexin 
A1 appears to enhance inward vesiculation, in a phosphorylation dependent manner.  
 
Annexin A2 is also implicated in the biogenesis of MVBs, specifically in the budding of 
MVBs  from  the  early  endosome  [88].  Labelled  EGF  was  used  to  follow  endosomal 
trafficking in annexin A2 depleted cells. In these cells EGF was not rapidly degraded as in 
control cells, but accumulated in early endosomes.  Similarly,  labelled  dextran  which in 
control  cells  trafficked  from  early  to  late  endosomes,  was  only  detected  in  the  early 
endosomes  of  annexin  A2  depleted  cells.  Electron  microscopy  of  knock  down  cells 
showed that regions of multivesiculation were present, suggesting inward vesiculation was 
viable.  However  these  regions  were  often  incorporated  within  the  early  endosomes. 
Therefore  annexin  A2  appears  to  play  an  important  role  in  early  to  late  endosome 
trafficking  via  its  regulation  of  the  endocytosis-mediated  formation  of  MVBs.  The 
phosphorylation state of annexin A2 has since been found to be important in early to late 
endosome  trafficking  [89].  Isolated  early  endosomes  were  shown  to  contain  tyrosine 
phosphorylated annexin A2. Furthermore N terminal tyrosine phosphorylation mutants of 
annexin A2 demonstrated that phosphorylation at tyrosine 23 was required for efficient 
endosome binding. Phosphomimetic and non-phosphorylable forms of annexin A2 were 
expressed in annexin A2 depleted cells. The block in early to late endosome transport 
observed  in  knock  down  cells,  was  rescued  by  the  expression  of the  phosphomimetic 
mutant  but  not  the  non-phosphorylable  mutant.  So  as  in  the  case  of  annexin  A1,  the 
phosphorylation state of annexin A2 regulates its endocytic function.  
 
The  roles  suggested  here  for  annexins  A1  and  A2  focus  on  the  early  stages  of  the 
endocytic pathway. Annexin A6 however has been implicated in both the early and late 
stages  of  endocytosis.  Annexin  A6  has  been  shown  to  bind  β-spectrin  [90],  a  protein 
capable of binding lipid membranes and the actin cytoskeleton. In vitro budding assays 
have shown the addition of recombinant annexin A6 to promote budding, associated with 
the loss of β-spectrin from membranes. The ability of annexin A6 to bind membranes in 
this assay was inhibited by the addition of the recombinant annexin A6 binding domain of 
β-spectrin. In vivo budding was inhibited by the cysteine protease inhibitor N-acetyl-leucyl- 
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leucyl-norleucinal (ALLN), resulting in a delay but not complete inhibition in the uptake of 
low  density  lipoprotein  (LDL).  Clathrin-coated  vesicle  (CCV)  budding  of  ALLN  treated 
membranes was shown to occur in vitro without the need for annexin A6. Taken together 
these experiments suggest that annexin A6 is involved in ALLN-sensitive, CCV budding 
from  the  plasma  membrane.  This  is  likely  to  be  mediated  through  the  annexin  A6 
dependent  activation  of  a  cysteine  protease,  resulting  in  the  separation  of the  clathrin 
lattice from the spectrin membrane cytoskeleton [91].  This specificity of annexin A6 for a 
subset of CCV budding provides a possible explanation for the efficient endocytosis seen 
in A431 cells, which do not express annexin A6 and do not show enhanced endocytosis 
upon annexin A6 over-expression [92].  
 
More recent work has focused on the role of annexin A6 in the later stages of endocytosis, 
in  particular  MVB  and  lysosome  fusion.  Annexin  A6  localises  to  late  endosomal  and 
prelysosomal compartments as shown by immunofluorescence and electron microscopy 
[93]. Trafficking of low density lipoprotein (LDL) through the endocytic pathway has shown 
that annexin A6 is associated with LDL vesicles throughout the endocytic pathway, even at 
late  stages  [94].  Subcellular  fractionation  also  detected  annexin  A6  throughout  the 
endocytic  pathway,  with  higher  amounts  in  late  endosomal  fractions.  In  addition, 
microinjection of an N terminal deletion mutant of annexin A6 resulted in the accumulation 
of LDL in large endosomal compartments and a delay in its degradation, suggesting a 
block in late endosome to lysosome trafficking [95]. Collectively these studies suggest a 
role for annexin A6 in modulating late endosome to lysosome trafficking. However it should 
be noted that the annexin A6 knock out mouse is generally considered normal, therefore 
the role for annexin A6 in this trafficking pathway is likely to be non-essential.  
 
In vitro data supporting the role of the annexins in endocytosis is now being substantiated 
in vivo, through the use of knock out mouse cell lines as well as siRNA depletion and over-
expression in transformed cell lines. As yet no specific molecular mechanism has been 
uncovered for the annexins in endocytosis. However a model has been put forward for the 
annexin  A1-S100A11  tetramer  in  membrane  aggregation  [96],  which  may  also  be 
applicable to the conformationally similar annexin A2-S100A10 tetramer. In this model the 
annexin A1-S100A11 heterotetramer is suggested to stabilise membrane interactions in 
order to allow endocytosis to proceed. In response to calcium binding a conformational 
change may occur to expose the N terminal domain, allowing it to either bind another  
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membrane surface directly or via the formation of a heterotetramer with S100A11. Annexin 
A1 phosphorylation is involved in MVB inward vesiculation [24] and in the context of this 
model N terminal phosphorylation could make annexin A1 more susceptible to proteolysis. 
Resulting  cleavage  could  destabilise  the  heterotetramer  and  aid  in  the  completion  of 
vesicle fission.  
 
1.1.4 Annexins in Membrane Organisation  
Annexins have been shown to organise the lipid composition of membranes both in vitro 
and in vivo. Much of the initial evidence for this originated from scanning force microscopy 
of in vitro systems. Annexin A2, as part of a heterotetramer with S100A10, was shown to 
bind to artificial lipid bilayers made of phosphatidylcholine (PC) and phosphatidylserine 
(PS) in the presence of calcium. Furthermore this binding resulted in the redistribution of 
PS microdomains, such that they were significantly depleted in the vicinity of annexin A2 
protein clusters [97]. Similarly annexin A4 binding to PC and phosphatidylglycerol (PG) 
membranes in vitro was shown to redistribute PG to sites where annexin A4 was bound, 
as  shown  using  a  fluorescently  labelled  PG  derivative  [98].  In  vivo  work  has  shown 
annexin  A2,  in  complex  with  its  binding  partner  S100A10,  to  colocalise  with 
phosphatidylinositol-4,5-bisphosphate (PtdIns4,5P2) at F-actin enriched sites of the plasma 
membrane.  In  vitro  liposome  co-pelleting  assays  demonstrated  a  direct  interaction 
between PtdIns4,5P2 and the annexin A2-S100A10 complex, with an affinity similar to that 
of  a  known  PtdIns4,5P2-binding  pleckstrin  homology  domain  [52].  In  this  instance  it  is 
believed that the induction of PtdIns4,5P2 accumulations at the plasma membrane induces 
the recruitment of annexin A2 to these sites, which then facilitates the reorganisation of the 
actin  cytoskeleton.  However  in  vitro  studies  have  shown  that  annexin  A2  itself  can 
stimulate the accumulation of discrete patches of PtdIns4,5P2, as shown by imaging of 
fluorescently labelled annexin A2 and PtdIns4,5P2 [99]. This did not occur in the presence 
of annexin A2 PtdIns4,5P2-binding mutants. Therefore in vivo and in vitro evidence has yet 
to  reach  a  consensus  on  whether  annexin  A2  determines  lipid  organisation  within  the 
plasma membrane or whether the localisation of annexin A2 is simply a consequence of 
established lipid domains.  
 
Annexin A6 is also implicated in membrane organisation in smooth muscle cells. Upon 
contraction  annexin  A6  has  been  shown  to  relocalise  from  the  cytoplasm  to  the  
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sarcolemmal membrane. In the presence of calcium annexin A6 was shown to be in a 
complex  with  actomyosin  and  cholesterol-  and  sphingomyelin-enriched  sarcolemmal 
membrane  fractions,  which  are  known  to  be  associated  with  caveolae.  In  vitro 
reconstitution experiments using these purified constituents resulted in the formation of a 
structured precipitate, similar to that formed from in vivo preparations [47]. Taken together 
annexin A6 is suggested to have a role in regulating the sarcolemmal membrane upon 
contraction. Annexin A2 is also implicated in organising the sarcolemmal membrane of 
smooth muscle cells, as it has been demonstrated to promote the aggregation of lipid raft 
microdomains  in  these  cells  in  a  calcium  dependent  manner  [100].  The  contraction 
induced association of annexin A2 with the sarcolemmal membrane was shown to be lost 
upon proteolytic cleavage of annexin A2 [101]. This degradation was significantly blocked 
upon treatment with a calpain inhibitor. It is therefore believed that calpain may regulate 
annexin  A2  binding  to  lipid  rafts,  providing  a  means  by  which  the  signalling  events 
triggered by these lipid raft associations can be terminated.  
 
1.1.5 Annexins and Ion Channels 
The first annexin demonstrating an effect on ion flow was annexin A6 [102], in an in vitro 
system of reconstituted sarcoplasmic reticulum membranes. Annexin A6 was shown to 
increase the frequency of opening and the open time of the calcium release channel. In 
this system annexin A6 was added to the luminal side of the lipid bilayer, however in vivo 
annexin  A6  is  predominantly  exposed  to  the  cytosolic  face  of  the  membrane.  In  vivo 
studies in neuronal cultures have since shown annexin A6 to regulate ion channels via the 
cytoplasmic  surface  of  the  membrane  [103].  The  interaction  of  annexin  A6  with  the 
phospholipid membrane was disrupted via the intracellular perfusion of anti annexin A6 
antibodies. This resulted in an increase in the magnitude of calcium currents in spinal cord 
neurons and of potassium currents in both spinal cord and dorsal root ganglion neurons.  
Conversely  the  over-expression  of  plasma  membrane  targeted  annexin  A6  has  been 
shown to decrease store-operated calcium entry [62]. In vitro studies have now shown that 
annexin  A6  exhibits  ion  channel  properties  in  the  absence  of  other  proteins,  as 
demonstrated by electrophysiological experiments in an artificial membrane system [8]. 
Therefore the effects on calcium currents observed in the previous studies, may not be 
due to the modulation of calcium channels by annexin A6, but by annexin A6 itself acting 
as a calcium channel.  
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Stronger evidence for the annexins themselves acting as ion channels followed on from 
the crystal structure analysis of annexin A5. Annexin A5 comprises a central pore region 
lined with polar residues [16] (Figure 4). Evidence for calcium channel activity came from 
calcium imaging experiments and electrophysiological recordings. Imaging of the calcium 
fluorophore Fura-2 in liposomes across which a calcium gradient had been established 
[104], showed that the addition of annexin A5 caused an influx of calcium which did not 
occur upon application of the N terminal deletion mutant. Patch clamp experiments on 
liposomes further demonstrated the requirement of specific residues within annexin A5 
[105]. The mutation of a key glutamic acid residue within the channel pore resulted in 
decreased  conductance  for  calcium  and  increased  conductance  for  sodium  and 
potassium, as shown by single channel recordings. Mutational analysis has also led to the 
hypothesis that certain glutamic acid residues determine the conductance of the channel 
by regulating its diameter [106].  Although there is a substantial amount of data supporting 
the in vitro function of annexin A5 as a calcium ion channel, this has yet to be definitively 
proven in vivo. 
 
 
 
Figure 4 Crystal Structure of the Annexin A5 Pore 
The ion channel properties of annexin A5 are thought to arise from its ability to form a hydrophilic pore from 
four alpha helices (depicted here in blue and red). Two salt bridges (shown in blue and yellow) which extend 
into the pore have been shown via mutational analysis to be necessary for the voltage sensing ability of the ion 
channel. Taken from [13].  
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A more convincing case has been put forward for the role of the annexins as modulators of 
ion channel activity, with particular regard to annexin A2 and its interaction with S100A10. 
Disruption  of  this  interaction  through  the  injection  of  a  truncated  annexin  A2  peptide 
encoding the S100A10 binding site, resulted in a gradual decrease in the amplitude of 
chloride channel currents in vascular endothelial cells [107]. S100A10 itself is implicated in 
promoting the expression of several ion channels through regulating their translocation to 
the plasma membrane. This is mediated through direct interactions with the channels, as 
exemplified by the binding of S100A10 to  the sensory neuron-specific sodium  channel 
[108],  the  widely  expressed  potassium  channel  TASK-1  [109]  and  the  neuronally 
expressed sodium channel ASIC1a [110]. Although S100A10 alone is able to direct the 
targeted expression of ion channels, its interaction with annexin A2 has also been shown 
to be necessary in certain circumstances. S100A10 binds the epithelial calcium channels 
TRPV5 and TRPV6. Both annexin A2 and S100A10 have been shown to be in complex 
with  TRPV5  and  to  colocalise  with  TRPV5  and  TRPV6.  Moreover,  siRNA-mediated 
depletion  of  annexin  A2  results  in  diminished  TRPV5  and  TRPV6  calcium  currents, 
highlighting the importance of annexin A2 in this complex [33]. In this context annexin A2 
may regulate the trafficking of ion channels to the cell surface, as S100A10 does and in 
addition may be involved in tethering the channels to the plasma membrane given the 
membrane and cytoskeletal binding properties of this annexin.  
 
1.1.6 Extracellular Roles of the Annexins 
The  annexins  are  not  known  to  contain  signals  targeting  them  for  secretion  into  the 
extracellular  milieu,  nevertheless  studies  have  shown  several  of  the  annexins  to  be 
involved in extracellular events. Particular importance has been placed on annexin A2 in 
plasmin production (discussed in 1.1.7 Annexins in Disease), annexin A1 in inflammation 
and annexin A5 in cell death and blood clotting. 
 
Annexin  A5  binds  phosphatidylserine  (PS),  which  in  dying  cells  is  flipped  to  the  outer 
leaflet of the lipid bilayer. It is this characteristic which has led to the use of annexin A5 as 
a marker of dying or dead cells, not only in vitro but also in vivo in patients (reviewed in 
[111]). Upon binding of PS annexin A5 self-associates to form a trimer, resulting in the 
formation  of  a  membrane  bound  lattice  [112].  This  binding  requires  calcium  and  is  
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enhanced in the presence of zinc [113], at levels which occur naturally in the extracellular 
environment such as circulating blood where annexin A5 and also annexin A4 have been 
detected [114]. 
 
Autoantibodies against annexin A5 in the circulating blood of pregnant women have been 
correlated  with  a  tendency  towards  miscarriage  [115].  It  is  hypothesised  that  these 
antibodies disrupt the anti-coagulant properties of the annexin A5 lattice on the surface of 
placental synctiotrophoblasts, resulting in increased clotting and subsequent miscarriage 
[116]. The anti-coagulant activity of annexin A5 has also been shown to act directly on 
platelets.  Binding  of  annexin  A5  to  activated  platelets,  via  exposed  PS  on  the  platelet 
membrane, prevented the binding of the pro-coagulant Factor Xa which is necessary for 
the formation of the prothrombinase complex [117]. It is therefore suggested that annexin 
A5 can inhibit coagulation through the disruption of activation complexes on the platelet 
cell surface, thus preventing the formation of thrombin. 
 
The  extracellular  function  of  annexin  A1  also  targets  cells  of  the  circulatory  system, 
specifically of the innate immune system. In vitro and in vivo studies have shown that after 
the translocation of annexin A1 to the cell surface of leukocytes following adhesion to 
endothelial cells, a small proportion of this pool of annexin A1 is proteolytically cleaved and 
released into the extracellular environment in its truncated inactive form [118]. Neutralising 
antibodies against the cell surface-attached form of annexin A1 enhanced extravasation in 
a  mouse  model,  supporting  the  role  of  annexin  A1  in  the  inhibition  of  leukocyte 
transmigration. The mechanism by which annexin A1 exerts these effects has since been 
investigated in vitro. Annexin A1 has been shown to inhibit leukocyte adhesion through the 
binding  of  the  formyl  peptide  receptor  (FPR)  family  which  activates  downstream  ERK 
(Extracellular  Signal-regulated  Kinase)  cascades  [119].  Neutralising  antibodies  against 
annexin A1 prevented this decrease in adhesion. In further support of this, leukocytes from 
the annexin A1 knockout mouse demonstrate an increased ability to transmigrate [120]. 
The function of annexin A1 in this process is of particular significance as glucocorticoid 
treatment has been shown to inhibit leukocyte adhesion and delay transmigration whilst 
also up-regulating annexin A1 expression  in these cells [121]. Annexin A1 is therefore 
believed to be a key regulator of the anti-inflammatory effects of glucocorticoid treatment 
not only in the innate immune system, but also the adaptive immune system (reviewed in 
[122]).   
-37- 
 
1.1.7 Annexins in Disease  
The annexins have been implicated in a range of pathological conditions, although to date 
no annexin has been found to be the root cause of a disease. Nevertheless the annexins 
are  proving  to  be  important  markers  and  targets  in  a  range  of  disease  pathologies 
including cancer, diabetes and autoimmune disease.  
 
Cancer 
In terms of the prognostic value of the annexins in disease, there is much emphasis on 
annexin expression in cancer progression. Tissue microarray analysis has shown several 
annexins to be down-regulated in prostate cancer [123]. Annexin A1 in particular has been 
verified as down-regulated in both patient samples [124] and a prostate cancer cell line 
[125]. Further investigation into prostate cancer has highlighted a potential mechanistic 
role for annexin A7 in cancer pathology. Annexin A7 was shown to be down-regulated 
[126] in prostate cancer, with enhanced loss of expression in metastatic tissue samples 
compared to primary prostate tumour samples. A similar trend was observed in breast 
cancer  samples  [127].  A  loss  of  heterozygosity  was  detected  in  regions  of  the 
chromosome flanking the annexin A7 gene locus in both prostate cancer [126] and breast 
cancer  samples  [128].  Furthermore  the  annexin  A7  heterozygous  knockout  mouse  is 
prone to tumour development [129]. Collectively these studies suggest annexin A7 may 
act as a tumour suppressor gene.  
 
In terms of harnessing the annexins as therapeutic targets in cancer, annexin A2 has been 
the focus of several studies. Immunohistochemical analysis has shown the expression of 
annexin A2 in ductal epithelia from invasive breast cancer tissues, which was absent in 
normal  or  non-invasive  breast  cancer  tissues  [130].  The  up-regulation  of  annexin  A2 
expression is suggested to affect the invasive nature of cancer cells, as shown through the 
comparison of metastatic and non-metastatic breast cancer cell lines [130]. In line with 
data collected from ductal tissue samples, annexin A2 expression was absent in the non-
invasive cell line and present in the invasive cell line. Annexin A2 is a known receptor for 
tissue plasminogen and tissue type plasminogen activator and so promotes the conversion 
of plasminogen to plasmin [131]. The cells of the invasive breast cancer cell line were able 
to carry out this function, however cells of the non-invasive cancer cell line were not [130].  
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This provides a possible mechanism by which annexin A2 regulates cancer cell invasion, 
as plasmin can degrade the extracellular matrix, so aiding migratory behaviour. This is 
supported  by  the  detection  of  increased  mRNA  and  protein  levels  of  annexin  A2  in 
migrating cells relative to stationary cells [54]. Annexin A2 may also contribute to tumour 
cell invasiveness by increasing motility through its known interactions with F-actin [51,53]. 
This is supported by investigations into anti-cancer drug treatment strategies targeting this 
protein, namely the use of the steroidal lactone withaferin A [55]. 
 
Withaferin A treatment of invasive cancer cells showed a marked decrease in migration, 
suggested to be due to the  effects  on  annexin A2 and  its  ability to regulate  the actin 
cytoskeleton [55]. In vitro studies showed withaferin A could bind annexin A2 and promote 
annexin A2 dependent F-actin bundling, which was also observed in vivo. This effect was 
shown to be annexin A2 dependent, as cells with low endogenous levels of annexin A2 
were  more  resistant  to  this  effect  and  cells  over-expressing  annexin  A2  were  more 
sensitive to this effect. Therefore annexin A2 represents a potential therapeutic target in 
the treatment of cancer through restricting its spread.  
 
Diabetes 
In addition to its affects on the cytoskeleton, annexin A2 promotes plasmin production as 
previously  mentioned  [131].  Although  this  has  implications  in  cancer  pathology,  it  is 
especially significant in diabetes. Annexin A2 has been implicated in the pathology of both 
type  I  and  type  II  diabetes,  due  to  its  role  in  vascular  endothelial  biology  and 
hypercoagulation which occurs in both forms of diabetes. The production of plasmin, which 
dissolves blood clots so preventing excessive coagulation, is reduced in high glucose and 
insulin  conditions.  This  reduction  was  partially  prevented  upon  addition  of  annexin  A2 
[132].  The  addition  of  annexin  A2  via  injection  in  a  mouse  model  of  diabetes  also 
decreased the effects of diabetic nephropathy and again it is suggested to be due to the 
anti-coagulation properties of annexin A2 [133]. The inability of endogenous annexin A2 to 
exert these anti-coagulant effects in diabetes is suggested to be due to its glycation in high 
glucose  and  high  insulin  conditions  [134].  Annexin  A2  may  also  contribute  to  disease 
pathology  through  its  phosphorylation.  Insulin-dependent  tyrosine  phosphorylation  of 
annexin A2 is known to result in changes in the actin cytoskeleton [50]. This remodelling 
significantly  alters  the  cell  morphology,  such  that  actin  domes  are  formed,  and  also 
diminishes cell adhesion. This may result in as yet undetermined effects in vivo in the  
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context of diabetes.  
 
Autoimmune Diseases 
The role of the annexins in autoimmune disease is less clear than that of diabetes and 
cancer.  However  autoantibodies  against  the  annexins  have  been  detected  in  many 
autoimmune  diseases.  Anti-phospholipid  syndrome  (APS),  an  autoimmune  diease 
characterised by increased thrombosis, has in particular been associated with annexin A2. 
Alongside  the  major  autoantibody  present  in  APS  against  β2-glycoprotein  I  (β2-GPI), 
autoantibodies against annexin A2 have also been detected in APS patient sera [135]. In 
vitro binding assays have shown annexin A2 to bind β2-GPI and the over-expression of 
annexin  A2  in  endothelial  cells  was  shown  to  enhance  β2-GPI  binding  to  the  plasma 
membrane. Taken together this supports a role for annexin A2 as a receptor for β2-GPI 
[45]. This model in which β2-GPI binds to endothelial cells via annexin A2 is suggested to 
activate  these  cells,  so  promoting  the  formation  of  pro-coagulant  complexes  on  their 
surfaces  and  therefore  thrombi.  Autoantibody  production  in  APS  is  also  suggested  to 
promote  coagulation  by  disrupting  the  cell  surface  distribution  of  annexin  A5  and 
subsequently inhibiting its anti-coagulant activities [136]. Autoantibodies against annexin 
A11  have  also  been  detected  in  APS  and  in  several  other  autoimmune  diseases,  as 
discussed  in  1.2  Annexin  A11,  specifically  in  1.2.10  The  Immune  System  and  1.2.11 
Disease. 
 
1.2 Annexin A11  
The initial identification of annexin A11 is most likely to have come from early studies on a 
„synexin-like‟ protein. This 56kDa calcium binding protein was first discovered in adrenal 
medulla and liver tissue in 1983 [137]. It was shown to have characteristics similar to that 
of  synexin,  in  that  it  enhanced  the  aggregation  of  chromaffin  granules  and 
phosphatidylserine liposomes. However protease treatments of these two proteins showed 
them to have different sensitivities and peptide maps. Several years later, a „synexin-like‟ 
protein was also found in human blood platelets  [138]  with  the suggestion  that  it  may 
belong to a newly identified family of proteins, called annexins.  
 
In 1992 the primary structure of annexin A11 was elucidated, following its purification from 
rabbit lung as a “calcyclin associated protein” [139]. It was then named CAP-50, calcyclin  
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associated  protein-50,  but  following  protease  digestion  was  shown  to  belong  to  the 
annexin family. It exhibited properties common to annexin family members, including the 
inhibition of phospholipase A2 and calcium dependent binding of anionic phospholipids – in 
this  case  phosphatidylserine,  phosphotidylinositol,  phosphatidylethanolamine  and 
phosphatidic acid. 
 
1.2.1 Primary Structure  
Annexin A11, known as CAP-50 when it was first classified as an annexin in 1992 [139], 
was  purified  from  bovine  lung  [140]  for  further  characterisation.  In  this  study  it  was 
identified as a unique annexin, distinct from synexin (now reclassified as annexin A7) to 
which  it  is  closely  related.  Primary  structure  analysis  of  partial  amino  acid  sequences 
showed bovine lung CAP-50 to have 91% homology with rabbit lung CAP-50, which was 
first highlighted as being an annexin, but only 63% homology with human synexin. Further 
sequence  analysis  was  carried  out  after  cloning  of  CAP-50  cDNA  from  bovine 
chondrocytes [141] and from a rabbit lung cDNA library [142].  
 
 
 
Figure 5 Schematic of Annexin A11 Protein Showing N Terminal and C Terminal Domains 
Annexin A11 is a 54kDa protein of 505 amino acids. It comprises a C terminal core and an N terminal head. 
The C terminal core contains four highly conserved sub-domains called annexin repeats, with calcium binding 
properties. The long N terminal head is proline (P), glycine (G) and tyrosine (Y) rich.  
 
Results from both studies showed annexin A11 to be a 505 amino acid protein of 54kDa. 
On SDS PAGE, annexin A11 runs at 55 to 56kDa, most likely due to its proline rich content 
which can restrain the conformation of denatured proteins. The C terminus was shown to 
contain four highly conserved annexin repeats with an overall 50% homology with other 
vertebrate annexin C termini [142]. The N terminus of annexin A11 is the longest of all the 
annexins and is rich in proline, glycine and tyrosine residues (Figure 5). It shows little 
homology with the N termini of the rest of the annexins, other than annexin A7, confirming 
the identification of CAP-50 as a new annexin family member [139].  
  
-41- 
1.2.2 Isoforms 
The continued study of bovine annexin A11, one of the first species in which annexin A11 
was identified, uncovered the existence of two isoforms; annexin A11-A and A11-B [143]. 
These isoforms differ in their N termini due to alternative splicing of exons 3a and 3b. 
Northern blot analysis however could not detect the annexin A11-B transcript, indicating 
very  low  expression  levels.  Moreover  this  splice  variant  is  not  expressed  in  mice  or 
humans [144], nor is its peptide sequence conserved in nine other investigated species.  
 
There are three annexin A11 isoforms which have been identified in humans [144], one of 
which is also present in mice (Figure 6). However these isoforms result from alternative 
mRNA splicing of exons 1a, b and c in the 5‟ UTR (untranslated region) of annexin A11 
and therefore are also of uncertain functional importance. 
 
1.2.3 Tertiary Structure 
Although  the  primary  and  secondary  structures  of  annexin  A11  have  now  been  well 
characterised,  little  is  known  of  its  tertiary  structure  as  the  protein  has  not  yet  been 
crystallised.  However  the  tertiary  structure  of  its  C  terminal  domain  in  high  calcium 
conditions has been predicted using x-ray crystallography data obtained from annexin A1 
and A5 [145]. As with other annexins the calcium binding sites appear to be located along 
the convex surface of the molecule, whilst the N terminus is exposed to the cytosol, on the 
concave side of the molecule. Calcium binding is predicted to alter the exposure of several 
tyrosine residues in the N terminal domain, which may affect functionality.  
 
1.2.4 Gene Structure  
Annexins  A7,  A11  and  A13  are  believed  to  have  evolved  from  a  common  vertebrate 
ancestor, about 700 Mya [144], with annexin A11 being the last of the three to diverge 
from this ancestor. Analysis of the core domain of annexin A11, which contains the four 
annexin repeats, showed identical intron and exon splice patterns to all the annexins, with 
the  exceptions  of  annexin  A7  and  A13.  This  suggests  annexin  A11  is  the  paralogous 
ancestor of the other nine vertebrate annexins.  
 
The human annexin A11 gene is located on chromosome 10 (Chr10q23) and contains  
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fifteen exons. Exon 1 is untranslated and is followed by intron 1, which comprises almost 
half of the gene, then exons 2 to 5 which encode the N terminus, and lastly exons 6 to 15 
which encode the C terminus. The untranslated exon 1 can be subdivided into exons 1a, b 
and c, combinations of which produce the 5‟ UTR splice variants of annexin A11; isoform a 
encoding 1a, isoform b encoding 1a and 1c and isoform c encoding 1a, 1b and 1c (Figure 
6). 
 
 
 
Figure 6 Human Annexin A11 mRNA Transcript Splice Variants 
The annexin A11 mRNA transcript is encoded by 2,486 base pairs arranged from exons 1 to 15. Exons 2 to 15 
are translated into protein, whereas exon 1 encodes the untranslated 5‟ UTR. Exon 1 is subdivided in exons 
1a, 1b (green) and 1c (red), which are alternatively spliced into three annexin A11 isoforms. Isoform c contains 
exons 1a, 1b and 1c, whereas isoform b lacks exon 1b and isoform a lacks both exons 1b and 1c. 
 
1.2.5 Tissue and Cellular Distribution  
Annexin A11 is expressed in a wide range of tissues including spleen, heart, lung and 
testis [140] (Figure 7). At the subcellular level annexin A11 expression has been examined 
in several cell lines. It was initially shown to be predominantly nuclear, but excluded from 
the nucleoli in rat  3YI embryonic fibroblasts [140]. This has since also been shown in 
chicken  embryonic fibroblasts  [146],  as  well  as  transformed  cell  lines  including  human 
epidermoid  carcinoma  (A431)  [147]  and  human  cervix  adenocarcinoma  (HeLa)  [146]. 
However,  further  investigation  has  shown  this  expression  pattern  to  be  dependent  on 
several factors.  
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Figure 7 Tissue Distribution of Annexin A11 mRNA 
Annexin A11 is expressed at different levels in a wide range of tissues, with high expression patterns detected 
in thymus, lung and smooth muscle and low expression patterns in testis, adrenal glands and brain. Image 
produced by [148].  
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Annexin  A11  expression  is  differentially  regulated  during  tissue  development. 
Immunostaining of adult rat tissues shows mainly cytoplasmic staining with weak staining 
in the nucleus. The opposite was observed in rat embryonic tissues. However, nuclear 
staining is not a hallmark of embryonic tissue, as endodermal cells were shown to lack 
nuclear staining throughout development [149]. The general difference in nuclear staining, 
between adult tissue comprising mainly post mitotic cells and embryonic tissue, suggests a 
role for annexin A11 in the regulation of cell proliferation.  
 
In cultured cells, cell-cell contact also affects the subcellular distribution of annexin A11. 
Nuclear staining is present in both subconfluent and confluent cells. However, in confluent 
cells there is also strong staining for annexin A11 at the plasma membrane along cell-cell 
contacts. In subconfluent cells staining outside the nucleus is restricted to vesicles in the 
cytoplasm, similar to that seen in cells at the boundary of a confluent monolayer. These 
annexin A11 positive vesicular structures are closely apposed to the microtubule network 
[146]. Annexin A11 may therefore have some involvement in vesicular trafficking along 
these networks.  
 
Another major regulator of annexin A11  distribution  is calcium. In A431 cells a rise  in 
intracellular calcium causes a partial relocalisation of annexin A11 to the nuclear envelope. 
This sensitivity to calcium is determined by the C terminal domain. However the specificity 
of the response towards the nuclear envelope appears to be determined by the N terminus 
[146]. This correlates with earlier work suggesting that the N terminus of annexin A11 
contains its nuclear localisation signal [27].  
 
Given that the expression of annexin A11 is widespread in a range of tissues and cell 
types, it is likely to be involved in  basic cellular processes fundamental to all cells. In 
addition, as its distribution is affected by several factors, it may have a variety of roles 
dependent on both the intra- and intercellular environment. 
 
1.2.6 The Cell Cycle  
It is known that as the cell cycle progresses the distribution of annexin A11 changes [150]. 
In interphase cells of cultured cell lines, as previously mentioned, it is mainly nuclear with 
some cytoplasmic staining. However as prophase progresses it partially translocates to the  
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degenerating  nuclear  envelope.  By  metaphase  annexin  A11  is  present  along  mitotic 
spindles and at anaphase it begins to concentrate along the central spindle. At telophase 
annexin  A11  begins  to  accumulate  at  the  midbody,  as  well  as  the  reforming  nuclear 
envelope  [147].  At  cytokinesis  it  is  concentrated  at  the  midbody  in  two  parallel  disc 
structures [146]. The presence of annexin A11 at both the degenerating and reforming 
nuclear envelope,  as well as its co-localisation at  these times with the nuclear protein 
LAP2,  confirmed  its  association  with  microtubule-induced  nuclear  folds  [147].  This 
suggests a possible role of annexin A11 in regulating nuclear envelope degeneration and 
regeneration.  
 
The function of annexin A11 at the midbody has been further investigated, with respect to 
membrane  trafficking.  It  has  previously  been  noted  that  annexin  A11  positive  vesicles 
appear bound to the microtubule network [146]. It has also been shown that Brefeldin A 
(BFA), an inhibitor of vesicle trafficking, delays the completion of cytokinesis [151]. In A431 
cells this results in binucleate cells. However annexin A11 accumulation at the midbody 
was  BFA-insensitive,  suggesting  that  the  presence  of  annexin  A11  at  the  midbody  is 
independent of BFA-sensitive vesicular trafficking. Therefore the contribution of annexin 
A11 to cytokinesis may not relate to membrane expansion but to a more specific role at 
the point of abscission.  
 
The importance of annexin A11 in abscission at cytokinesis has been further highlighted 
by  siRNA-mediated  depletion,  which  results  in  the  absence  of  a  midbody  and  as  a 
consequence abortive cytokinesis. Daughter cells furrow normally, but are unable to sever 
the cytoplasmic bridge connecting them, leading to apoptosis [150]. Cytokinetic defects 
also are seen with the loss or mutation of other constituents of the midbody matrix, such 
as the mammalian motor protein CHO1. 
 
1.2.7 Phosphorylation and Proteolysis 
Annexin A11 is known to be phosphorylated by both serine/threonine kinases and tyrosine 
kinases. In vitro kinase assays have shown increased tyrosine phosphorylation of annexin 
A11 by PDGF-R (platelet derived growth factor receptor), Src kinase, EGF-R (epidermal 
growth factor receptor) and CADTK (calcium dependent tyrosine kinase) [152]. Increased 
tyrosine phosphorylation of annexin A11 has also been shown in cultured smooth muscle  
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cells in response to treatment with PDGF-BB (platelet derived growth factor BB) [152]. 
 
In addition to being a tyrosine kinase substrate, in vitro kinase assays have shown that 
MAPK  (mitogen  activated  protein  kinase)  phosphorylates  annexin  A11  on  serine  and 
threonine residues [153]. This was observed in rat embryonic fibroblasts transformed with 
the viral oncogene v-src.  An increase in serine and threonine phosphorylation of annexin 
A11 was detected in the v-src transformed cells when compared to untransformed control 
cells [153]. This is due to the activation of downstream serine and threonine kinases by v-
src,  in  particular  MAPK  which  was  shown  to  be  constituitively  activated  in  v-src 
transformed cells. This increase in phosphorylation altered the mobility of annexin A11 in 
SDS PAGE and appeared to mark out the cytoplasmic pool of annexin A11, as shown by 
subcellular fractionation. 
 
Annexin  A11  has  therefore  been  shown  to  respond  to  physiological  phosphorylation 
signals  and  to  be  phosphorylated  by  several  important kinases.  Though  the functional 
significance of these modifications is as yet  unknown,  initial findings suggest a role in 
regulating the localisation of annexin A11 [153]. 
  
With  regard  to  proteolysis,  annexin  A11  has  been  shown  to  be  degraded  by  intrinsic 
proteases in rat lung homogenates into four smaller polypeptides of 42, 47, 49 and 52kDa, 
in the absence of calcium [26]. In the presence of calcium this degradation was limited to a 
single break down product of 52kDa. It is suggested that the N terminus of annexin A11 
makes this annexin more prone to degradation as it houses a strong PEST signal. PEST 
signals  are  sequences rich  in  proline  (P), glutamate  (E), serine (S)  and  threonine  (T), 
which  are  associated  with  rapidly  degraded  proteins.  Its  degradation  however  is  not 
attributed to the lysosomal pathway as it is does not contain a KFERQ-like motif, which is 
associated with lysosomal targeting and is present in several other annexins. 
 
1.2.8 Interacting Proteins  
ALG2 
Apoptosis Linked Gene 2 (ALG2) is a 22kDa calcium binding, penta EF hand protein with 
homologs in Drosophila melangoaster, Caenorhabditis elegans, Dictyostelium discoideum  
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and plants [154]. This family of proteins contain five EF hand motifs in their C termini and 
have N termini rich in glycine and hydrophobic residues.  
 
ALG2 was first identified in a screen for genes involved in apoptosis, using a „death trap‟ 
assay in mouse T-cell hybridoma cells [155]. This showed that the knockdown of ALG2 
results  in  increased  resistance  to  apoptosis  induced  by  T-cell  receptor  stimulation, 
staurosporine, and the glucocorticoid dexamethasone. In contrast the over-expression of 
ALG2  in  mouse  fibroblasts  resulted  in  enhanced  sensitivity  to  apoptosis  induced  by  a 
combination of the phorbol ester PMA and the calcium ionophore ionomycin. The function 
of  ALG2  in  apoptosis  is  thought  to  be  downstream  of  the  caspases  or  caspase 
independent, as these enzymes were normally activated in response to cell death-inducing 
stimuli in ALG2 depleted cells.  
 
ALG2  is  known  to  interact  with  several  proteins,  most  notably  with  Alix/AIP1  (ALG2 
Interacting Protein X/ALG2 Interacting Protein 1) in a calcium dependent manner, via a 33 
amino acid stretch within the proline rich C terminus of Alix [156]. Alix has been shown to 
play a vital role in the cell cycle via its interaction with the ESCRT I (Endosomal Sorting 
Complex Required for Transport I) machinery through its binding to Cep55 and CHMP4b 
[157-159]. The ESCRT machinery has been implicated in the final stages of the cell cycle 
at abscission, during which time it is thought ESCRT I recruits ESCRT III to serve as the 
executer of membrane fission between the two daughter cells [158]. Tsg101 is part of the 
ESCRT I complex involved in this process and is known to interact directly with ALG2 in a 
calcium dependent manner [158,160].  
 
The interaction between ALG2 and annexin A11 was first shown by a yeast two-hybrid 
screen and then verified by expression of recombinant proteins and  in vitro interaction 
assays [68]. This interaction was also proven to be calcium dependent and has since been 
demonstrated  in  vivo,  via  the  immunoprecipitation  of  annexin  A11  [personal 
communication, Dr Hideki Shibata, University of Nagoya, Japan]. Both proteins have a 
cytoplasmic  and  nuclear  distribution.  Following  stimulation  with  the  calcium  ionophore 
ionomycin, they have been shown to partially co-localise - not only with each other but also 
with the COP II component Sec31A [personal communication, Dr Hideki Shibata]. Using 
recombinant proteins, a direct interaction has been shown between ALG2 and Sec31A 
[161].   
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Although the functional significance of the interaction of ALG2 with these various proteins 
has not yet been clearly elucidated, a picture is emerging for a role of ALG2 in membrane 
trafficking. 
 
S100A6 
S100A6, also known as calcyclin, belongs to the S100 family of calcium binding proteins, 
all of which comprise two EF hand motifs. It was first identified in Ehrlich ascites tumour 
cells and found to exist as a non-covalent dimer. Several protein interactions involving 
S100A6 have been shown in vitro but have yet to be confirmed in vivo [162]. Some of 
these interactions include the annexins, namely annexins A2, A6 and A11 [139,163] – all 
shown initially via calcyclin affinity chromatography.  
 
Annexin A11 was originally discovered via its calcium dependent interaction with S100A6 
and was so named CAP-50, calcyclin associated protein-50 [139]. It was later shown, via 
the  expression  of  recombinant  proteins,  that  S100A6  binds  the  N  terminal  domain  of 
annexin A11 in vitro [20]. The possibility of this interaction occurring in vivo was previously 
thought to be limited, as they do not co-localise in resting interphase cells. During this time 
annexin  A11  remains  in  the  cytoplasm  and  nucleoplasm  and  S100A6  at  the  nuclear 
envelope [147]. However, a rise in calcium provides an opportunity for them to interact, as 
annexin A11 translocates to the nuclear envelope, a process which naturally occurs at 
prophase [147]. Annexin A11 has since also been shown to co-localise with S100A6 in 
proliferating cells of the mouse embryonic testis, both in the cytoplasm and nucleus [164].  
 
S100A6, like annexin A11, is cell cycle regulated. Its peak expression occurs between G1 
and S phase in smooth muscle cells [165]. In addition, its expression is known to be up-
regulated in several types of cancer, including that of the bile duct [166,167], the pancreas 
[167] and leukocytes [139]. Given these properties it is possible that the S100A6-annexin 
A11 complex may function to regulate the cell cycle.  
 
CHO1  
CHO1  belongs  to  the  kinesin-6  family  of  plus  end  directed  motor  proteins,  previously 
known  as  the  MKLP1  (Mitotic  Kinesin-like  Protein-1)  family  [168],  which  also  includes  
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pavarotti in  Drosophila  melanogaster  [169], zen-4 in Caenorhabditis elegans  [170]  and 
MKLP-1  and  2  in  humans  [171].  CHO1  is  known  to  interact  with  annexin  A11  at 
cytokinesis,  as  shown  by  the  immunoprecipitation  of  endogenous  annexin  A11  from 
synchronised human epidermoid cells [146].  
 
The kinesin-6 family  in  particular  has  been  strongly  implicated  in  cell  cycle  regulation. 
Pavarotti in D.melanogaster has been to shown to be important in oogenesis, where it 
localises  to  ring  canals  –  the  equivalent  of  the  midbody  structure  of  the  mammalian 
cleavage  furrow.  The  expression  of  pavarotti  mutants  in  nuclear  localisation  or  ATP 
binding, leads to sterile ovaries [172]. Zen-4 in C.elegans localises to the mitotic spindle 
and the midbody matrix. When depleted in embryos, embryogenesis proceeds temporarily 
without  completion  of  cytokinesis,  leading  to  multinucleate  cells.  The  end  result  is 
embryonic lethal [170]. zfMKLP1 in D.rerio also localises to the mitotic spindle and the 
midbody matrix. The expression of dominant negative zfMKLP1 in early embryos resulted 
in the failure of cytokinesis and multinucleated blastomeres [173].  
 
This family of proteins is  equally important  in humans.  MKLP2 localises to the central 
spindle and the cleavage furrow on either side of the midbody. Depletion of MKLP2 results 
in the mislocalisation of important cell cycle regulators, including INCENP, Cdc14, Aurora 
B kinase and Plk1 [174,175]. The resulting failure in cytokinesis [175] is a phenotype also 
seen with the depletion of MKLP1. However the defect caused by MKLP1 depletion takes 
effect at a slightly earlier time point in daughter cell separation, whereby furrow ingression 
fails to complete. In cells depleted of MKLP2 furrow ingression does complete, resulting in 
the formation of intercellular bridges. In both cases abscission does not occur and the 
furrow or intercellular bridge regresses, forming binucleate cells [176].  
 
Given  the  established  roles  for  kinesin-6  family  members  in  the  cell  cycle,  it  is  not 
surprising to find that disruption of CHO1, either by mutation, antibody blockade or knock 
down [177,178,178]    perturbs cytokinesis, preventing furrow ingression completion and 
producing binucleate cells. The function of CHO1 during the cell cycle relates to its ability 
to  bind  components  of  the  cytoskeleton.  It  has  been  shown  to  cross  link  anti-parallel 
microtubules  in  vitro  [171],  akin  to  the  overlapping  microtubules  found  at  the  spindle 
midzone  where  CHO1  is  known  to  localise  [178].  It  also  binds  F-actin  and  antibody 
blockade of this F-actin binding domain results in incomplete cytokinesis and formation of  
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multinucleate cells [177]. Though much is known about the role of CHO1 in the cell cycle, 
there is still little understanding of what role CHO1 may play in interphase cells.  
 
1.2.9 Phosphoinositides 
Annexin A11 like all other annexins is capable of binding phospholipids. As previously 
mentioned annexin A11 distribution is regulated during mitosis. It has also been noted that 
several  phosphoinositides  are  temporally  and  spatially  regulated  during  the  cell  cycle 
[179]. Phosphatidylinositol-4,5-bisphosphate (PtdIns4,5P2) in particular accumulates at the 
cleavage furrow. Preventing PtdIns4,5P2 accumulation at the furrow inhibits the completion 
of cytokinesis resulting in multinucleated cells [180]. Furthermore PtdIns4,5P2 hydrolysis at 
the  furrow  has  been  shown  to  be  necessary  for  the  completion  of  cytokinesis  [181]. 
PtdIns4,5P2 has also been proposed to be important in maintaining the tight association 
between the plasma membrane and the midbody during the final stages of cytokinesis 
[182]. Annexin A11 is suggested to interact with a range of specific phosphoinositides, as 
detected  via  an  in  vitro  PIP  (phosphatidylinositol  phosphate)  strip  assay  [146].  In  the 
presence of calcium, this assay demonstrated the ability of annexin A11 to strongly bind 
phosphatidylinositol,  phosphatidylinositol-3-phosphate,  phosphatidylinositol-4-phosphate, 
phosphatidylinositol-5-phosphate,  phosphatidylinositol-3,4-bisphosphate, 
phosphatidylinositol-3,5-bisphosphate and also to a lesser extent phosphatidylinositol-4,5-
bisphosphate  (PtdIns4,5P2)  [146].  The  ability  to  associate  with  PtdIns4,5P2  may  be  of 
particular relevance at cytokinesis.  
 
The  binding  of  annexin  A11  to  phospholipids  has  been  shown  to  be  phosphorylation 
dependent,  with  phosphorylated  annexin  A11  having  a  reduced  affinity  for  
phosphatidylserine  (PS)  binding  in  v-src  transformed  rat  embryonic  fibroblasts  [153]. 
Annexin A11 is not only phosphorylated on serine/threonine residues in response to v-src, 
but also on tyrosine residues in response to platelet-derived growth factor (PDGF). The 
effect of tyrosine phosphorylation on phospholipid binding is however unknown.  
 
1.2.10 The Immune System 
Several groups have identified annexin A11 expression in cells of the immune system, 
such as macrophages [183,184], neutrophils [185] and T cells [186]. Annexin A11 is also  
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highly expressed in dendritic cells and monocytes (Figure 7). In neutrophils, it has been 
found to translocate from the cytosol to granule membranes in vitro [185] and to localise to 
periphagosomal regions during phagocytosis [187]. It is therefore speculated that annexin 
A11 may affect neutrophil mediated immune responses by regulating phagocytosis. A role 
in phagocytosis is also implied in macrophages, where annexin A11 has been shown to 
localise  to  phagosomes,  using  subcellular  fractionation  before  and  after  phagocytosis 
stimulation [188].  
 
The importance of annexin A11 in normal immune responses is highlighted by the fact that 
autoantibodies against this protein have been identified in several autoimmune diseases, 
where the balance between self and non-self immune responses is disrupted. Autoimmune 
diseases identified with this characteristic include systemic lupus erythematosus (SLE), 
rheumatoid  arthritis,  Sjorgens  syndrome,  Raynauds  disease  and  polymyisitis  [189]. 
Several of these diseases, such as Sjorgens syndrome, rheumatioid arthritis and SLE are 
more prevalent in women. Changing oestrogen levels are believed to affect the immune 
response  and  it  has  been  shown  that  annexin  A11  mRNA  levels  are  increased  in 
oestrogen pre-treated macrophages, following withdrawal of this hormone [190].   
 
1.2.11 Disease  
The significance of annexin A11 in disease pathology is unclear. However, as described 
above, annexin A11 is suggested to have a role in the immune system and possibly in a 
number of autoimmune diseases. In addition to this, the involvement of annexin A11 has 
been alluded to in retinal diseases such as age-related macular degeneration (AMD) [191] 
and proliferative vitreoretinopathy (PVR) [192]. This is due to its detection in Drusen, a 
collection  of  extracellular  aggregates  within  the  retina,  as  well  as  its  expression  in 
dedifferentiated, cultured human retinal pigment epithelial (RPE) cells. 
 
One of the most notable suggestions for the involvement of annexin A11 in disease is in 
sarcoidosis. Sarcoidosis is a systemic immune disorder with a phenotype of epithelioid 
granulomas, which result in the accumulation of lesions affecting many organs, such as 
the lungs, kidney, skin and eyes. A recent genome-wide study of a set of German patients 
and control subjects, identified a single nucleotide polymorphism (SNP) in annexin A11 as 
the most highly associated susceptibility locus [193]. Further investigation of annexin A11  
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in control subjects demonstrated that annexin A11 mRNA was expressed in a range of 
immune  cells  and  was  strikingly  decreased  in  activated  CD8  and  CD19  positive  cells 
compared to their resting counterparts. The cause and mechanism of this disease is not 
well understood and it may be that annexin A11 has a role in its initiation. It is speculated 
that it may be through an effect on apoptosis or perhaps through altering the fine balance 
of signalling between immune cells like CD8 and CD19 lymphocytes.   
 
More recent work has also uncovered a role for annexin A11 in ovarian cancer. Annexin 
A11 was found to be differentially expressed in ovarian cancer cell lines that were either 
sensitive or resistant to the anti-cancer drug, cisplatin. This was detected through antibody 
microarrays and confirmed through immunoblotting, as well as immunohistochemistry of 
tissue samples [194]. Autoantibodies against annexin A11 have also been shown to be 
significantly raised in primary ovarian cancer patients, with a smaller proportion of patients 
with recurrent tumours also showing raised levels [195]. This appeared to be specific to 
ovarian cancer as no significant difference was detected in patients with colon, breast, 
pancreatic and prostate cancer or diabetes.  Further work demonstrated that the knock 
down of annexin A11 negatively regulated the proliferation of ovarian cancer cell lines and 
conferred resistance to cisplatin [196]. This collection of studies strongly suggests a role 
for annexin A11 in ovarian cancer pathology. 
 
1.2.12 Membrane Fusion 
Annexin  A11  has  been  shown  to  be  present  in  the  outer  acrosomal  membrane  of 
spermatozoa  in  the  presence  of  calcium,  suggesting  a  possible  involvement  in  the 
acrosomal reaction. During this reaction the acrosomal membrane fuses with the plasma 
membrane  and  releases  acrosomal  enzymes,  allowing  penetration  of  the  ova  by  the 
spermatozoa [197].  
 
Annexin A11 is also speculated to be involved in membrane fusion events in pancreatic β 
cells. Annexin A11 was shown by immunofluorescence to be present in the cytoplasm of 
pancreatic endocrine cells and in the pancreatic β cell line MIN6.  Electronmicroscopy of 
MIN6 cells revealed annexin A11 to be in insulin granules. Furthermore treatment of these 
cells  with  anti-annexin  A11  antibodies  inhibited  calcium  and  GTP-γS  induced  insulin 
secretion [198].  
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1.2.13 Therapy 
Annexin A11 has been investigated as a possible therapeutic tool, whereby it is fused to 
staphylokinase  (SAK),  a  fibrin-selective  thrombolytic  protein.  By  exploiting  the 
phosphatidylserine (PS)  binding  ability of annexin A11  it  has been suggested that  this 
fusion protein could be used to resolve blood clots, as activated platelets expose PS in 
their membranes [199].  
 
1.3 Thesis Aims 
Annexin A11 was first identified over 25 years ago, however not much is known about its 
physiological  activity  within  the  cell.  In  more  recent  years functional  associations  have 
been suggested with the cell cycle [150] and the autoimmune diseased state [193].  
 
This  thesis  aims  to  investigate  the  role  of  annexin  A11  in  sarcoidosis,  a  granuloma 
associated autoimmune disease. The role of annexin A11 in the cell cycle shall also be 
further elucidated, both with regards to its distribution and to its function at cytokinesis with 
the motor protein MKLP1/CHO1. In addition to published links within the aforementioned 
fields,  the  cellular  distribution  of  annexin  A11  shall  be  characterised  with  the  view  to 
uncovering  previously  unknown  localisations  to  better  understand  its  role  during  both 
mitosis and interphase.  
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Chapter Two: 
Materials and Methods  
-55- 
2. Materials and Methods 
 
2.1 Cell Culture 
HeLa  (human  cervix  adenocarcinoma),  A431  (human  epidermoid  carcinoma),  ARPE19 
(human retinal pigment epithelium) and CaCo-2 (human colorectal adenocarinoma) cells 
were  cultured  in  DMEM  (Dulbeccos  minimal  essential  media,  Gibco)  with  10%  heat-
inactivated FCS, 100IU/ml penicillin, 100g/ml streptomycin and 292g/ml L-glutamine and 
incubated at 37C with 5% CO2.  
 
2.2 Cell Synchronisation 
Cells  were  plated  at  30%  confluency.  The  next  day  cells  were  incubated  in  media 
containing 5mM thymidine (Sigma) to cause cell cycle arrest in early S phase. This was 
carried out overnight for 16h. Cells were then washed in PBS three times and released 
into  media  containing  100ng/ml  nocodazole  for  7h,  resulting  in  a  prometaphase  block. 
Alternatively,  unsynchronised  cells  were  incubated  overnight  in  100µM  monastrol, 
producing a prometaphase block. Prometaphase arrested cells were then washed in PBS 
three times and released into fresh media. Cells were fixed and permeabilised at 0, 15, 30, 
45  and  60min  post  release,  using  4%  paraformaldehyde  (PFA)  for  10min  at  room 
temperature or -20˚C methanol for 5min. 
 
2.3 Polymerase Chain Reactions 
PCR primers used were designed using online resources [200,201] (see table 1).  
 
Primer 
 
Orientation 
 
Species  Sequence 
 
Use 
 
A11  R230C 
F 
Forward  Human  GACTGCCTGGGGAGTTGCTCC
AACAAGCAGCGG 
Annexin  A11  Mutagenesis 
(production of R230C mutant) 
A11  R230C 
R 
Reverse  Human  GCTGCTTGTTGGAGCAACTCC
CCAGGCAGTC 
Annexin  A11  Mutagenesis 
(production of R230C mutant) 
A11  R230C 
Seq 
Forward  Human  CCCAGTTTGGAAGCCGAGGC  Annexin  A11  Sequencing  of  R230C 
site 
A11 cDNA F  Forward  Human  GGGCCATGGG  TATGAGCTAC 
CCTGGCTATC C  Annexin A11 cDNA amplification 
A11 cDNA R  Reverse  Human  CCCGGATCCT  GGTCATTGCC 
ACCACAGATC TTCAG  Annexin A11 cDNA amplification 
    Table 1 Primers Used for PCR Reactions  
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PCR reactions were performed using Platinum Pfx (Invitrogen) with dNTP mixes (Bioline) 
in a Mastercycler Gradient (Eppendorf). PCR products were analysed by electrophoresis 
using  ethidium  bromide-containing  agarose  gels  (0.8%  in  TAE  buffer,  National 
Diagnostics) and imaged using a Syngene Transilluminator. The DNA was gel extracted 
using a QIAquick Gel Extraction Kit (QIAGEN). 
 
2.4 Plasmid Construction 
The  purified  PCR  products  were  cloned  into  TOPO  vectors  using  a  TOPO  cloning  kit 
(Invitrogen).  The  constructs  were  then  digested  using  the  appropriate  restriction 
endonuclease (New England Biolabs) and ligated into the necessary vector using T4 DNA 
ligase (New England Biolabs) (see table 2).   
 
Plasmid 
 
Vector  Insert  Cloning Kit (Invitrogen) 
 
GST-A11  pGEX-4T-2 (Amersham)  Human annexin A11 full length 
coding sequence  TOPO TA Cloning Kit * 
A11-GFP  pEGFP-N1 (Clontech)  Human annexin A11 full length 
coding sequence  TOPO TA Cloning Kit * 
A11-Nt-GFP  pEGFP-N1 (Clontech)  Human  annexin  A11  N 
terminal  TOPO TA Cloning Kit * 
A11-Ct-GFP  pEGFP-C3 (Clontech)  Human  annexin  A11  C 
terminal  TOPO TA Cloning Kit * 
A11-R230C-GFP 
pEGFP-C3 (Clontech)  Human annexin A11 full length 
coding  sequence  with  R230C 
mutation 
Stratagene  Quikchange  II 
Site-Directed  Mutagenesis 
Kit 
A11-Ct-R230C-GFP 
pEGFP-C3 (Clontech)  Human  annexin  A11  C 
terminal with R230C mutation 
Stratagene  Quikchange  II 
Site-Directed  Mutagenesis 
Kit 
 
Table 2 Plasmids, Vectors and Inserts Used 
* Made by Dr Alejandra Tomas 
  
2.5 Site Directed Mutagenesis 
Site directed mutagenesis was carried out in plasmids containing the desired gene insert. 
Single  amino  acid  changes  were  made  using  two  oligonucleotide  primers  which  were 
complimentary to the target gene, but were designed to contain the appropriate mutation in 
the middle of the primer. PCR reactions were carried out using 125ng of each primer, 50ng 
of the plasmid containing the gene insert, dNTP mix and Platinum Pfx (Invitrogen) in a 50μl 
volume.  The  PCR  reaction  was  performed  for  18  cycles  of  30s  at  95˚C  (to  separate  
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template strands), 1min at 55˚C (to anneal the primers) and finally 4min at 68˚C (to extend 
from the primers). The reaction was then cooled to 4˚C and digested at 37˚C for 1h with 
1μl  Dpn1  to  remove  the  parental  methylated  and  hemimethylated  DNA.  15μl  of  this 
reaction was transformed into competent XL-1 Blue E.coli. 
 
2.6 Plasmid Amplification 
Plasmids were transformed into chemically competent bacteria and grown overnight in LB 
broth (Fisher Scientific) with the appropriate selective antibiotic (50g/ml kanamycin or 
ampicillin)  at  37C in a shaking incubator. Plasmids were then purified using QIAGEN 
Plasmid  Mini,  Midi  or  Maxi  kits,  depending  on  the  volume  of  culture grown.  0.75ml of 
bacterial culture was kept aside to which 0.25ml of glycerol was added to make a glycerol 
stock, stored at -80C.  
 
DNA concentrations of the purified plasmids were determined using absorbance readings 
measured by a BioPhotometer (Eppendorf). 
 
2.7 Transient Transfections 
Cells were plated at 50% confluency on 35mm glass bottomed microwell dishes (MatTek) 
in DMEM containing 10% heat-inactivated FCS without antibiotics. Following an overnight 
incubation at 37C with 5% CO2 the cells were transfected. Cells were transfected with 
3g of plasmid DNA using 9l of TransIt LT1 transfection reagent (Mirus). 9l of TransIt 
LT1  transfection  reagent  (Mirus)  was  incubated  with  DMEM  containing  10%  heat-
inactivated FCS without antibiotics, for 15min at room temperature. 3g of plasmid DNA 
was then added to this solution and incubated for a further 30min at room temperature. 
The volume of DMEM used in the transfection complex was such that the total volume 
reached 100l. 
 
2.8 Immunofluorescence Analysis and Fluorescence Probes 
Cells were fixed using 4% paraformaldehyde (PFA) for 20min at room temperature and 
then permeabilised for 10min at room temperature with 0.2% Triton in PBS. Alternatively 
cells were fixed using pre-chilled methanol for 5min at -20˚C and then rehydrated at room  
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temperature  by  incubating  three  times  with  PBS  for  15min.  Next  cells  were  put  into 
blocking solution of 1% BSA in PBS, for 30min at room temperature.  
 
Cells were then incubated with primary antibody (see table 3) made up in 1% BSA in PBS 
(Sigma) overnight at 4˚C. Following three washes with PBS the cells were incubated with 
secondary antibody made up in 1% BSA in PBS for 1h at room temperature (see table 3). 
Cells  in  35mm  glass  bottomed  microwell  dishes  were  then  mounted  with  Vectashield 
mounting medium (VectorShield Laboratories).  
 
Primary Antibody 
 
Target  Species  Source  Dilution 
 
L-19  Annexin A11  Goat anti human  Santa Cruz Biotech  1/50 
MKLP1  MKLP1  Rabbit anti human  Santa Cruz Biotech  1/100 
Alpha Tubulin   -tubulin  Mouse anti human  Zymed  1/50 
PLK1  P1k1  Rabbit anti mouse  Abcam  1/1000 
INCENP  INCENP  Rabbit anti human  Abcam  1/1000 
Aurora B  Aurora B  Rabbit anti human  Abcam  1/1000 
HH7  Annexin A2  Rabbit anti human  *  1/60 
N-19  Annexin A7  Goat anti human  Santa Cruz Biotech  1/100 
Pericentrin  Pericentrin  A 
and B  Rabbit anti mouse  Abcam  1/1000 
γ tubulin  γ tubulin  Rabbit anti human  *
2  1/1000 
Secondary Antibody 
 
Target  Species  Source  Dilution 
 
Anti goat Alexa 488    Donkey  Molecular Probes  1/500 
Anti rabbit Alexa 647    Donkey  Molecular Probes  1/500 
Anti mouse Alexa 555    Donkey  Molecular Probes  1/500 
 
Table 3 Primary and Secondary Antibodies Used for Immunofluorescence 
* Kind gift from Gift from Prof Volke Gerke, Westfalische Wilhelms-Universitat Munster, Germany 
*
2 Kind gift from Prof Karl Matter, Institute of Ophthalmology, UCL 
 
Cells were visualised using an inverted Leica TCS SP2 AOBS confocal microscope using 
a  63x  oil/water  immersion  lense.  Images  were  analysed  and  processed  using  Leica 
Confocal Software Version 2.6.1 and Zeiss LSM Image Browser Version 4.2.0.121. 
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2.9 Live Confocal Imaging and Calcium Imaging 
Cells were transfected with the appropriate construct and incubated overnight at 37C with 
5% CO2 in DMEM containing 10% heat-inactivated FCS without antibiotics. Cells were 
then washed once in DMEM without phenol red (Invitrogen) and imaged in DMEM without 
phenol red at 37C on an inverted Leica TCS SP2 AOBS confocal microscope. 
 
For calcium  imaging,  following a single wash in DMEM  without  phenol red,  cells were 
incubated with 5µM Fura Red AM in DMEM without phenol red for 30min at 30C and then 
30min 37C. Cells were washed three times in DMEM without phenol red and imaged in 
DMEM without phenol red. Images were analysed and processed using Leica Confocal 
Software Version 2.6.1 and Zeiss LSM Image Browser Version 4.2.0.121. 
 
2.10 Polyacrylamide Gel Electrophoresis 
Gels for SDS-PAGE were made using Acrylamide/Bis-Acrylamide (Sigma), Tris-HCl and 
10% SDS and were polymerised using TEMED (Sigma) and 10% APS. 10% acrylamide 
was used in the resolving gel and 4% in the stacking gel. Samples were boiled in SDS-
PAGE buffer before loading. The gels were run at 80V for the first 5min and then at 150V 
until the molecular weight ladder (BenchMark protein ladder, Invitrogen) had run the entire 
length of the gel.  
 
The gels were transferred onto Hybond PVDF Transfer membrane (Amersham) for 45min 
at 150mA per gel for Western blotting.  
 
2.11 Western Blotting 
Following transfer of the proteins to PVDF, membranes were blocked with 8% milk for 1h. 
Primary antibody also made up in 8% milk was then added and incubated overnight at 4C 
on an orbital shaker (see table 3). The membranes were washed three times in PBS + 
0.05% Tween for 10min each. Secondary HRP conjugated antibody made up in 8% milk 
was then added and incubated at room temperature on an orbital shaker for 1h (see table 
4). Following three PBS washes for 10min each, membranes were imaged using the ECL 
Western blotting detection system (GE Healthcare).  
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For  Western  blotting  against  phosphotyrosine-containing  proteins,  membranes  were 
blocked with 5% BSA in TBS for 1h. Primary antibody also made up in 5% BSA in TBS 
was then added and incubated overnight at 4C on an orbital shaker (see table 3). The 
membranes  were  washed  3  three  times  in  TBS  +  0.05%  Tween  for  10min  each. 
Secondary HRP conjugated antibody made up in 5% BSA in TBS was then added and 
incubated at room temperature on an orbital shaker for 1h (see table 4). Following three 
TBS washes for 10min each, membranes were imaged as above. 
 
Primary Antibody 
 
Target  Species  Source  Dilution 
 
L-19  Annexin A11  Goat anti human  Santa Cruz Biotech  1/200 
MKLP1  MKLP1  Rabbit anti human  Santa Cruz Biotech  1/100 
Alpha Tubulin   -tubulin  Mouse anti human  Zymed  1/1000 
HH7  Annexin A2  Mouse anti human  *  1/60 
ALG-2  ALG-2  Rabbit anti mouse  *
2  1/500 
4G10  phosphotyros
ine 
Mouse anti  human  Millipore  (Upstate 
Biotechonology)  1/1000 
EGFR  EGF receptor  Sheep anti human  Fitzgerald  Industries 
International  1/2000 
Secondary Antibody 
 
Target  Species  Source  Dilution 
 
HRP Goat anti rabbit  Rabbit  Goat  Dako  1/2000 
HRP Rabbit anti goat  Goat  Rabbit  Dako  1/2000 
HRP Goat anti mouse  Mouse  Goat  Dako  1/2000 
HRP Donkey anti sheep  Sheep  Donkey  Dako  1/2000 
 
Table 4 Primary and Secondary Antibodies Used for Western Blotting 
* Kind gift from Prof Volker Gerke, Westfalische Wilhelms-Universitat Munster, Germany  
*
2 Kind gift from Dr Hideki Shibata, Nagoya University, Japan 
 
2.12 Production of GST Fusion Proteins 
Plasmids  encoding  the  GST  fusion  proteins  were  transformed  into  BL21  bacteria  and 
grown  overnight  in  LB  broth  (Fisher  Scienific)  with  the  appropriate  selective  antibiotic 
(50g/ml kanamycin or ampicillin) at 37C in a shaking incubator. The initial starter culture 
of 20ml LB broth was then expanded to 200ml and grown until the OD, measured using a 
BioPhotometer (Eppendorf), was 0.8. The culture was then cooled to 27C in a shaking 
incubator for 1h, after which recombinant protein expression was induced with 1mM IPTG  
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(Invitrogen). Cultures were grown for another 4h at 27C.   
 
The cultures were centrifuged at 5000rpm for 15min at 4C. To obtain the protein, the 
pellets were resuspended in 20ml of cold resuspension buffer (1% Triton X-100, 1mg/ml 
lysozyme,  protease  inhibitors  (Sigma)  in  PBS).  1mM  EDTA  was  included  in  the  buffer 
when  obtaining  annexin  A11  GST  fusions,  in  order  to  chelate  the  calcium  to  prevent 
annexin  binding  to  cell  membranes.  The  resuspended  solution  was  then  thoroughly 
vortexed  and  sonicated  six  times  for  10s  each.  The  solutions  were  centrifuged  at 
10000rpm for 15 min at 4C. The supernatants were aliquoted and frozen at -80C for later 
use.  
 
2.13 GST Fusion Protein Pulldown Assays 
GST fusion proteins were first bound to glutathione beads (Sigma). A 1.5ml aliquot of 
previously purified GST fusion protein was incubated with 200l of 50% glutathione bead 
slurry for 2h at 4C on a rotator. The slurry was made up in lysis buffer containing protease 
inhibitors  (Sigma),  which  from  this  point  onwards  lacked  calcium  chelators  in  order  to 
facilitate  any  possible  annexin  A11  interactions.  Lysis  buffer  was  composed  of  10mM 
HEPES,  142.5mM  potassium  chloride,  0.2%  NP40,  100M  CaCl2,  2.5mM  sodium 
pyrophosphate, 1mM  glycerol phosphate and 1mM sodium orthovanadate. The beads, 
now bound to the GST fusion protein, were spun down at 9000rpm at 4C for 3min. The 
pellet  was  washed  three  times  in  1ml  PBS  +  0.03%  Tween  (Sigma)  with  protease 
inhibitors. To perform the pulldown the pellet was then incubated with whole cell lysate 
(from ~6x10
6 cells) containing protease inhibitors for 2h at 4C on a rotator. The beads 
were  spun  down  and  supernatants  kept.  The  beads  were  washed  with  lysis  buffer 
containing  protease  inhibitors  three  times.  Both  the  pellet  and  the  supernatants  were 
boiled with SDS-PAGE buffer, containing DTT (Sigma) for reduction. The samples were 
frozen at -20C and stored for later use in SDS-PAGE.  
 
2.14 Immunoprecipitation 
In  order  to  immunoprecipitate  specific  proteins  from  whole  cell  lysates,  Protein  G 
Sepharose beads (Sigma) were first bound to the appropriate antibody. This was done by 
incubating  30l  of  50%  bead  slurry,  made  up  in  lysis  buffer,  with  1g  of the  required  
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antibody, overnight at 4C on a rotator. Lysis buffer was composed of 10mM HEPES, 
142.5mM potassium chloride, 0.2% NP40, 100M CaCl2, 2.5mM sodium pyrophosphate, 
1mM  glycerol phosphate and 1mM sodium orthovanadate. The following day cells were 
lysed (in lysis buffer containing protease inhibitors, Sigma) and incubated with preclearing 
beads (30l of 50% bead slurry) on ice for 30min. The cell lysates were spun down at 
9000rpm for 5min at 4C. The previously antibody bound beads were also spun down and 
washed with lysis buffer. The supernatants from the centrifuged cell lysates were added to 
the antibody bound beads and incubated for 2h on a rotator at 4C.  
 
Following incubation, the reactions were spun  down at  9000rpm  at  4C for  3min. The 
supernatants were kept and boiled for 10min with an equal amount of SDS-PAGE buffer, 
containing  DTT  for  reduction.  The  pellets  were  washed  with  lysis  buffer  containing 
protease inhibitors (Sigma) four times and then resuspended in 60l SDS PAGE buffer, 
containing DTT for reduction and boiled for 10min. Samples were stored at -20C for later 
use. 
 
2.15 DSP Treatment 
In  order  to  stabilise  weak  protein-protein  interactions  prior  to  immunoprecipitation 
experiments, cells were treated with DSP (dithiodipropionic acid di(N-hydroxysuccinimide 
ester)) (Sigma), which couples molecules containing primary amines by the formation of 
amine bonds. Plated cells were washed thoroughly with PBS three times to remove any 
amines present in the media. Cells were then incubated in a crosslinking solution (50mM 
triethanolamine, 1.25M sucrose, 10mM CaCl2) containing 1mM DSP at room temperature 
for  30min.  This  solution  was  removed  and  the  cells  washed  once  in  blocking  solution 
(50mM triethanolamine, 1.25M sucrose, 10mM CaCl2, 250mM ethanolamine). Cells were 
then incubated in fresh blocking solution, twice, for 15min each time. Next the cells were 
washed three times in PBS and harvested by scraping the cells off and then centrifugation. 
The cell pellet was resuspended in lysis buffer containing protease inhibitors, sonicated for 
30s and centrifuged at 13,000rpm to remove any debris. The supernatant was removed 
and subjected to immunoprecipitation. 
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2.16 RNA Interference and Transfection of siRNA  
Commercially available annexin A11 siRNA was obtained (Dharmacon) and resuspended 
as per the instructions provided to a concentration of 20M. Aliquots were stored at -20C.  
 
Cells were plated at 30% confluency on 35mm glass bottomed microwell dishes (MatTek) 
in DMEM containing 10% heat-inactivated FCS without antibiotics. Following an overnight 
incubation at 37C with 5% CO2 the cells were transfected. For each dish, 8l of 20M 
annexin A11 siRNA was incubated with 152l of OptiMEM 1 medium (Gibco) and 5l of 
Oligofectamine (Invitrogen) was incubated with 35l of OptiMEM 1 medium. After a 15min 
incubation at room temperature the two solutions were mixed and left for a further 30min 
incubation at room temperature. The final solution was then added drop wise to the cells 
and left to incubate overnight. Cells were then transfected again a day later, with a second 
dose  of  siRNA  in  the  same  way.  Control  cells  were  treated  in  the  same  way  but 
transfected with 20µM mammalian All Star negative control siRNA (Qiagen). 
 
Cells were either fixed and permeabilised for staining and microscopy or lysed and boiled 
for 10min in a heating block with an equal volume of 2X SDS PAGE buffer for SDS PAGE. 
 
2.17 Silver Staining of Polyacrylamide Gels 
SDS PAGE gels were first fixed for 30min in 50% methanol/10% acetic acid solution and 
then in 5% methanol/7% acetic acid for another 30min. They were then rinsed twice in 
water  for  15min  each.  The  gels  were  sensitised  for  1min  in  sodium  thiosulphate 
(20mg/100ml),  rinsed  twice  in  water  for  2min  each  and  then  incubated  in  0.2% 
AgNO3/1mM formaldehyde. Gels were washed again in water for 1min and then developed 
in 6% Na2CO3/6mM formaldehyde. This reaction was stopped with 2.3M citric acid.  
 
2.18 Microtubule Co-sedimentation Assay 
Cells were harvested and lysed using a cell scraper in Brinkleys Buffer (BRB80; 80mM 
PIPES, 1mM MgCl2) containing protease inhibitors and 0.2% Triton X-100. Cells were then 
clarified by centrifugation at  165000g  for 20min  at  4˚C. The resulting supernatant was 
incubated  at  33˚C  with  2mM  GTP,  2mM  MgCl2  and  20µM  taxol  for  30min.  Control 
supernatants were incubated without taxol. 1.5mM AMP-PNP was then added and the  
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supernatants incubated for a further 20min at 33˚C. The samples were then spun through 
an equal volume of a 15% sucrose cushion at 165000g for 20min at 25˚C. The pellets 
were resuspended in 2X SDS PAGE buffer and boiled for 10min. The supernatants were 
collected and mixed with a greater volume of -20˚C acetone and centrifuged at 13,000rpm 
for 2min. The resulting supernatants were discarded and the pellets resuspended in 2X 
SDS PAGE buffer and boiled for 10min.  
 
2.19 RNA Isolation and cDNA Production 
Cells at 100% confluency in a T25 flask were washed twice with PBS. RNA was then 
isolated using the RNeasy kit (Qiagen). Following treatment of the cells in buffer RLT, as 
described in the Qiagen RNeasy kit protocol, cells were passed through a QIAshredder 
(Qiagen),  before  continuing  with  the  RNeasy  kit  protocol.  The  isolated  RNA  was  then 
DNase treated using amplification grade deoxyribonuclease I (Invitrogen), according to the 
manufacturers instructions. The resulting DNA-free RNA was reverse transcribed using the 
Roche Transcriptor High Fidelity cDNA Synthesis Sample Kit (Roche), according to the 
manufacturers instructions.  
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3.  Results:  Study  of  the  Annexin  A11  Sarcoidosis  Associated 
Mutant 
 
Sarcoidosis is a multisystem immune disorder, which results in the formation of epitheloid 
granulomas throughout the body, particularly affecting the lungs, eyes and skin.  It was 
first identified in 1869 by Jonathan Hutchinson and later named by Carl Boeck, both of 
whom initially recognised the dermatological symptoms of the disease [202].  
 
The immune systems of affected individuals show a delayed hypersensitivity response to 
skin tests, as well as a reduced number of lymphocytes in circulating blood. In contrast 
patients show an increase in CD3 and CD4 positive T cells in the lungs. Activated T cells 
from sarcoid lungs also overexpress several receptors, including interleukin-2 receptor (IL-
2R), and produce increased amounts of cytokines, including interleukin-2 (IL-2) [203] and 
interferon-γ (IFNγ) [204]. Moreover interferon-α (IFNα) induced production of IFNγ and IL-2 
has been reported to stimulate the development of sarcoidosis [205].  
 
Monocytes  and  macrophages  are  also  heavily  involved  in  the  formation  of  sarcoid 
granulomas [206].  Alveolar macrophages secrete a range of cytokines, including tumour 
necrosis factor α (TNFα) which is a current target for therapy, as increased production of 
TNFα has been associated with sarcoidosis [207]. In particular alveolar macrophages from 
sarcoidosis  patients  secrete  interleukin-15,  which  has  been  shown  to  bind  IL-2R  and 
induce T cell proliferation [208].  
 
Given the complex nature of the immune pathways involved and the interplay between 
different immune cell types, understanding the aetiology of sarcoidosis has proven difficult. 
However a working hypothesis of granuloma formation has emerged, whereby formation is 
initiated by antigen presentation to macrophages. Initially a phagosome is unable to form, 
resulting  in  „frustrated  phagocytosis‟.  Once  the  phagosome  does  form  the  antigen  is 
processed via the MHC class II (major histocompatibility complex class II) pathway, where 
it is degraded in lysosomes and presented on the cell surface by MHC class II proteins to 
T cells (Figure 8). CD4 positive T cells specific to this antigen proliferate and accumulate 
at the site of inflammation. If the initial immune response is too strong then eosinophils and 
neutrophils  may  also  be  recruited  here.  At  this  point  the  cocktail  of  cytokines  present  
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determine the lifespan of the granuloma [209].  
 
 
 
Figure 8 MHC Class II Pathway 
In the MHC class II pathway, once an antigen is phagocytosed by a macrophage, the endosomes containing 
the engulfed antigen fuse with lysosomes. Acid proteases within the endo-lysosomes degrade the antigen into 
short peptides. The endo-lysosomes then fuse with the MHC class II compartment, where the peptides are 
loaded onto MHC class II molecules. Vesicles containing peptide loaded MHC class II molecules are trafficked 
to and fuse with the plasma membrane. The cell is then able to present the processed antigen to CD4 positive 
T cells. 
 
The initiating antigen in this process is unknown, though viral and bacterial involvement 
have been speculated [210]. A better picture is however emerging for the genetic factors 
linked to susceptibility to sarcoidosis. Familial linkage studies, where regions containing 
alleles more commonly shared between affected family members were sought, uncovered 
the butyrophilin-like 2 (BTNL2) gene. BTNL2 lies within the MHC class II region and is a 
member of the B7 receptor family. It is thought to act as a costimulatory molecule for T cell 
activation.  
 
The SNP in BTNL2 causes a premature stop codon, producing a truncated protein with 
functional deficits, as it can no longer localise to membranes. Truncation of another B7 
family member, B7-1, in mice produced a proinflammatory effect. Therefore the BTNL2 
truncation may act in a similar manner, favouring pathological immune responses, as seen 
in sarcoidosis [211]. However the BTNL2 gene lies close to the human leukocyte antigen  
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DRB1 (HLA-DRB1) gene and shows a high likelihood (high linkage disequilibrium) of being 
inherited together with HLA-DBR1 [212]. Therefore it may be the HLA class II genes, like 
HLA-DRB1, that increase susceptibility to sarcoidosis.  
 
Several HLA genes have been implicated in association studies, with the suggestion that 
these  mutant  HLA  proteins  present  antigen  to  T  cells  in  a  manner  that  induces  a 
pathological immune response. These include both HLA class I genes, such as HLA-B7 
and B8, as well as HLA class II genes which are known to be upregulated on alveolar 
macrophages from sarcoidosis patients [212]. Thus far the focus on susceptibility genes 
has been restricted to MHC proteins. However a recent study has identified a non-MHC 
protein, namely annexin A11. 
 
The identification of annexin A11 was the result of a genome wide association study, using 
500 control and disease presenting individuals from a German population in order to find 
novel  genetic  markers  for  sarcoidosis.  Several  disease  associated  single  nucleotide 
polymorphisms  (SNPs)  were  found,  including  those  in  HLA  loci  and  the  BTNL2  gene, 
confirming previous work. Excluding these known areas of association, an individual SNP 
within the annexin A11 gene produced the highest association signal, alongside five other 
neighbouring  SNPs  within  this  haplotype  that  were  also  strongly  associated  with 
sarcoidosis [193]. Two alleles for annexin A11 were identified with differing rates of homo- 
and  heterozygosity  among  controls  and  sarcoidosis  patients.  The  distribution  of  the 
sarcoidosis associated SNP within these different alleles is as yet unknown.  
 
The non-synonymous SNP in annexin A11 results in the switch of a basic arginine to a 
polar  cysteine,  within  the  highly  conserved  region  of  the  first  annexin  repeat  in  the  C 
terminus. This SNP had previously been detected in a bioinformatic analysis of the human 
genome  for  non-synonymous  mutations  and  was  noted  as  an  SNP  likely  to  have  a 
deleterious  effect  [213].  Immunohistochemistry  of  control  and  sarcoidosis  patient  lung 
tissue  showed  no  difference  in  annexin  A11  expression;  expression  being  nuclear  in 
epithelial and mononuclear cells and within cilia of bronchial epithelial cells. Annexin A11 
mRNA was found to be expressed in CD4, CD8, CD14 and CD19 positive immune cells. 
Interestingly  in  control  individuals  annexin  A11  mRNA  expression  was  significantly 
reduced in active CD8 and CD19 positive cells compared to those at rest [193]. Whether 
this would also be true of the SNP variant is unknown.   
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The mechanism of action of annexin A11 in sarcoidosis is as yet unidentified. However a 
role in regulating apoptosis has been speculated and may have significance as a means of 
granuloma resolution [155]. In this context, annexin A11 is known to bind calcyclin and 
ALG-2, both of which are implicated in regulating apoptosis in caspase dependent and 
independent pathways, respectively [155,214].  
 
3.1 Characterisation of the Annexin A11 Single Nucleotide Polymorphism 
The single nucleotide polymorphism in annexin A11 which is associated with sarcoidosis 
was found in a genome wide study of a German population [155]. This study identified a 
substitution mutation, in exon 6 of the human annexin A11 gene, of a cytosine to a thymine 
(Figure 9B). This altered the codon from a basic arginine to a polar cysteine, at residue 
230. The R230C mutation is in the C terminal domain of annexin A11, within the first 14 
residues  of  the  first  annexin  repeat  (Figure  9A).  Analysis  of  the  protein  sequence  of 
annexin A11 in both vertebrates and invertebrates shows a high degree of homology in the 
regions flanking the mutated site, between species as distant as humans and zebrafish 
(Figure 9C). The annexin repeats are important domains required for the calcium binding 
properties  of  the  annexins.  A  mutation  in  this  region  could  therefore  have  significant 
functional consequences. In order to investigate this, first the distribution of the annexin 
A11
R230C was examined.  
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Figure 9 Annexin A11 Sarcoidosis Associated Single Nucleotide Polymorphism 
(A)  Full  length  wild  type  human  annexin  A11  protein  sequence.  N  terminal  domain  residues  (grey  box). 
Annexin repeats (bold). The sarcoidosis associated SNP results in a change in a single amino acid (red box) 
(B) Schematic of annexin A11, showing the mutation (arrow) lies within the first annexin repeat. Shown below 
is the nucleotide sequence of  the human wildtype and sarcoidosis associated SNP (red box) and flanking 
regions. (C) Evolutionary conservation of the amino acids surrounding the SNP affected amino acid (red box) 
in a range of different species. Residues conserved between all six species shown (bold).   
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This  required  the  expression  of  GFP  tagged  annexin  A11
WT  and  annexin  A11
R230C 
constructs in human cell lines. The main cell lines used in this study, A431 and HeLa, were 
first genotyped to determine which form of annexin A11 they endogenously expressed. 
The exon in which the mutation arises is small, less than 90 base pairs long, which would 
make  designing  effective  primers  for  genotyping  difficult.  Therefore  an  alternative 
approach  was  taken.  This  involved  isolating  the  RNA  from  the  cell  lines  and  reverse 
transcribing them into cDNA. The resulting cDNA represents the total expressed genes of 
the cell line and was used as a template to specifically amplify the annexin A11 gene, 
using primers designed against the start and end of the gene. This produced a 1512 base 
pair product visualised on an ethidium bromide agarose gel. This product is also seen in 
the positive control lane where the template used was a cDNA clone of annexin A11 (from 
Gene Services). No product was seen in the negative control lane, where no template was 
added, proving that there was no contamination of the samples during the experiment with 
extraneous DNA (Figure 10A). The annexin A11 cDNA products from the cell lines were 
extracted from the agarose gel, isolated and then subjected to sequencing. The results 
showed that both cell lines expressed the wild type (R230) form of annexin A11.  
 
The  A431 cell  line  was  then  used  to  express GFP  tagged  constructs of full  length,  N 
terminal domain and C terminal domain annexin A11. Cells were transfected by liposome 
delivery of the plasmid DNA and incubated overnight. The cells were then fixed in 4% PFA 
and imaged on a confocal microscope. Full length annexin A11 showed a nuclear and 
cytoplasmic  distribution  (Figure  10B),  in  line  with  previous  reports  of  endogenous 
expression patterns of annexin A11 in transformed cell lines [146,147]. Annexin A11-C-
terminal-GFP  was  predominantly  cytoplasmic  and  mostly  excluded  from  the  nucleus, 
whereas annexin A11-N-terminal-GFP was predominantly nuclear with weak cytoplasmic 
staining (Figure  10B). This also confirms previous reports showing that the N terminal 
domain  is  responsible  for  nuclear  targeting  and  the  C  terminal  domain,  lacking  this 
targeting signal, is excluded from this region [27,146].  
 
The  annexin  A11-GFP  and  annexin  A11-C-terminal-GFP  constructs  were  mutagenised 
using primers designed against the SNP site, which incorporated the mutation and flanking 
regions  15  base  pairs  either  side  of  the  mutation  site.  The  mutant  constructs  were 
expressed  in  A431  cells  and  showed  no  difference  in  distribution  to  their  wild  type 
counterparts. Annexin A11-R230C-GFP was both nuclear and cytoplasmic, as is annexin  
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A11-GFP and annexin A11-C-terminal-R230C-GFP was predominantly cytoplasmic with 
weak  nuclear  staining,  as  is  annexin  A11-C-terminal-GFP  (Figure  10B).  Therefore  the 
sarcoidosis associated SNP does not affect the localisation of annexin A11 in unstimulated 
A431 cells. 
 
 
 
Figure 10 Overexpresion of GFP Tagged Annexin A11
WT and Annexin A11
R230C 
(A) Agarose gel of amplified annexin A11 cDNA, obtained by reverse transcription of RNA isolated from HeLa 
and A431 cell lines. Negative control lane contains a reaction with no template included. Positive control lane 
contains a reaction with the annexin A11 cDNA clone (Gene Services). DNA ladder (L).  (B) Expression of 
annexin A11-GFP, annexin A11-Ct-GFP, annexin A11-Nt-GFP, annexin A11-R230C-GFP and annexin A11-Ct-
R230C-GFP in A431 cells transfected with 3µg of plasmid DNA and incubated overnight, prior to fixation in 
PFA. (Scale Bars 10µm)  
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3.2  The  Response  of  Annexin  A11
WT  and  Annexin  A11
R230C  to  Changes  in 
Intracellular Calcium 
The SNP in annexin A11 lies within its C terminal domain. The resulting change in amino 
acid from a basic arginine to a polar cysteine could alter the C terminal domain structure in 
a manner that could affect its calcium binding properties, particularly as this mutation lies 
within an annexin repeat. The effects of elevated calcium levels on the localisation of GFP 
tagged annexin A11
WT and annexin A11
R230C constructs were tested by stimulating cells 
with ionomycin or EGF (epidermal growth factor). 
 
A431 cells were transfected with plasmid DNA and incubated overnight. The cells were 
then transferred into media lacking phenol red and foetal calf serum (FCS), to decrease 
background fluorescence, and which was HEPES buffered to prevent large changes in pH 
during imaging. Cells were imaged for 5min, on an inverted confocal microscope with an 
incubator set at 37ºC, before treatment with either ionomycin or EGF. In both cases the 
treatment was applied in media equal in volume to that already in the culture dish, so 
minimising the effects of bolus administration. Images were taken every 9 – 12s.  
 
3.2.1 The Response of Annexin A11
WT and Annexin A11
R230C to Ionomycin 
Ionomycin  is  an  ionophore  which  raises  intracellular  calcium  levels  and  was  used  to 
stimulate transfected A431 cells. The addition of 1µM ionomycin to A431 cells expressing 
annexin  A11-GFP  caused  a  relocalisation  of  the  tagged  protein  (Figure  11).  Prior  to 
treatment  annexin  A11-GFP  was  diffuse  in  the  nucleus  and  cytoplasm.  Following 
treatment  it  first  relocalised  to  the  plasma  membrane,  depleting  cytosolic  GFP 
fluorescence whilst remaining constant in the nucleoplasm. Annexin A11-GFP was then 
lost from the nucleoplasm as it relocalised to the nuclear envelope. This process took 
place within 10min. Line scans were taken across the length of the cell, at a point crossing 
both  the  plasma  membrane  and  the  nuclear  envelope.  Prior  to  treatment,  line  scan 
analysis showed no discrete localisation of annexin A11-GFP to membranes. However 
following ionomycin treatment, line scans showed peaks of membrane enrichment; outer 
peaks representing the plasma membrane (PM) and inner peaks representing the nuclear 
envelope (NE) (Figure 11). A similar pattern of relocalisation was observed for stimulated 
A431 cells expressing annexin A11-R230C-GFP (Figure 12).  
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Figure 11 Annexin A11
WT Response to Ionomycin 
Real time imaging of annexin A11-GFP expressed in A431 cells transfected with 3µg of plasmid DNA and 
incubated overnight. Cells were imaged in DMEM without phenol red and treated with 1µM ionomycin. Time 
pre and post treatment noted. Line scans taken through the cell (red) and plotted in graphs below images; gray 
scale (y axis), position along line in pixels (x axis), plasma membrane (PM), nuclear envelope (NE), maximal 
cyto- or nucleoplasmic depletion (arrow) (Scale Bars 10µm) 
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Figure 12 Annexin A11
R230C Response to Ionomycin 
Real time imaging of annexin A11-R230C-GFP expressed in A431 cells transfected with 3µg of plasmid DNA 
and incubated overnight. Cells were imaged in DMEM without phenol red and treated with 1µM ionomycin. 
Time  pre  and  post  treatment  noted.  Line  scans  taken  through  the  cell  (red)  and  plotted  in  graphs  below 
images; gray scale (y axis), position along line in pixels (x axis), plasma membrane (PM), nuclear envelope 
(NE), maximal cyto- or nucleoplasmic depletion (arrow) (Scale Bars 10µm)  
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The time taken for both annexin A11-GFP and annexin A11-R230C-GFP to relocalise to 
the  plasma  membrane  and  the  nuclear  envelope  was  quantified.  The  time  taken  to 
relocalise to either compartment was defined as the maximal enrichment achieved during 
the time course of the experiment i.e. the point at which no more GFP tagged protein is 
lost  from  the  cytoplasm  to  the  plasma  membrane  or  the  nucleoplasm  to  the  nuclear 
envelope. This is illustrated by line scans showing clear peaks for membrane enrichment 
alongside troughs of maximally depleted cytoplasm or nucleoplasm. In the example shown 
for annexin A11-GFP maximal plasma membrane accumulation is achieved at 4min 18s 
post  stimulation,  where  the  two  plasma  membrane  peaks  are  clearly  defined  and  the 
trough representing cytoplasmic depletion drops no further (Figure 11).  In the example 
shown for annexin A11-R230C-GFP this occurs at 1min 33s post stimulation (Figure 12). 
Maximal nuclear envelope accumulation for the annexin A11-GFP expressing cell shown 
occurs  at  5min  3s  (Figure  11).  Again  there  are  two  clear  peaks  representing  nuclear 
envelope  localisation  and  a  trough  between  these  peaks  representing  nucleoplasmic 
depletion,  which  drops  no  further  beyond  this  time  point.  Maximal  nuclear  envelope 
accumulation for the annexin A11-R230C-GFP expressing cell shown occurs at 1min 51s 
(Figure  12).    The  time  taken  for  annexin  A11-GFP  and  annexin  A11-R230C-GFP  to 
relocalise to the plasma membrane and nuclear envelope was quantified in 36 cells each. 
On average the time taken for A11-GFP to relocalise to the plasma membrane in response 
to  ionomycin  was  458s  (+/-  70s)  and  for  A11-R230C-GFP  it  was  516s  (+/-  74s).  On 
average the time taken for A11-GFP to relocalise to the nuclear envelope in response to 
ionomycin was 483s (+/- 76s) and for A11-R230C-GFP it was 533s (+/- 75s). There was 
no significant difference between the wild type and mutant GFP tagged proteins in the time 
taken to relocalise to the plasma membrane (P=0.089) or the nuclear envelope (P=0.155), 
as determined by a two tailed student t-test (Figure 13).  
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Figure 13 Annexin A11
WT and Annexin A11
R230C Respond to Ionomycin in a Similar Manner 
Bar charts of the average time taken for Annexin A11-GFP and Annexin A11-R230C-GFP, expressed in A431 
cells, to relocalise to the plasma membrane (P=0.089) and nuclear envelope (P=0.155) in response to 1µM 
ionomycin . Errors bars represent standard errors of the mean from three experiments with n = 36 cells for 
each construct.  
 
The effect of ionomycin stimulation on annexin A11-C-terminal-GFP and annexin A11-C-
terminal-R230C-GFP  was  then  examined.    Initial  experiments  did  not  show  any 
relocalisation  of  either  wild  type  or  mutant  GFP  tagged  proteins  in  response  to  1µM 
ionomycin.  Both  mutant  and  wild  type  proteins  remained  excluded  from  the  nucleus, 
diffuse within the cytoplasm and without any membranous accumulation (Figure 14). In  
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order to confirm that the cells were responding to the ionomycin, calcium imaging was 
carried out. Following transfection and overnight incubation, cells were loaded with 5µM 
Fura Red AM (acetoxylmethyl) in order to visualise intracellular calcium levels. Fura Red 
AM  is  a  fluorescent  indicator  of  calcium  levels,  in  which  a  decrease  in  fluorescence 
corresponds to an increase in calcium. Fura Red AM was loaded onto the cells in media 
lacking  FCS,  to  prevent  cleavage  of  the  AM  group  by  esterases  before  the  calcium 
indicator could enter the cell. The cells were first loaded for 30min at 30ºC, to decrease 
compartmentalisation within the cell, and then 30min at 37ºC. Cells were subsequently 
imaged in media lacking phenol red and FCS.  Both the GFP and Fura Red signals were 
imaged.  
 
Annexin  A11  C-terminal-GFP,  annexin  A11  C-terminal-R230C-GFP  and  GFP  alone  all 
showed  a  lack  of  relocalisation  upon  ionomycin  treatment  (Figure  14).  The  cells  were 
responsive  to  ionomycin,  as  an  increase  in  intracellular  calcium  was  detected  by  a 
decrease in the Fura Red signal. This decrease in Fura Red fluorescence was quantified 
for individual GFP expressing cells (graphs in Figure 14). The Fura Red signal dropped an 
average of 4.6 gray scale units (n=9) in 1 minute post-ionomycin stimulation, compared to 
an  average  increase  of  1.1  gray  scale  units  (n=9)  in  5min  of  imaging  pre-stimulation. 
Therefore annexin A11-C-terminal-GFP and annexin A11 C-terminal-R230C-GFP do not 
relocalise to  the plasma membrane  or  nuclear envelope in response to  an ionomycin-
stimulated increase in intracellular calcium in A431 cells. 
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Figure 14 Annexin A11
WT and Annexin A11
R230C Respond to Ionomycin in a Similar Manner 
Real time imaging of annexin A11-Ct-GFP, annexin A11-Ct-R230C-GFP and GFP expressed in A431 cells 
transfected with 3 µg of plasmid DNA and incubated overnight. Prior to imaging cells were loaded with Fura 
Red AM in DMEM without phenol red for 30min at 30°C and then 30min at 37°C. Cells were then imaged in 
DMEM  without  phenol  red  and  with  treated  with  1µM  ionomycin.  GFP  construct  (green),  Fura  Red  (red). 
Graphs of Fura Red fluorescence correspond to the cells (1-3) shown in the images. Time pre- and post-
treatment noted. (Scale Bars 10µm) 
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3.2.2  The  Response  of  Annexin  A11
WT  and  Annexin  A11
R230C  to  Epidermal 
Growth Factor (EGF) 
Ionomycin is capable of eliciting rapid, large and sustained increases in calcium within the 
cell, however it is a non-physiological reagent. EGF is a well characterised physiological 
agonist, which also elicits a rapid rise in intracellular calcium levels via the EGF receptor. 
The A431 cell line is particularly responsive to EGF as it expresses elevated levels of the 
EGF receptor on its plasma membrane [215]. The addition of 100ng/ml of human EGF to 
A431  cells  expressing  annexin  A11-GFP,  annexin  A11-R230C-GFP,  annexin  A11-C-
terminal-GFP,  annexin  A11-C-terminal-R230C-GFP  and  GFP  alone,  did  not  elicit  a 
relocalisation  of  the  proteins  during  the  10  minute  time frame  imaged post  stimulation 
(Figure 15A). Annexin A11-GFP and annexin A11-R230C-GFP remained diffuse within the 
cytoplasm and nucleoplasm. Annexin A11-C-terminal-GFP and annexin A11-C-terminal-
R230C-GFP remained excluded from the nucleus and diffuse throughout the cytoplasm. 
None  of  the  GFP  tagged  annexin  A11  proteins  or  GFP  alone  showed  membranous 
accumulations upon EGF treatment. 
 
In order to verify that the cells were responsive to EGF, the cells were lysed in SDS-PAGE 
buffer immediately after the experiment and the samples subjected to SDS-PAGE. Control 
samples of transfected, imaged, but unstimulated A431 cells were also prepared. Western 
blotting  for  the  EGF  receptor  showed  that  the  receptor  was  expressed  by  these  cells 
(Figure 15B). Furthermore a phosphotyrosine blot showed an increase in the strength of a 
protein band at 170kDa in stimulated cells but not unstimulated cells (Figure 15B). This 
band size corresponds to the phosphorylated EGF receptor, which upon binding of EGF 
autophosphorylates. Therefore the stimulated A431 cells imaged are responsive to EGF, 
though  no  relocalisation  was  observed  of  the  GFP  tagged  annexin  A11  proteins 
expressed.  
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Figure  15  Annexin  A11
WT  and  Annexin  A11
R230C  Do  Not  Relocalise  in  Response  to  EGF 
Treatment 
(A) Real time imaging of annexin A11-GFP, annexin A11-R230C-GFP, annexin A11-Ct-GFP, annexin A11-Ct-
R230C-GFP and GFP expressed in A431 cells transfected with 3µg of plasmid DNA and incubated overnight. 
Cells were imaged in DMEM without phenol red and with treated with 100ng/ml of EGF (human epidermal 
growth factor). Time pre and post treatment noted. (Scale Bars 10µm) (B) Following imaging of the transfected 
cells, the cells were lysed in boiling SDS-PAGE buffer and subjected to SDS-PAGE and Western blotting. EGF 
receptor was blotted for using a polyclonal sheep anti-EGFR antibody (1/2000 dilution) and phosphorylated 
proteins using a monoclonal mouse anti-phosphotyrosine antibody (1/1000 dilution). Band corresponding to the 
size of the phosphorylated EGF receptor shown in the phosphotyrosine blot (arrow).  
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3.3 Discussion 
A recent study, in a German population, identified a single nucleotide polymorphism in 
annexin  A11  as  the  most  highly  associated  susceptibility  locus  for  the  autoimmune 
disorder  sarcoidosis  [193].  Until  this  study  the  association  of  annexin  A11  with 
autoimmune diseases, such as systemic lupus erythrematosus, rheumatoid arthritis and 
Raynauds  disease,  was  limited  to  the  detection  of  autoantibodies  [216].  Given  the 
ubiquitous expression of many annexins, including annexin A11, it is not surprising that it, 
along  with  other  annexins  [217,218]  have  been  detected  in  sera  from  patients  with 
autoimmune diseases. Therefore the finding of a mutation in annexin A11 which could 
potentially predispose an individual to the development of sarcoidosis is significant.  
 
The mutation (R230C) is not present in endogenous annexin A11 of A431 cells. Following 
confirmation  of  the  normal  annexin  A11  genotype  in  this  cell  line,  we  went  on  to 
characterise  annexin  A11
R230C  through  over-expression  experiments.  As  the  mutation 
arises in the C-terminal domain of annexin A11, GFP tagged constructs of both full length 
and  C-terminal  domain  annexin  A11  were  expressed.  No  difference  was  seen  in  the 
localisation  of  GFP  tagged  annexin
WT  or  annexin  A11
R230C  in  resting  A431  cells.  This 
suggested that under unstimulated conditions annexin A11
R230C can localise normally and 
so possibly function in the same way as annexin A11
WT. This led us on to investigate the 
effect of calcium on annexin A11
WT and annexin A11
R230C. 
 
Initial experiments in A431 cells over-expressing GFP tagged annexin A11, were carried 
out  using  ionomycin.  Ionomycin  is  a  potent  calcium  ionophore  that  produces  large, 
irreversible rises in intracellular calcium levels. This resulted in the relocalisation of GFP 
tagged annexin A11
WT first to the plasma membrane and then the nuclear envelope. The 
lag between these two relocalisations is most likely due to the strong calcium buffering 
capability of the nucleus [219]. This redistribution to the plasma membrane and nuclear 
envelope confirms previous reports of GFP tagged annexin A11
WT relocalising to these 
domains in ionomycin-stimulated cells. This was shown to occur both in the presence and 
absence of extracellular calcium [147]. The relocalisation to the nuclear envelope has also 
been demonstrated in ionomycin-stimulated cells endogenously expressing annexin A11 
[147],  however  a  plasma  membrane  relocalisation  was  not  observed,  highlighting  a 
difference between endogenous expression and over-expression of GFP tagged annexin  
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A11
WT.  
 
The localisation of endogenously expressed annexins to the nuclear envelope in response 
to ionomycin is also known to occur with annexins A4 and A5 [220], which under resting 
conditions have both a nuclear and cytoplasmic distribution. This has been observed in  
human foetal lung fibroblasts, as well as human foreskin fibroblasts which are suggested 
to also show some weak plasma membrane relocalisation [221].  Although all the annexins 
have  lipid  membrane  binding  capabilities,  they  do  not  all  relocalise  to  the  plasma 
membrane  and  nuclear  envelope  in  response  to  ionomycin.  Annexin  A2,  which  under 
resting conditions is diffuse in the cytoplasm, takes on a granular appearance in response 
to ionomycin [221]. Annexin A6 which is excluded from the nucleus in resting cells, has 
been suggested to redistribute throughout the plasma membrane in human foetal lung 
fibroblasts  [221]  but  to  relocalise  to  secretory  granules  and  early  endosomes  in  T 
lymphocyte cells [222] – thus highlighting cell type specific differences.   
 
With  regards  to  over-expression  studies,  GFP  tagged  annexin  A7  which  has  both  a 
nuclear and cytoplasmic distribution, has also been shown to relocalise in response to 
ionomycin [223]. This relocalisation mimics that of GFP tagged annexin A11
WT, as the 
protein first localises to the plasma membrane and then the nuclear envelope.  This is 
unsurprising given the high homology between annexin A7 and annexin A11, annexin A7 
being the most closely related vertebrate annexin to annexin A11. It is interesting to note 
that the annexins which show a similar response to annexin A11 when cells are stimulated 
with ionomycin, share more homology with annexin A11 than those which show a different 
response. Within the vertebrate  annexins,  sequence homology to annexin  A11 can be 
ranked from most homologous to least as follows; annexin A7, annexin A4, annexin A6, 
annexin A5, annexin A8, annexin A3, annexin A13, annexin A1, annexin A2, annexin A10, 
and annexin A9. In the annexins examined thus far, annexin A7 shows the most similarity 
to annexin A11 in its response to ionomycin, followed by annexins A4, A5 and A6 which 
show partial similarity and lastly annexin A2 which shows no similarity in relocalisation. 
Therefore,  aside  from  the  affinity  of  the  annexins  for  phospholipids,  similar  targeting 
sequences may also be involved in their binding to specific domains in response to a rise 
in intracellular calcium.  
 
The arginine residue which is mutated in annexin A11
R230C is however conserved in all  
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vertebrate annexins and so is unlikely to be part of a specific targeting sequence. This is 
illustrated by the mutation of this residue in annexin A11, demonstrating no effect on the 
relocalisation of GFP tagged annexin A11
R230C in response to ionomycin. That is to say the 
cytoplasmic  pool  of  GFP  tagged  annexin  A11
R230C  also  translocated  to  the  plasma 
membrane and the nuclear pool of GFP tagged annexin A11
R230C to the nuclear envelope. 
Furthermore  this  occurred  with  approximately  the  same  time  course  as  its  wild  type 
counterpart.  It  is  however  still  possible  that  a  subtle  difference  in  the  time  taken  to 
relocalise to these membranous compartments may occur, but only be detectable using a 
far greater number of cells.  
 
It  should  be  noted  that  the  GFP  tagged  C-terminal  domain  constructs  showed  no 
significant relocalisation upon ionomycin treatment for either annexin A11
WT or annexin 
A11
R230C.  This is in contrast to previous reports carried out in the same cell line, showing a 
relocalisation to large vesicular  structures within the cell  [147]. This difference may be 
attributed  to  a  difference  in  the  passage  number  of  the  cell  line,  which  may  affect  its 
responsiveness to calcium. The cells imaged in this study were nevertheless responsive to 
ionomycin treatment, as demonstrated by a drop in Fura Red fluorescence representing a 
rise in intracellular calcium levels. The C-terminal domain of annexin A11 is responsible for 
its calcium-binding properties. Taken together it is likely that although the GFP tagged C-
terminal domains of annexin A11 are calcium  sensitive,  without  the N-terminal domain 
prolonged  attachment  to  the  plasma  or  nuclear  membrane  is  not  possible.  However  it 
should be taken into consideration that the live images were taken every 9 seconds and it 
is therefore theoretically possible that the membranous accumulations were not captured 
at the time points imaged. This could also be true for the live imaging of both GFP tagged 
full length and C-terminal domain annexin A11
WT and annexin A11
R230C, in response to 
EGF (epidermal growth factor).  
 
In all four cases no relocalisation of the fluorescently labelled annexin A11 was observed 
in response to EGF, although the cells themselves appeared to be responsive to EGF. 
This  was  confirmed  through  Western  blotting  for  phosphotyrosine-containing  proteins 
immediately  after  the  experiments  were  performed.  In  cells  treated  with  EGF,  a 
phosphotyrosine  band  corresponding  in  size  to  the  phosphorylated  EGF  receptor  is 
enhanced. It is therefore possible that the rise in intracellular calcium in response to EGF 
is too transient and/or too small to stimulate the membranous relocalisation of annexin  
-85- 
A11. This has been shown to be true for the calcium-induced relocalisation of endogenous 
annexin A4. Relocalisation occurred in response to ionomycin but not to more transient 
calcium waves induced by agonists such as bradykinin [220]. Calcium levels are sustained 
upon treatment with ionomycin, whereas the rise in EGF-stimulated calcium levels has 
been shown to return to basal levels after 30s to one minute [224]. Furthermore, EGF 
stimulation  of  A431  cells  is  known  to  increase  calcium  levels  to  between  400nM  and 
700nM, whereas ionomycin raises levels into the low micromolar range. Taken together 
the  lack  of  response  of  annexin  A11  to  EGF,  as  well  as  the  delay  in  response  to 
ionomycin, suggests annexin A11 is not particularly sensitive to calcium, which is in line 
with other studies [225]. The delayed response to ionomycin may be due to other essential 
calcium-dependent events preceeding relocalisation, such as protein-protein interactions 
with known binding partners such as ALG-2 [68] or tyrosine phosphorylation of annexin 
A11 which is known to occur in response to ionomycin  [147]. Therefore future studies 
should involve the testing of different calcium agonists, which elicit changes in calcium 
levels to different degrees and durations. In addition it would be interesting to mutate the 
known  phosphorylation  sites  of  annexin  A11,  which  lie  within  the  last  three  annexin 
repeats of the C-terminal domain [226], to assess whether this affects the response of 
annexin A11
WT and annexin A11
R230C to these calcium agonists. 
 
Although  no  functional  difference  could  be  detected  in  response  to  calcium  between 
annexin  A11
WT  and  annexin  A11
R230C,  structural  analysis  suggests  that  the  R230C 
mutation  may  yet  exert  a  functional  effect  on  annexin  A11.  The  tertiary  structures  of 
several of the annexins have been elucidated, though not that of annexin A11. Of the 
known crystal structures, the two annexins with the highest degree of homology to annexin 
A11 are annexin A8, showing 53% sequence identity and 71% sequence similarity, and 
annexin A5, showing 53% sequence identity and 73% sequence similarity. The arginine at 
residue  230  in  annexin  A11  is  conserved  between  annexins  A5  and  A8.  Furthermore 
annexin A11 contains six cysteine residues (Figure 16A), two of which are conserved in 
annexin  A8  and  one  of  which  is  conserved  in  annexin  A5  (Figure  16B).  This  is  of 
importance as the mutation in annexin A11 which is associated with sarcoidosis, results in 
a switch from an arginine to a cysteine, and cysteine residues are able to covalently bind 
to each other through the formation of disulphide bridges.  
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Figure 16 Annexin A11 Amino Acid Sequence 
(A) Annexin A11 contains six cysteine residues, two of which are conserved in annexin A8 (red box), one of 
which is conserved in annexin A5 (green box) and the remaining three which are not conserved in either 
annexins  A5  or  A8  (yellow  box).  Annexin  repeats  (bold). Residue  230  (blue)  (B)  Annexin  A11  sequences 
aligned against annexin A8 and annexin A5. Conserved residues (bold). Conserved cysteines (bold, red box). 
 
Crystal structure analysis shows that in both annexin A8 and annexin A5 the conserved 
arginine at residue 230 lies near the start of an alpha helix (Figure 17A, B). In the case of 
annexin A8, the conserved cysteine residues (C206 and C250) are not in the vicinity of this 
arginine (Figure 17A). However in annexin A5 the conserved cysteine residue (C316) lies 
opposite this arginine, with the arginine pointing away from the cysteine (Figure  17B). 
Upon mutation of this arginine to a cysteine it is possible that a new conformation could 
arise in which the two cysteine residues are facing each other. If close enough together, 
this could facilitate the formation of a disulphide bridge between the sulphydryl groups of 
the cysteine residues and may therefore affect the alpha helical structure of this annexin 
repeat. This may be more likely to occur between cysteine 230 and the nearby cysteine 
226, which is unfortunately not conserved in annexin A5 or A8 and so was not modelled in 
the crystal structures presented here.  
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Figure 17 Crystal Structure Analysis of Annexin A8 and A5 
The crystal structures of annexin A8 (A) and annexin A5 (B) were modelled in RasMol (Version 2.6). The 
arginine which is mutated in annexin A11
R230C is conserved between annexin A5 and A8 and is depicted in the 
crystal structures in blue. Residues either side of the arginine are shown in green. Cysteine residues which are 
conserved between annexin A11 and annexin A5 or annexin A8 are shown in magenta. The crystal structure of 
annexin A8 depicted, highlights conserved residues R50, S51, C206 and C250 and unconserved R44. The 
crystal structure of annexin A5 depicted, highlights conserved residues S44, R45, S46 and C316. The residues 
highlighted in annexin A5 and A8 are within the first annexin repeat, shown in the corresponding amino acid 
codes which have been aligned against annexin A11 - conserved residues (bold), mutation associated arginine 
(red box).  
-88- 
Disulphide bridge formation would only be possible in the endoplasmic reticulum or the 
extracellular  environment,  where  a  sufficiently  oxidising  milieu  is  present.  Interestingly, 
annexin A11 has been shown to be secreted by activated neutrophils [227], although it 
does not contain a recognised secretion signal. This is in common with other annexins, 
such  as  annexins  A1  and  A2,  which  are  also  known  to  be  secreted  and  lack  known 
secretion signals [228,229]. Therefore under certain conditions annexin A11 may indeed 
be  secreted.  Furthermore  autoantibodies  against  annexin  A11  have  been  detected  in 
several  autoimmune  diseases  [216],  suggesting  that  annexin  A11  is  released  into  the 
extracellular environment at some point, whether through secretion or perhaps following 
cell death. In sarcoidosis therefore, the presence of annexin A11
R230C extracellularly may 
be  of  equal  or  greater  importance  than  any  intracellular  role  it  plays.  Conformational 
changes  that  could  arise  intracellularly  may  involve  the  N-terminal  domain.  Structural 
analysis of annexin A5 shows that the conserved arginine, which is mutated in annexin 
A11
R230C, lies in close proximity to the N-terminus (Figure 17B). This residue may therefore 
be involved in interactions with the N-terminus, and a switch from a basic arginine to a 
polar cysteine may disrupt or alter such interactions. 
 
The speculations inferred from the crystal structures of annexins A5 and A8 provide some 
insight into how the tertiary structure of annexin A11 may be affected and also contribute 
to  the  predictive  model  of  annexin  A11  (produced  by  [230]).  This  model  depicts  the 
positions of cysteine residues within annexin A11 relative to the arginine at residue 230 
(Figure 18A). Annexin A11 is strikingly rich in cysteines, relative to the other vertebrate 
annexins, and contains a total of six cysteines (Figure 18A). Mutation of residue 230 from 
an arginine to a cysteine is not predicted to grossly affect the 3D structure of annexin A11 
(Figure 18B), though slight changes in the angles of the helices and loops cannot be ruled 
out. In annexin A11
R230C the cysteine at residue 230 is in closest proximity to the cysteine 
at residue 226. However their sulphur head groups appear to be positioned away from 
each other, making disulphide bridge formation sterically difficult. As this is a predictive 
model this does not categorically rule out the suggestion made previously, from analysis of 
the  crystal  structure  of  annexin  A5,  that  intramolecular  disulphide  bridges  could  form. 
However this model does not favour this scenario. A more likely outcome of intermolecular 
disulphide bridge formation is still possible, as the additional cysteine residue in annexin 
A11
R230C may be better placed to interact with any of the six or seven other cysteines 
within annexin A11
WT or annexin A11
R230C molecules that are in close enough proximity.  
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Figure 18 Predictive Model of Annexin A11
WT and Annexin A11
R230C 
The models of annexin A11
WT (A) and annexin A11
R230C (B) were calculated (EMBL) and modelled in RasMol 
(Version  2.6).  The  arginine  at  residue  230 in annexin  A11
WT  is  highlighted  in  blue.  Cysteine  residues  are 
highlighted in magenta. In annexin A11
R230C the sulphydyrl groups of these residues are depicted in yellow.  
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If structural changes do occur in annexin A11
R230C, it is not clear whether these would be 
sufficient to result in functional effects. It is possible that although the mutation identified in 
annexin  A11  is  strongly  associated  with  sarcoidosis,  susceptibility  to  the  disease  and 
cellular dysfunction requires the complete haplotype to be present. This includes five other 
non-coding single nucleotide polymorphisms surrounding the R230C mutation, which were 
also  validated  as  being  strongly  associated  with  sarcoidosis  [193].  There  are  a  large 
number  of  other  SNPs  within  annexin  A11,  with  414  results  listed  on  the  NCBI  SNP 
search, however only the R230C mutation has been linked to disease, with the remaining 
SNPs having no known function.  
 
Future studies into annexin A11
R230C should focus on the role of this mutation in cell types 
more  relevant  to  the  disease,  such  as  cells  of  the  immune  system.  For  example 
macrophages and monocytes which form part of the granulomas themselves [206], CD4 
positive T cells which increase in number in the lungs of sarcoid patients [231] and CD8 
positive T cells and CD19 positive B cells  which strongly down-regulate expression of 
annexin A11 upon activation [193], suggesting a particular role for this protein in these 
cells. It may also be of importance to examine the role of annexin A11
WT and annexin 
A11
R230C in cells and tissues of the organs most affected by sarcoidosis, such as the lungs 
and skin.  
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Motor Protein CHO1 During 
Mitosis  
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4.  Results:  Study  of  Annexin  A11  and  the  Motor  Protein  CHO1 
During Mitosis 
 
CHO1 is a plus end directed motor protein with orthologues in both vertebrates, such as 
pavarotti  in  Drosophila  melanogaster  [169]  and  invertebrates,  such  as  zen-4  in 
Caenorhabditis elegans [170]. These proteins all belong to the kinesin-6 family and are 
known to interact with proteins involved in the cell cycle, such as the polo-like kinase Plk1 
[232], the Aurora kinase AIR-2 [233] and the Rho GAP cyk-4 [234]. CHO1 was initially 
identified in Chinese Hamster Ovary cells by the immunisation of mice with CHO mitotic 
spindle components. One of the monoclonal antibodies produced bound to the spindles 
and midbodies in cultured mammalian cells  [235]. This antibody, cho1,  recognised the 
subsequently named protein CHO1.  
 
CHO1 is a 105kDa protein consisting of three domains; an N-terminal motor domain, an 
alpha helical coiled-coil stalk domain and a C-terminal tail domain (Figure 19) [236]. It is 
capable of cross-linking anti-parallel microtubules in vitro [171]. CHO1 contains both ATP-
dependent  and  ATP-independent  microtubule  binding  sites  within  its  motor  domain. 
Furthermore, the N terminal domain co-sediments with  taxol-stabilised microtubules [237]. 
CHO1 also contains an F-actin interacting domain within its tail, making it unique amongst 
kinesin-6 family members. It is the alternatively spliced exon 18 which is responsible for 
this domain in CHO1 and results in a 100 amino acid stretch within its tail domain which is 
absent in full length human MKLP1 [177]. 
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Figure 19 MKLP1/CHO1 Structure and Function 
Both MKLP1 and CHO1 comprise three domains; a motor domain which binds microtubules, a stalk domain 
which  dimerises  the  protein  and  a  tail  domain.  CHO1  differs  from  MKLP1  in  its  tail  domain,  due  to  the 
alternative splicing of exon 18 of the MKLP1 gene. The translation of this exon in CHO1 provides CHO1 with 
an F-actin binding domain. This property makes CHO1 unique amongst this family of kinesins.  
 
Mutation of the ATP-binding site in the motor domain of CHO1, or antibody blockade of the 
F-actin  interacting  domain,  both  disrupt  cytokinesis  [177,178].  In  both  cases  furrow 
ingression is initiated but separation of the daughter cells fails, resulting in the two cells 
fusing back together to form binucleates. This phenotype also occurs in cells depleted of 
CHO1 using siRNA, with the additional loss of the midbody matrix [238].    
 
It has been shown that the dynamic expression patterns of both CHO1 and annexin A11 
during the cell cycle are strikingly similar [146]. Both localise to the nucleus of interphase 
cells, then to the spindle poles,  spindle midzone and finally midbody as the  cell  cycle 
progresses (Figure 20). CHO1 also shows a high degree of co-localisation from anaphase 
onwards  with  other  proteins  that  target  to  the midbody.  These  include  INCENP  (Inner 
Centromere Protein) [239] which is part of the chromosomal passenger complex and Plk1 
(Polo-like kinase 1) [232]. CHO1 does not appear to interact with INCENP, but does bind 
Plk1 [232]. 
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Figure 20 Cell Cycle Progression 
Mitosis begins with prophase, where the nuclear envelope of the cell degenerates and the DNA contained 
within the nucleus begins to condense into chromosomes. At metaphase the microtubule network reassembles 
to form the mitotic spindle, emanating from the spindle poles towards the cell equator. The chromosomes line 
up at the cell equator and attach to the plus ends of the spindle microtubules. At anaphase, as the spindle 
elongates,  the  sister  chromatids  are  pulled  apart.  As  the cell  progresses  from  anaphase  to telophase  the 
spindle midzone becomes compacted into the forming cleavage furrow. At the centre of this furrow resides the 
protein dense midbody matrix. At cytokinesis, karyokinesis completes and the nuclear envelope regenerates. 
The  furrow  continues  to  regress  until  membrane  abscission  occurs  resulting  in  the  separation  of  the  two 
daughter cells.  
 
The strong co-localisation of CHO1 and annexin A11 throughout the cell cycle was further 
investigated. Immunoprecipitation of annexin A11 uncovered an interaction with CHO1, 
specifically  at  cytokinesis  [146].  It  is  thought  that  this  interaction  could  facilitate  the 
completion  of  cytokinesis,  following  actomyosin  ring  disassembly  and  central  spindle 
separation – a point at which it is suggested that the plasma membrane would need to be 
tightly bound to midbody microtubules [150,177]. CHO1 alone, which binds microtubules, 
is unlikely to fulfil this role as there is no evidence of it being able to also bind the plasma 
membrane.  It  has  however  been  suggested  that  annexin  A11,  with  its  ability  to  bind 
phospholipids and the midbody matrix via CHO1, could facilitate this association [146,150].  
  
-95- 
4.1 Annexin A11 Distribution During the Cell Cycle in PFA Fixed Cells 
The distribution of annexin A11 in cells at interphase has been characterised in a variety of 
cell lines [140,146,147,149,150], where it has been shown to have both a nuclear and 
cytoplasmic  distribution.  In  addition,  it  localises  to  the  cell  membrane  in  confluent 
monolayers of epithelial cells [146].  
 
During  the  cell  cycle  however  this  distribution  changes  significantly  [150]. 
Immunofluorescence  analysis  in  both  transformed  A431  cells  (Figure  25)  and  non-
transformed, spontaneously immortalised ARPE19 cells (Figure 21) confirms this pattern. 
Annexin  A11  localisation  was  followed  during  the  cell  cycle  by  using  confocal 
immunofluorescence microscopy of PFA fixed cells. DNA and α tubulin staining were used 
to determine the position of cells within the cell cycle.  
 
At prophase annexin A11 localises to the degenerating nuclear envelope (Figure 25). At 
metaphase  annexin  A11  can  be  found  diffusely  distributed  throughout  the  cytoplasm 
(Figure 25) or additionally localised to the cell membrane with a slight accumulation at the 
spindle poles (Figure 21). Both of these localisations were observed in all three of the cell 
lines investigated (HeLa, A431, ARPE19), without an apparent preference for either state. 
These different distributions may therefore reflect two separate phases during metaphase, 
for  example  early  and  late.  At  anaphase  annexin  A11  is  consistently  localised  to  the 
spindle midzone. Upon closer inspection it appears to cap the plus ends of central spindle 
microtubules (Figure 26). By telophase and cytokinesis it concentrates at the midbody, a 
protein  dense  structure  located  in  the  middle  of  the  cleavage  furrow.  This  midbody 
localisation  is  consistent  in  several  cell  lines  (Figure  22A-C).  However,  this  was  not 
observed for other annexins (Figure 22D and E), namely annexin A2 and annexin A7 - 
annexin A7 being the most closely related to annexin A11. 
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Figure 21 Annexin A11 Localisation During the Cell Cycle in ARPE19 Cells 
ARPE19 cells were fixed in 4% PFA and stained for annexin A11 using a polyclonal goat anti-annexin A11 
antibody (1/50 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution) and DNA 
using DAPI (1/500 dilution). Location of midbody (arrowhead). (Scale Bars 10µm) 
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Figure 22 Annexin A11 Localises to the Midbody in Several Cell Lines 
Annexin A11 is present at the midbody during cytokinesis in (A) A431, (B) ARPE19 and (C) HeLa cells. (D) 
Annexin A2 in A431 cells is not present at the midbody. (E) Annexin A7 in HeLa cells is not present at the 
midbody. All cells were fixed in 4% PFA. Cells were stained for tubulin using a monoclonal mouse anti-alpha 
tubulin antibody (1/100 dilution) and either annexin  A11 using a polyclonal goat anti-annexin A11 antibody 
(1/50 dilution), or annexin A2 using a polyclonal rabbit anti-annexin A2 antibody (1/60 dilution) or annexin A7 
using a polyclonal goat anti-annexin A7 antibody (1/50 dilution). (Scale Bars 10µm) 
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The intracellular targetting of the different domains of annexin A11 to the midbody was 
investigated through the overexpression of GFP tagged annexin A11 constructs in A431 
cells. Both full length annexin A11 and its truncated forms, comprising either the C terminal 
or  N  terminal  domains,  localised  to  the  midbody  (Figure  23A-C).  GFP  alone  when 
expressed at low levels did not localise to the midbody (Figure  23D). This was further 
illustrated graphically by taking line scans through the length of the cleavage furrow, in 
order to detect the GFP and tubulin signals in this particular region. In all four cases the 
tubulin signal is seen to drop at the point where the midbody is localised (Figure 24A–D). 
In the cases of GFP tagged full length annexin A11 and its truncated forms (Figure 24A-
C), this drop in tubulin signal is concurrent with a peak in GFP signal. This peak in GFP 
signal was not seen with the low expression of GFP alone. However increased expression 
of GFP did result in targeting to the midbody (Figure 23E and 24E). Therefore expression 
to sufficient levels of the GFP tag alone can result in midbody targeting.  
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Figure 23 Localisation of Annexin A11-GFP Constructs in A431 Cells at Cytokinesis 
Expression of (A)  A11-GFP, (B) A11-C-terminal-GFP, (C) A11-N-terminal-GFP and (D, E) GFP in A431 cells. 
Cells were transfected with 3µg of plasmid DNA and incubated overnight, prior to fixation in 4% PFA. Cells 
were stained for tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution). Arrows point to 
midbodies. White lines denote where line scans were taken (See Figure 24) (Scale Bars 10µm)  
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Figure 24 Line Scans of the Localisation of Annexin A11-GFP Constructs in A431 Cells at 
Cytokinesis 
Graphs corresponding to line scans in Figure 23 (white line in merges of Figure 23 (A) – (E)) taken through the 
midbody (arrow head in merges of Figure 23 (A) – (E)) of A431 cells at cytokinesis expressing (A)  A11-GFP, 
(B) A11-C-terminal-GFP, (C) A11-N-terminal-GFP and (D, E) GFP. Cells were transfected with 3µg of plasmid 
DNA and incubated overnight, prior to fixation in 4% PFA. Cells were then stained for tubulin using a polyclonal 
mouse anti-tubulin antibody (1/100 dilution). 
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4.2 Annexin A11 and MKLP1/CHO1 Distribution during the Cell Cycle in PFA 
Fixed Cells 
CHO1 is a plus end directed motor protein, belonging to the MKLP1 (mitotic kinesin like 
protein 1) family of mitotic kinesins. In humans both CHO1 and MKLP1 are co-expressed. 
CHO1  is  a  splice  variant  of  MKLP1  containing  an  additional  100  base  pairs  in  its  C 
terminal domain, derived from the alternative splicing of exon 18 which is not expressed in 
the truncated MKLP1 variant. This domain is responsible for the additional ability of CHO1 
to bind F-actin, unlike MKLP1. Current commercially available antibodies are not able to 
distinguish  between  the  two  isoforms.  Therefore  both  MKLP1  and  CHO1  have  been 
immunostained, without any differentiation between the two isoforms.  
 
Previous  work  has  shown  that  CHO1  co-localises  with  annexin  A11  consistently 
throughout the cell cycle [150]. Immunostaining using an anti-MKLP1 antibody and an anti-
annexin A11 antibody in PFA fixed A431 cells, shows that annexin A11 and MKLP1/CHO1 
co-localise at  several points  during the cell cycle.  Annexin A11 and MKLP1/CHO1 co-
localise  at  the  degenerating  nuclear  envelope  at  prophase,  at  the  spindle  midzone  at 
anaphase  and  at  the midbody  at  telophase  and  cytokinesis  (Figure  25).  At  anaphase, 
unsurprisingly for a plus end directed motor protein, MKLP1 appears to specifically cap the 
plus ends of the midzone microtubules, where annexin A11 also accumulates (Figure 26). 
At  metaphase  MKLP1/CHO1  is  consistently  diffuse  throughout  the  cytoplasm,  whilst 
annexin A11 can be found diffusely distributed in the cytoplasm (Figure 25) or also partially 
localised to the spindle poles (Figure 21). In either instance the localisation of annexin A11 
at metaphase does not appear to co-localise with MKLP1/CHO1.  
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Figure 25 Annexin A11 and MKLP1 Co-localise During the Cell Cycle in A431 Cells Fixed 
Using PFA 
Cells were fixed in 4% PFA and stained for annexin A11 using a polyclonal goat anti-annexin A11 antibody 
(1/50 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution), MKLP1 using a 
polyclonal rabbit anti-MKLP1 antibody (1/100 dilution) and DNA using DAPI (1/500 dilution). (Scale Bars 10µm) 
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Figure 26  Annexin  A11  and MKLP1 Co-localise  at  Anaphase  at Microtubule Plus  Ends In 
HeLa Cells Fixed Using PFA 
(A) HeLa cell at anaphase (Scale Bar 10μm) (B) HeLa cell at anaphase magnified (Scale Bar 3μm). HeLa cells 
were fixed in 4% PFA and stained for annexin A11 using a polyclonal goat anti-annexin A11 antibody (1/50 
dilution),  tubulin  using  a  monoclonal  mouse  anti-alpha  tubulin  antibody  (1/100  dilution),  MKLP1  using  a 
polyclonal rabbit anti-MKLP1 antibody (1/100 dilution) and DNA using DAPI (1/500 dilution). 
 
4.3  Annexin  A11  and  MKLP1/CHO1  Distribution  during  the  Cell  Cycle  in 
Methanol Fixed Cells 
The distribution of annexin A11 and MKLP1/CHO1 has only been examined in PFA fixed 
cells.  However  it  is  well  known  that  methanol  fixation  can  produce  different  staining 
patterns, in particular with regard to tubulin and tubulin associated proteins. PFA fixation 
works by cross-linking proteins, whereas methanol fixation works by dehydrating the cell 
and simultaneously denaturing the proteins. PFA fixation at room temperature occurs at a 
slower rate than methanol fixation at -20°C, resulting in increased levels of microtubule 
depolymerisation caused by the dynamic instability of the tubulin filaments. This is due to 
the dramatic decrease in GTP levels once the cell is permeabilised, which affects not only 
the immunostaining of microtubules but also of proteins bound to microtubules, such as 
MKLP1/CHO1.  
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Methanol  fixation  revealed  an  enhanced  staining  pattern  for  both  annexin  A11  and 
MKLP1/CHO1 during the cell cycle, which was consistent at all stages of mitosis imaged 
(Figure  27).  This  is  most  strikingly  seen  at  metaphase,  when  both  annexin  A11  and 
MKLP1/CHO1 invariably co-localise to the entire length of the mitotic spindle, including the 
spindle poles. At anaphase annexin A11 localises to the spindle midzone and also the 
length of the midzone microtubules. MKLP1/CHO1 however is restricted to the spindle 
midzone alone, where it co-localises with annexin A11. At telophase and cytokinesis, both 
proteins co-localise strongly to the midbody. However whilst MKLP1/CHO1 is restricted to 
this structure, annexin A11 is present throughout the cleavage furrow in a manner that 
appears coincident with the microtubules. 
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Figure 27 Annexin A11 and MKLP1 Co-localise during the Cell Cycle in HeLa Cells Fixed 
Using Methanol 
 
HeLa  cells  were  fixed  in  methanol  and  stained  for  annexin  A11 using a  polyclonal goat  anti-annexin  A11 
antibody (1/50 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution), MKLP1 
using a polyclonal rabbit anti-MKLP1 antibody (1/100 dilution) and DNA using DAPI (1/500 dilution). (Scale 
Bars 10µm)  
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4.4 Annexin A11 and CHO1 Interaction 
Given  the  strong  colocalisation  of  annexin  A11  and  MKLP1/CHO1,  alongside  previous 
data  suggesting  an  interaction  [150],  immunoprecipitations  and  GST  pulldowns  were 
conducted to determine whether A11 and CHO1 interact. As the interaction between these 
two  proteins  was  thought  to  occur  at  cytokinesis,  cells  were  first  subjected  to 
synchronisation. Two main methods were utilised; monastrol and thymidine-nocodazole. 
 
Monastrol is a cell permeable, 1,4-dihydropyrimidine-based compound which inhibits Eg5 
kinesin by binding to its motor domain [240]. Eg5 kinesin is a minus-end directed motor 
protein  which  binds  microtubules  and  plays  a  role  in  assembling  the  mitotic  spindle. 
Inhibition of this kinesin by monsatrol prevents centrosome separation, resulting in  the 
production of mono-astral spindles (Figure 28A).  
 
Thymidine is a pyrimidine deoxynucleoside which inhibits DNA synthesis, resulting in an S 
phase  block.  Following  thymidine  treatment the  next  stage  of  synchronisation  involved 
arresting the cells at prometaphase. The carbamate, nocodazole, achieves this by binding 
β tubulin subunits to prevent tubulin polymerisation. Cells are therefore unable to pass the 
spindle assembly checkpoint. Recovery from nocodazole treatment is rapid, so following 
several PBS washes fully formed mitotic spindles can be seen after the cells were fixed 
(Figure 28B).  
 
Following  release  from  prometaphase  arrest,  both  methods  produced  similar  levels  of 
synchronisation,  with  cells  enriched  at  cytokinesis  after  about  1  hour  (Figure  28C). 
However the thymidine-nocodazole method was chosen, as this is both a less expensive 
and more specific method of synchronisation. Although monastrol is not known to inhibit 
other kinesins [241], it may inhibit other proteins due to the high concentrations it must be 
used at, so producing unknown non-specific effects.   
 
Cytokinesis-enriched cell lysates were used to perform immunoprecipitations and annexin 
A11-GST  pull-downs.  Annexin  A11-GST  was  purified  from  bacteria  following  IPTG 
induction over several hours, as described in Materials and Methods 2.12 (Figure 29A). 
The GST fused annexin A11 was then purified from the bacterial lysate using glutathione 
beads, with which synchronised cell lysates were incubated. However it was not possible 
to detect MKLP1/CHO1 in annexin A11-GST pull-downs (Figure 29B).  
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Figure 28 Synchronisation of HeLa Cells Using Thymidine, Nocodazole and Monastrol 
 
HeLa cells cultured in media containing (A) 100µM monastrol for 16h or (B) 5mM thymidine overnight, followed 
by 100 ng/ml nocodazole for 7h. Both treatments result in a prometaphase block in the majority of cells. (C) 1h 
post release into normal media (DMEM, 10% FCS and antibiotics) from treatment in (B). Cells at cytokinesis 
marked by their cleavage furrows (arrowheads). All cells were fixed in 4% PFA and then stained for tubulin 
using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution) and DNA using DAPI (1/500 dilution). 
(Scale Bars 10µm)  
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Figure 29 Annexin A11 and CHO1 Cannot Be Shown to Interact 
 
(A) Coumassie stain of an SDS-PAGE gel containing annexin A11-GST production samples from bacterial 
lysates of BL21 E.coli transformed with plasmid DNA encoding annexin A11-GST. (B) Western blots of an 
annexin  A11-GST  pull-down  using  HeLa  whole  cell  lysates  from  cells  synchronised  at  cytokinesis,  in  the 
presence of 200µM calcium. Annexin A11 was blotted for using a polyclonal goat anti-annexin A11 antibody 
(1/200 dilution) and MKLP1 using a polyclonal goat anti-MKLP1 antibody (1/200 dilution) made up in 8% milk 
(C)  Western  blots  of  an  annexin  A11  immunoprecipitation  using  A431  whole  cell  lysates  from  cells 
synchronised at cytokinesis and treated with or without DSP. 1µg of polyclonal goat anti-annexin A11 antibody 
was used for immunoprecipitation of annexin A11. Annexin A11 was blotted for using a monoclonal mouse 
anti-annexin A11 antibody (1/1000 dilution) and MKLP1 using a polyclonal goat anti-MKLP1 antibody (1/200 
dilution). IN (whole cell lysate input). 
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As an alternative strategy, annexin A11 immunoprecipitations were carried out in order to 
avoid  the  use  of  GST  tagged  annexin  A11,  which  may  disrupt  interactions  by  altering 
tertiary structures. Initial immunoprecipitations from cytokinesis-enriched cell lysates also 
failed  to  pull  down  detectable  MKLP1/CHO1  (Figure  29C).  In  order  to  strengthen  a 
possibly weak interaction, immunoprecipitations were repeated using the chemical cross-
linker  DSP.  DSP  creates  disulphide  bridges  between  cysteines  of  interacting  proteins. 
CHO1 however was also not pulled down with annexin A11 using this technique (Figure 
29C).  
 
Despite the apparent absence of CHO1 in these pulldown experiments, other proteins 
were pulled down upon annexin  A11  immunoprecipitation,  in both unsynchronised and 
synchronised cells (Figure 30A). In unsynchronised cells a protein band at approximately 
37kDa  was  present  and  in  synchronised  cells  two  bands  at  approximately  37kDa  and 
65kDa were present. In all three cases these bands did not appear in the control IgG 
immunoprecipitates and they appeared stronger upon DSP treatment. However as these 
bands could be the result of non-specific antibody binding, as opposed to genuine protein-
protein interactions with annexin A11, a known interaction was tested – that of annexin 
A11 and ALG2. In this case the immunoprecipitation of annexin A11, from cells stimulated 
with  1µM  ionomycin  for  10min  and  then  treated  with  DSP,  was  able  to  verify  this 
interaction (Figure 30B).  
 
Given these findings supporting the experimental procedure used, the lack of any apparent 
interaction between annexin A11 and CHO1 may be due to its transient nature i.e. it may 
only occur during a small window of cytokinesis which was not captured. In addition, the 
original  experiments  demonstrating  this  interaction  used  a  polyclonal  antibody  raised 
specifically against the CHO1 isoform [150]. However these experiments used a polyclonal 
antibody  raised  against  a  peptide  mapping  the  N  terminus  of  MKLP1.  Although  this 
suggests that the antibody would detect both MKLP1 and CHO1, one cannot be certain 
that  the  epitopes  used  for  antibody  production  are  accessible  when  the  protein  is 
embedded into the midbody or bound to annexin A11.  
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Figure 30 Annexin A11 Immunoprecipitations Pull Down Other Protein Interactors 
(A) Silver stain of an SDS PAGE gel containing samples from an annexin A11 immunoprecipitation using HeLa 
whole cell lysates from unsynchronised cells or cells synchronised at cytokinesis, treated with or without DSP. 
1µg of polyclonal goat anti-annexin A11 antibody was used for the immunoprecipitation of annexin A11. Arrows 
point to protein bands present in annexin A11 lanes that are absent in IgG control lanes. (B) Western blot of 
annexin A11 immunoprecipitation in A431 cells incubated in media containing 1µM ionomycin for 10min and 
treated with DSP. 1µg of polyclonal goat anti-annexin A11 antibody was used for the immunoprecipitation of 
annexin A11. Annexin A11 was blotted for using a polyclonal goat anti-annexin A11 antibody (1/200 dilution) 
and ALG2 using a polyclonal rabbit anti-ALG2 antibody (1/1000 dilution). 
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4.5 Discussion 
The cell cycle distribution of annexin A11 has previously been described in tumour cells 
[150] and this study has confirmed these findings in several cell lines of both a transformed 
and a spontaneously immortalised nature. Initial experiments were conducted in cells fixed 
using PFA and under these conditions the metaphase localisation of annexin A11 was 
inconsistent.  Annexin  A11  either  remained  diffuse  in  the  cytoplasm  or  showed  some 
enrichment at the spindle poles of the mitotic apparatus. Consistency was achieved for all 
other stages of mitosis, where annexin A11  was detected at the degenerating nuclear 
envelope at prophase, the spindle midzone at anaphase and the midbody at telophase 
and cytokinesis.  
 
At prophase, in PFA fixed cells, annexin A11 was shown to co-localise at the degenerating 
nuclear envelope with the motor protein MKLP1. The localisation of annexin A11 to this 
region confirms previous studies of the cell cycle [150]. Furthermore, localisation to the 
nuclear envelope has also been shown to occur in interphase cells, in response to a rise in 
intracellular calcium [147]. Such a rise in intracellular calcium is known to occur in both the 
cytoplasm surrounding the nucleus and in the nucleus itself just prior to nuclear envelope 
breakdown at prophase, as demonstrated in syncytial Drosophila embryos [242]. During 
prophase,  nuclear  envelope  breakdown  is  achieved  through  the  employment  of  the 
microtubule network [243]. Other motor proteins, such as the dynein-dynactin complex, 
have also been shown to localise to the nuclear envelope at prophase [244]. This complex 
is  suggested  to  stabilise  the  plus  ends  of  microtubules  growing  towards  the  nuclear 
envelope  [245].  Taken  together  a  model  was  suggested  whereby  this  motor  complex 
stabilises  microtubules growing  towards  the  nuclear  envelope,  facilitates  attachment of 
plus  ends  to the  envelope  and  subsequently  pulls  apart  the  nuclear  envelope  through 
tension created via the microtubules and the movement of dynein towards the forming 
spindle poles [243,245]. The novel localisation of MKLP1 to the nuclear envelope may also 
regulate  this  process,  as  MKLP1  can  bind  microtubules  [171].  It  should  be  noted  that 
immunofluorescence analysis of MKLP1 utilises an antibody which detects both MKLP1 
and CHO1. An interaction between CHO1 and annexin A11 has previously been shown to 
occur at cytokinesis [150]. It is therefore possible that the targeting of annexin A11 to the 
degenerating nuclear envelope may act as an anchor for CHO1. This would reinforce the 
interaction between the nuclear envelope and microtubular network at a time when this  
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interaction is critical to the onset of karyokinesis. 
 
At  anaphase,  in  PFA  fixed  cells,  annexin  A11  co-localises  with  MKLP1  at  the  spindle 
midzone. Closer inspection showed that the midzone accumulation was specific to the plus 
ends of the overlapping microtubules. Annexin A11 co-localises at these points with the 
motor protein MKLP1, which may facilitate its attachment to the microtubule plus ends as 
MKLP1 has been shown in vitro to cross-link anti-parallel microtubules [171] and its splice 
variant  CHO1  has  been  shown  to  interact  with  annexin  A11  [150].  The  localisation  of 
MKLP1  to  the  plus  ends  of  the  spindle  midzone  microtubules  corroborates  previous 
studies [246,247] and fits with the functional data presented.  In vitro assays using the 
C.elegans homologue of MKLP1, ZEN-4, demonstrated the ability of this protein to induce 
microtubule  gliding  in  a  phosphorylation-dependent  manner  [246].  This  ability  was 
diminished upon phosphorylation of a threonine residue within the motor domain of ZEN-4, 
by cyclin-dependent kinase 1 (Cdk1). In human cells, Cdk1 is suggested to temporally 
regulate  the  microtubule-dependent  association  of  MKLP1  to  the  spindle  midzone  at 
anaphase. Phosphorylation of MKLP1 is said to prevent the precocious bundling of anti-
parallel  microtubules  at  metaphase,  which  would  result  in  inefficient  chromosome 
segregation  if  a  kinetochore  microtubule  from  one  pole  was  inadvertently  bundled  to 
microtubules emanating from the  opposite  pole. This  was  confirmed  through  the  over-
expression of non-phosphorylable MKLP1, which resulted in segregation defects [246]. At 
anaphase however, the bundling of anti-parallel microtubules by MKLP1 is beneficial as it 
is helps maintain the cleavage furrow [170] and assemble the contractile ring [169], both of 
which are necessary for the successful completion of cytokinesis.  
 
The localisation of annexin A11 to this same region suggests that it may also have a role 
in this process. It is not yet known whether the spindle midzone microtubules directly bind 
the overlying plasma membrane, though signalling between these two regions is known to 
be essential for cleavage furrow ingression [248]. Furrow initiation has been shown to be 
regulated  by  stable  astral  microtubules  which  contact  the  cell  cortex  [249].  It  is 
hypothesised  that  MKLP1  can  then  traffic  along  these  microtubules  and  induce  the 
accumulation  of  the  centralspindlin  complex,  resulting  in  contraction  of  the  cell  cortex 
[250].  Following initiation of this process, annexin A11 may participate in the stabilisation 
of  potential  spindle  midzone-plasma  membrane  interactions,  through  its  ability  to  bind 
phospholipids [146].   
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MKLP1 and annexin A11 also co-localise at telophase in PFA fixed cells, at  a protein 
dense  structure  called  the  midbody.  MKLP1  has  previously  been  identified  as  a 
component of the midbody [235,251]. A proteomic study of the midbody also identified 
annexins A5, A6 and A7 as midbody components, although these localisations were not 
corroborated  via  immunofluorescence  [251].  Previous  studies  of  annexin  A11  and  the 
MKLP1 splice variant CHO1, have shown that these two proteins not only co-localise at 
cytokinesis  at  the  midbody,  but  also  interact  at  this  point  [150].  This  interaction  is 
speculated  to  help  maintain  a  tight  association  between  the  midbody  and  the  plasma 
membrane, during a time when significant forces are being exerted at the cleavage furrow. 
Maintenance of this association is thought to be required for the successful completion of 
cytokinesis [238]. CHO1 alone cannot bind the plasma membrane but annexin A11 can, 
therefore helping to bridge the gap between the midbody and the plasma membrane.  
 
This interaction was not confirmed in this study, however an antibody specific to CHO1 
was not available. It is therefore likely that without enrichment of this particular variant of 
MKLP1 an interaction cannot readily be detected or that the epitopes detected using this 
antibody are not longer detectable once CHO1 is embedded at the midbody. One method 
used for the detection of this interaction was the immunoprecipitation of annexin A11, from 
both non-syncrhonised and synchronised cell lysates. Silver staining of SDS-PAGE gels 
with these samples uncovered the presence of annexin A11-interacting proteins, which 
differed between non-synchronised and synchronised cell lysates, suggesting that annexin 
A11  interacts  with  different  proteins  during  the  cell  cycle.  Mass  spectrometry  of  these 
proteins  would  be  beneficial  in  understanding  the  mechanism  by  which  annexin  A11 
regulates the cell cycle at cytokinesis. We also attempted to determine which domain of 
annexin A11 was responsible for midbody targeting through the over-expression of GFP-
tagged annexin A11 constructs. However as GFP alone targeted to the midbody this was 
not resolved using this method. Future studies will require the over-expression of annexin 
A11 labelled with a smaller tag that is less likely to target to the midbody itself. 
 
Further immunofluorescence studies of annexin A11 and MKLP1 during the cell cycle were 
carried  out  using  methanol  fixation.  Both  PFA  and  methanol  fixation  can  result  in 
denaturation  of  cellular  protein,  but  function  through  two  different  mechanisms.  PFA 
fixation acts through the cross-linking of proteins, via the reaction of formaldehyde with  
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amino groups. This reaction results in the production of methylol groups, which can go on 
to form methylene bridges between polypeptides [252]. Extensive cross-linking allows the 
cellular architecture to be maintained. This process is slower than that of methanol fixation, 
which involves solubilisation of lipid membranes, dehydration of the cell and precipitation 
of the proteins. This method of fixation is known to better preserve microtubule integrity, as 
it acts faster allowing less time for microtubule depolymerisation which can result in the 
loss of associated proteins. What was most striking about the localisations of both annexin 
A11 and MKLP1 upon methanol fixation, was the consistent localisation of both proteins 
along  the  length  of  the  mitotic  spindle  at  metaphase.  From  anaphase  through  to 
cytokinesis the localisation of MKLP1 in methanol fixed cells was the same as that seen in 
PFA fixed cells. However annexin A11 showed a more widespread distribution; along the 
length  of  the  spindle  midzone  at  anaphase  and  throughout  the  cleavage  furrow  at 
telophase and cytokinesis. The fact that this is not seen with MKLP1 supports the notion 
that this is not merely an artefact of methanol fixation, particularly as MKLP1 is known to 
bind microtubules [171]. The distribution of annexin reflects an enhanced association of 
annexin  A11  with  the  microtubule  network  and  suggests  that  annexin  A11  may  be 
trafficked along the mitotic spindle throughout mitosis. It is already known that treatment of 
cells with Brefeldin A, which disrupts trafficking through the Golgi [253] via the inhibition of 
Sec7 domain-containing ARF guanine nucleotide exchange factors [254], does not prevent 
the accumulation of annexin A11 at the midbody [150]. It would therefore be of interest to 
observe the localisation of annexin A11 upon disruption of the microtubular network at 
different  points  of  the  cell  cycle,  in  order  to  determine  if  this  would  affect  midbody 
targeting.  
 
Another  avenue  for  investigation  concerns  the  phosphorylation  state  of  annexin  A11. 
Phosphorylation of midbody proteins is known to be important for their targeting to this 
domain. For example serine phoshphorylation of MKLP1 by Aurora B kinase is required for 
its  retention  at  the  midbody  and  subsequent  completion  of  cytokinesis  [247].  Similarly 
targeting of Inner Centromere Protein (INCENP) to the cleavage furrow requires  serine 
phosphorylation by polo-like kinase 3 (Plk3) [255]. Annexin A11 has also been shown to 
be phosphorylated during cytokinesis, however on tyrosine residues [146]. In a separate 
phosphoproteomic study several tyrosine phosphorylation sites within annexin A11 were 
identified in lung cancer cell lines [226]. These three tyrosine phosphorylation sites all lie 
within  the  C  terminal  domain  of  annexin  A11  (Figure  31A),  specifically  within  annexin  
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repeats II, III and IV (Figure 31B).  
 
 
 
Figure 31 Predicitve Model of Annexin A11 Highlighting Known Tyrosine Phosphorylation 
Sites 
Predictive models of annexin A11 were calculated (EMBL) and modelled in RasMol (Version 2.6).  (A) Side 
view of annexin A11 with the known tyrosine phosphorylation sites (identified in [226]) highlighted in blue. (B) 
View of annexin A11 from its concave surface, with the three known tyrosine phosphorylation sites (Y279, 
Y365, Y482) highlighted in blue. Each of these sites lies within an annexin repeat (outlined in black). 
 
Tyrosine  phosphorylation  is  of  particular  interest  as  it  has  been  shown  that  tyrosine 
phosphorylated proteins are delivered to the midbody via Rab11 GTPase positive vesicles. 
Furthermore it was shown that down-regulation of tyrosine phosphorylation through the 
inhibition of Src family kinases results in a decrease of tyrosine phosphorylated proteins at 
the midbody and a failure to complete cytokinesis [256]. Interestingly cytokinesis fails due 
to the inability of the daughter cells to abscise from each other. This results in the cells 
remaining  connected  by  a  long  intercellular  bridge  of  membrane  –  as  has  also  been 
observed upon knock down of annexin A11 [150], although the midbody is also lost in the 
latter instance.  
 
The role for tyrosine de-phosphorylation at the midbody is less clear. Studies were carried 
out on the tyrosine phosphatase, PTP-BL, which like annexin A11 targets to the midbody 
[257]. Over-expression of PTP-BL resulted in a failure in cytokinesis, though in this case 
the  daughter  cells  fused  back  together  to  form  multi-nucleated  cells.  However  over-
expression of wildtype or phosphatase inactive PTP-BL produced the same cytokinetic  
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defect, suggesting that the tyrosine phosphatase activity of PTP-BL is not directly involved 
in the regulation of cytokinesis. Conversely, investigations into the tyrosine phosphatase 
PTP-PEST have shown that PTP-PEST
-/- fibroblast populations have an increased number 
of cells at cytokinesis, suggestive of a block at this stage [258]. These cells also showed 
increased  tyrosine  phosphorylation  of  PSTPIP  (proline,  serine,  threonine  phosphatase 
interacting protein). PSTPIP is known to be a substrate of PTP-PEST and to localise to the 
actin ring at the cleavage furrow of cytokinetic mammalian cells [259]. The over-expression 
of PTP-PEST in yeast has been shown to inhibit cell cleavage at cytokinesis [259]. 
 
Taken  together  these  studies  illustrate  the  importance  of  tyrosine  phosphorylation  at 
cytokinesis  and  demonstrate  that  a  fine  balance  between  phosphorylation  and  de-
phosphorylation must be maintained in order for successful completion of this process. 
Therefore it would be of interest to investigate the effects of mutagenesis on the known 
tyrosine  phosphorylation  sites  within  annexin  A11.  This  would  shed  light  on  whether 
tyrosine phosphorylation is required for the various cell cycle localisations of annexin A11 
and whether this regulates not only cytokinesis, but the entire process of mitosis. 
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5. Results: Study of Annexin A11 and Tubulin 
 
Tubulin monomers are the basic building blocks of the microtubule network, which gives a 
cell its structure, provides a framework for intracellular traffic, coordinates the cell cycle 
and carries out a host of other complex processes. The microtubule network is one of 
three major polymer systems, the others being intermediate filaments and actin, which 
together  compose the cytoskeleton.  Early insights into the structure of the microtubule 
cytoskeleton  were  carried  out  using  naturally  occurring  drugs  that  target  its  individual 
components [260]. This led to the discovery that microtubules are made of heterodimers of 
alpha and beta subunits and polymerise by harnessing GTP hydrolysis at the beta tubulin 
subunit [261]. These heterodimers go on to form linear protofilaments, which collectively 
form hollow, cylindrical tubes, 25 nm in diameter i.e. microtubules [262] (Figure 32). 
 
 
 
Figure 32 Microtubule Structure 
Alpha and beta tubulin monomers form the basis of the microtubule network. Monomers combine to form 
heterodimers,  which  polymerise  to  form  protofilaments.  The  protofilaments  comprise  the  tubular  structures 
known as microtubules. These hollow structures are 25 nm in diameter and vary in length. 
 
Microtubules are polar structures with a minus end,  located at the MTOC (microtubule 
organising  centre)  in  centrosomally  organised  microtubule  networks,  and  a  plus  end 
located distally, emanating out towards the cell cortex. The alpha and beta tubulin subunits 
are exposed at the minus and plus ends respectively. This polar structure sets the stage 
for a process termed „microtubule treadmilling‟, whereby tubulin subunits are lost from the 
minus end and gained at the plus end. In steady state conditions, where the length of the 
microtubule does not change, the process of extension at  the  plus end equals that of 
retraction at the minus end. This process is dependent on a phenomenon called „dynamic 
instability‟,  where  microtubule  ends  switch  between  phases  of  polymerisation  and  
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depolymerisation  in  a  stochastic  manner.  Polymerisation  involves  the  binding  of  GTP 
bound tubulin subunits, which upon GTP hydrolysis become GDP-bound tubulin subunits 
that are subsequently released from the polymer [263,264] (Figure 33).  
 
 
 
Figure 33 Microtubule Polymerisation 
Microtubules are highly dynamic structures and their rates of polymerisation and depolymerisation are highly 
dependent on GTP levels within the cell. Tubulin heterodimers, made of a beta and alpha subunits, bind GTP. 
In this form they promote addition to the plus end of a microtubule resulting in polymerisation. Hydrolysis of the 
bound GTP causes the release of a single phosphate group, leaving behind GDP bound tubulin heterodimers. 
In this form their association with the microtubule is inherently unstable and results in depolymerisation. The 
balance between these two states determines whether the microtubule is growing or shrinking. 
 
Microtubule stability depends not only on the rate of GTP hydrolysis and the amount of 
monomeric tubulin available, but also on microtubule stabilising proteins, such as the well 
known  MAPs (microtubule associated proteins)  and  a variety of other proteins ranging 
from the Ras GTPase, Ran [265] to the STOP (stable tubule-only polypeptide) protein 
[266]. At the opposite end of microtubule stabilisation is microtubule severing, originally 
characterised by the action of the AAA ATPase (ATPases Associated with diverse cellular 
Activities) katanin [267], which was later shown to be the major component responsible for 
mitotic microtubule severing [267,268].  
 
Several naturally occurring substances and synthetic chemicals are known to destabilise 
the  microtubule  network  and  have  been  used  experimentally  to  better  understand  the  
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function of these structures. One such substance is nocodazole, a synthetic carbamate 
with reversible effects on the microtubule network. Nocodazole has been shown to bind 
the beta subunit of tubulin at two sites [269]. This interaction sequesters the free tubulin 
dimers  and  prevents  their  incorporation  into  microtubules,  so  inhibiting  any  further 
polymerisation.  This  results  in  the  eventual  net  depolymerisation  of  the  microtubule 
network  due  to  inherent  dynamic  instability.  Colchicine,  a  naturally  occurring  alkaloid, 
stimulates  microtubule  depolymerisation  in  the  same  manner  and  competes  with 
nocodazole  for  binding to  beta  tubulin  subunits  [270].  Nocodazole  and  colchicine  both 
preferentially bind to free tubulin unlike the microtubule polymerising drug taxol. Taxol, 
also  known  as  paclitaxel,  is  a  naturally  occurring  diterpene  which  preferentially  binds 
microtubules  through  its  interaction  with  beta  tubulin  subunits  [271].  Taxol  promotes 
microtubule  polymerisation  both  in  vitro  [272]  and  in  vivo  [273]  and  its  effects  are 
prevented by colchicine co-treatment. 
 
The use of these drugs has shed light on the role of the microtubule network in a vast 
array of cellular processes which occur both during interphase and during mitosis, when 
the microtubule network is particularly dynamic. However, these drugs target beta tubulin 
and therefore preodominantly affect the alpha-beta tubulin protofilaments. Although these 
are the two major tubulin subunits, of which there are several subtypes, it should be noted 
that several additional tubulin genes have been discovered. These include gamma, delta, 
epsilon, zeta and eta. Only alpha, beta and gamma are present in all eukaryotes, whilst 
the remaining forms are often organism specific [274].  An additional layer of functional 
variation is imposed by the post-translational modification of tubulin.  
 
There  are  four  well  characterised  post  translational  modifications  [275].  Firstly  tubulin 
acetylation, associated with stable microtubules, involves the addition of an acetyl group to 
lysine  residue  40  on  alpha  tubulin.  Deacetylation  is  carried  out  by  HDAC6  (histone 
deacetylase  6)  and  SIRT2  (silent  mating  type  information  regulation  2),  however  the 
acetylating  enzyme  is  still  unknown.  Alpha  tubulin  is  also  the  target  of  detyrosination, 
whereby the C terminal tyrosine residue is cleaved. This residue can be added back by 
tubulin tyrosine ligase. Detyrosinated microtubules show a preference for binding kinesin 1 
motors,  which  could  help  specify  cargo  trafficking  along  certain  routes.  Lastly 
polyglutamylation and polyglycation occur on both alpha and beta tubulin and involve the 
addition  of  glutamate  or  glycine  residues  respectively  to  their  C  termini.  These  
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polymodifications  have  been  suggested  to  support  microtubule  severing  by  katanin. 
Therefore  subtle  differences  in  tubulin  structure  can  exert  distinct  effects  on  the 
interactions  of  the  microtubule  network  with  its  binding  proteins.  This  can  result  in 
downstream effects on all manner of cellular processes, including cell morphology and 
cargo transport.  
 
5.1 Annexin A11 and Tubulin Co-localisation 
Annexin A11 is distributed in both the nucleus and cytoplasm of several cultured cell lines, 
including HeLa and A431 cells [146,147,150]. However during the cell cycle annexin A11 
relocalises  to  discrete  structures  (Figure  25).  This  includes  the  nuclear  envelope  at 
prophase,  the  mitotic  spindle  at  metaphase  and  anaphase,  and  the  midbody  at 
cytokinesis.  It  was  observed  that  the  distribution  of  annexin  A11,  as  determined  by 
immunofluorescence of fixed cells, was enhanced in methanol fixed cells relative to PFA 
fixed  cells.  Methanol  fixation  better  preserves  the  integrity  of  the  microtubules.  Under 
these conditions annexin A11 co-localises strongly with tubulin of the mitotic spindle, in 
particular the midzone, kinetochore microtubules and later with tubulin of the cleavage 
furrow (Figure 27). To determine whether annexin A11 co-localised with tubulin in cells at 
interphase, HeLa cells were fixed in methanol, annexin A11 and tubulin were stained for 
and the cells imaged on an inverted confocal microscope. The distribution of annexin A11 
was both nuclear and cytoplasmic. The cytoplasmic staining was punctate in appearance 
and upon closer inspection a number of puncta localised along microtubule tracks (Figure 
34A).  
 
In order to determine whether the co-localisation of annexin A11 and tubulin at interphase 
signifies  an  interaction  between  these  two  proteins,  microtubule  co-sedimentation  was 
performed.  HeLa cells were harvested and lysed in Brinkley‟s buffer, which is optimal for 
microtubule preservation, either in the presence of 200µM calcium or 1mM EGTA. Cell 
lysates were incubated with or without taxol. Taxol is a taxane family drug, which stabilises 
microtubules through binding the beta monomer of tubulin. Lysates were incubated with 
2mM GTP to compensate for the decrease in GTP levels upon cell lysis, which is a key 
factor in microtubule depolymerisation rates. In addition to GTP, 1.5mM AMP-PNP (non-
hydrolysable ATP) was added which is known to promote the association of microtubule 
binding  proteins,  such  as  MAPs  to  microtubules.  The  samples  were  spun  through  a  
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sucrose cushion to separate soluble and insoluble fractions of tubulin i.e. tubulin subunits 
and  microtubule  filaments,  respectively.  Pellets  (insoluble  fraction)  and  supernatants 
(soluble  fraction)  were  then  subjected  to  SDS-PAGE.  Western  blotting  for  tubulin  and 
actin, showed that in the absence of taxol neither tubulin nor actin pelleted, but in the 
presence  of  taxol  tubulin  did  pellet  but  actin  still  remained  in  the  supernatants.  This 
confirms  that  without  taxol  microtubules  depolymerised  during  the  course  of  the 
experiment resulting in all the cellular tubulin concentrating in the soluble fraction (Figure 
34B). This was true both in the presence of calcium or EGTA. Western blotting for annexin 
A11 showed that in the presence or absence of taxol, with calcium or with EGTA, annexin 
A11 resided in the soluble fractions and could not be detected in the insoluble fractions. 
Therefore annexin A11 does not appear to co-sediment with tubulin.  
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Figure 34 Annexin A11 Punctae Localise Along Microtubules 
(A) HeLa cells were fixed in methanol and stained for annexin A11 using a polyclonal goat anti-annexin A11 
antibody (1/50 dilution) and tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution). 
Three representative cells are shown (1-3). Insets show annexin A11 puncta along microtubules (arrowheads). 
(Scale  bars  10μm)  (B)  HeLa  cell  lysates  were  subjected  to  microtubule  cosedimentation  (as  detailed  in 
Materials and Methods 2.18). Resulting pellets and supernatants were subjected to SDS-PAGE and Western 
blotting. Annexin A11 was detected using a polyclonal goat anti-annexin A11 antibody (1/200 dilution), tubulin 
using a monoclonal mouse anti-alpha tubulin antibody (1/1000 dilution) and actin using a monoclonal mouse 
anti-beta actin antibody (1/5000 dilution).  
-124- 
5.2 Annexin A11 Knock Down and Overexpression: Effect on the Microtubule 
Network 
Although annexin A11 does not appear to co-sediment with tubulin, its co-localisation with 
tubulin as detected by immunofluorescence of fixed cells, suggests it may yet be involved 
with the microtubule network. In order to further investigate this annexin A11 was knocked 
down in A431, HeLa and CaCo-2 cells using RNA interference. Cells were plated at 30% 
confluency and transfected the following day with a pool of four different siRNA constructs 
targeting four different regions of the annexin A11 gene. Cells were treated with a second 
dose of siRNA three days after plating. Cells were lysed for SDS PAGE analysis on days 
2, 3 and 6. Western blotting for annexin A11 and tubulin showed significant knockdown of 
annexin A11 in cells treated with annexin A11 siRNA compared to control cells treated with 
negative  control  siRNA  (Figure  35A).  On  average  by  day  6  annexin  A11  levels  had 
dropped by 95% in A431 cells, 82% in HeLa cells and 89% in CaCo-2 cells (Figure 35B). 
The knockdown was also observed via immunofluorescence. On day 6 cells were PFA 
fixed and stained for annexin A11 and alpha tubulin. In siRNA treated cells, expanses of 
cells were seen with highly diminished levels of annexin A11 staining, compared to control 
cells where annexin A11 staining was strongly present in all cells. In annexin A11 siRNA 
treated cells the microtubules appeared unchanged in comparison to control cells. A dense 
network of tubulin filaments was present in both cases, as illustrated in A431 (Figure 36) 
and CaCo-2 cells (Figure 37).  
 
The  effect  of  over-expression  of  annexin  A11  on  the  microtubule  network  was  also 
investigated. A431 cells were transfected with GFP tagged annexin A11 constructs and 
incubated overnight. Cells were then methanol fixed and stained for alpha tubulin. The 
mirotubular  network  appeared  unchanged  in  cells  overexpressing  annexin  A11-GFP, 
annexin  A11-R230C-GFP,  annexin  A11  N-terminal-GFP,  annexin  A11-C-terminal-GFP, 
annexin  A11-C-terminal-R230C-GFP  and  GFP  alone  when  compared  to  neighbouring 
untransfected cells (Figure 38).  
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Figure 35 Annexin A11 Knock Down in Several Cell Lines Using RNA Interference 
(A) Western blot of whole cell lysates from A431, HeLa and CaCo-2 cells treated with 20µM annexin A11 
siRNA or 20µM scrambled control siRNA for 2, 3 and 6 days, with two treatments administered on day 1 and 
day 3. Annexin A11 was blotted for using a polyclonal goat anti-annexin A11 antibody (1/200 dilution) and 
tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/1000 dilution) (B) Graphs of average annexin 
A11 protein levels normalised to tubulin in siRNA and control treated A431, HeLa and CaCo-2 cells, n=3 for 
each cell line.  
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Figure 36 Annexin A11 Knock Down in A431 Cells Using RNA Interference 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then PFA fixed on day 6 and stained for annexin A11 
using a polyclonal goat anti-annexin A11 antibody (1/50 dilution) and tubulin using a monoclonal mouse anti-
alpha tubulin antibody (1/100 dilution). (Scale bars 50μm, zoom 20μm) 
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Figure 37 Annexin A11 Knock Down in CaCo-2 Cells Using RNA Interference 
CaCo-2 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with 
two treatments administered on day 1 and day 3. Cells were then PFA fixed on day 6 and stained for annexin 
A11 using a polyclonal goat anti-annexin A11 antibody (1/50 dilution) and tubulin using a monoclonal mouse 
anti-alpha tubulin antibody (1/100 dilution). (Scale bars 50μm, zoom 20μm) 
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Figure 38 Overexpression of Annexin A11-GFP Constructs in A431 Cells Does Not Affect the 
Gross Morphology of the Microtubule Network 
A431 cells were fixed in methanol and then stained for annexin A11 using a polyclonal goat anti-annexin A11 
antibody (1/50 dilution) and tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution). 
(Scale Bars 10µm)  
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5.3 Annexin A11 Localisation Upon Tubulin Depolymerisation 
The  knockdown  or  overexpression  of  annexin  A11  had  no  detectable  effect  on  the 
microtubule network. Therefore the inverse relationship was investigated next, in which the 
effect  of  disrupting  the  microtubule  network  on  the  distribution  of  annexin  A11  was 
examined. HeLa cells were incubated for 3 hours in 100ng/ml nocodazole. Nocadazole 
binds to the beta subunits of tubulin and prevents their dimerisation with beta subunits, this 
result in the net depolymerisation of tubulin. Following treatment with nocodazole, the cells 
were fixed in methanol, stained for alpha tubulin and annexin A11, and imaged on an 
inverted confocal microscope. Remnants of nocodazole resistant microtubule structures 
were present, particularly in perinuclear regions. Annexin A11 was diffuse in the cytoplasm 
and nucleus, but interestingly also showed discrete accumulations in perinuclear regions 
along the nocodazole resistant microtubules (Figure 39). The co-localisation of annexin 
A11  and  tubulin  therefore  appeared  to  be  enhanced  when  cells  were  treated  with 
nocodazole, compared to untreated cells with intact microtubule networks.  
 
This data suggests that whilst the integrity of the microtubule network is not dependent on 
annexin A11, annexin A11 localisation requires intact microtubules. 
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Figure 39 Annexin A11 Localisation Along Microtubules upon Nocadazole Treatment 
HeLa cells were incubated for 90min in media containing 100ng/ml nocodazole, prior to fixation in methanol. 
Cells were then stained for annexin A11 using a polyclonal goat anti-annexin A11 antibody (1/50 dilution) and 
tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution). (Scale bars 10μm) 
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5.4 Discussion 
The intracellular localisation of annexin A11 in this study has been investigated during the 
cell  cycle,  under  both  methanol  and  PFA  fixation  conditions  (as  discussed  in  4.5 
Discussion of Annexin A11 and CHO1). Methanol fixation was adopted as this is known to 
better preserve the integrity of the microtubule network, as fixation occurs faster than with 
PFA. This is due to the mechanism of action employed by each fixative, as explained 
previously in 4.5 Discussion of Annexin A11 and CHO1. The speed at which methanol 
fixes  the  cells  provides  less  time  for  the  highly  dynamic  microtubule  filaments  to 
depolymerise. In addition to the preservation of the microtubules, methanol fixation results 
in the loss of some of the cytoplasmic staining of annexin A11. This allowed a clearer 
visualisation of annexin A11 puncta in interphase cells.  
 
These  puncta  of  annexin  A11  appeared  to  line  up  along  microtubule  filaments.  The 
microtubule  network  traffics  a  large  number  of  vesicles  to  different  cellular  domains 
through  the  use  of  the  motor  proteins,  kinesin  and  dynein,  which  link  microtubules  to 
vesicles [276]. The puncta of annexin A11 may represent such vesicles. It has been shown 
that  a  population  of  these  puncta  are  also  COPII  (Coat  Protein  Complex  II)  positive 
[personal  communication,  Dr  Hideki  Shibata,  University  of  Nagoya,  Japan].  COPII  is 
comprised of three main subunits; Sar1p, Sec13/31p and Sec23/24p, which act together to 
bud off vesicles from the endoplasmic reticulum for transport to the Golgi apparatus [277]. 
COPII vesicles have been shown to associate with the microtubule network [278] through 
an interaction between the human COPII component, Sec23p, and dynactin, an accessory 
protein of the dynein complex.  Furthermore the human COPII component Sec31A has 
been  shown  to  directly  interact  with  ALG2  (Apoptosis-Linked  Gene  2)  in  a  calcium 
dependent manner  [279].  ALG2 was also shown to  partially colocalise with  Sec31A  at 
endoplasmic reticulum (ER) exit sites, again in a calcium dependent manner, as a calcium 
binding mutant of ALG2 no longer interacted with Sec31A or localised to ER exit sites. In 
line with these data, knock down of Sec31A also prevented ALG2 localisation at ER exit 
sites. Equally, knock down of ALG2 perturbed the localisation of Sec31A at these sites, 
with diminished levels detected here [279].  
 
These observations suggest that ALG2 has a role in ER to Golgi trafficking and its calcium 
dependent  regulation.  The  partial  co-localisation  of  annexin  A11  and  COPII  vesicles,  
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alongside the known interaction between annexin A11 and ALG2 [68], tentatively suggests 
a role for annexin A11 in this process. Furthermore, given that COPII vesicles have been 
shown to associate with microtubules [278] and a subpopulation of annexin A11 puncta 
have been shown in this study to localise along these structures, it is possible that annexin 
A11  is  specifically  trafficked  from  the  ER  to  the  Golgi  along  the  microtubules.  This 
transport could be mediated by a protein complex involving annexin A11, ALG2, COPII 
components and the dynactin-dynein complex or some other motor protein such as CHO1 
(Figure 41). Work is currently underway to determine whether annexin A11 interacts with 
the COPII component Sec31 [personal communication, Dr Hideki Shibata, University of 
Nagoya, Japan]. It would also be of interest to investigate the effect of depletion of the 
proteins within this hypothetical complex on the distribution of annexin A11. 
 
 
 
Figure 40 Hypothetical Model for Annexin A11 Trafficking Along Microtubules 
Annexin A11 may be transported along microtubules via its known direct interaction with ALG2. ALG2 has 
been shown to interact with Sec31, a component of the COPII vesicle coat with which annexin A11 has been 
shown  to  partially  co-localise.  COPII  vesicles  are  capable  of  associating  with  microtubules  through  the 
interaction of Sec24 with the dynactin-dynein motor protein complex, which directly binds microtubules and 
directs cargo to the microtubule minus end.  
 
The pool of annexin A11 observed in this study to be associated with the microtubule 
network appears to represent a small proportion of the total annexin present in the cell, as 
judged  by  immunofluorescence.  This  may  account  for  the  lack  of  any  visible  co-
sedimentation of annexin A11 with tubulin. However this could also be due to limitations of 
the microtubule co-sedimentation procedure. More specifically, the microtubule network is 
first depolymerised during lysis and clarification, and is only then subjected to treatment  
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with  GTP  and  magnesium  ions  to  re-polymerise  the  network.  This  network  is  then 
stabilised through the addition of taxol. Therefore the interaction with annexin A11 may be 
lost  upon  depolymerisation  and  not  easily  regained  once  the  cellular  architecture  is 
disrupted and potentially essential proteins required for this interaction are diluted. None of 
the other vertebrate annexins have been shown to directly interact with tubulin, although 
annexin A1 has been shown to co-localise with tubulin-rich focal patches at the plasma 
membrane of A549 human lung adenocarcinoma cells [280]. Annexin A2 is also suggested 
to  co-immunoprecipitate  with  beta  and  gamma  tubulin  from  rod  photoreceptor  outer 
segments [281], although this interaction was not confirmed through immunofluorescence 
analysis  or  co-sedimentation  assays.  The  only  other  annexin  known  to  associate  with 
tubulin is annexin E1 of the flagellated protozoan Giardia lamblia [282], as shown via co-
localisation from immunocytochemical analysis and affinity chromatography.  
 
In order to determine whether annexin A11 has a role in the regulation of the microtubule 
network, aside from being transported along it, annexin A11 was knocked down in several 
cell lines. Subsequent immunofluorescence analysis of the microtubule network showed 
no apparent, defects in knock down cells as compared to control cells. The overexpression 
of annexin A11 also did not affect the microtubule network. Therefore annexin A11 does 
not appear to regulate this network, but is tightly associated with it during both the cell 
cycle and in interphase cells. The association with microtubules can be more strikingly 
seen  upon  treatment  of  cells  with  nocodazole.  Nocodazole  causes  the  net 
depolymerisation of the microtubule network [269], however more stable tubulin structures 
tend to be more resistant to nocodazole treatment [283]. The resistance to nocodazole and 
enhanced stability can be mediated by the post-translational acetylation of alpha tubulin at 
lysine 40 [283]. Microtubule structures such as the centrosome are known to be acetylated 
and therefore are inherently more stable [284]. This is in line with the data presented in 
this study showing nocodazole-resistant structures present in a perinuclear region, upon 
which  annexin  A11  accumulates.  Acetylated  tubulin  has  been  shown  to  promote  the 
binding  of  microtubule  motors  [285,286]  and  enhance  protein  trafficking  [287].  The 
enrichment  of  annexin  A11  on  nocodazole-resistant  structures  may  therefore  reflect  a 
specific  association  of  annexin  A11  on  stable,  acetylated  microtubules.  The 
depolymerisation  of  the  rest  of  the  microtubule  network  could  result  in  a  block  in  the 
transport of annexin A11 positive vesicles, resulting in their accumulation perinuclearly. It 
would be of interest to investigate the effect of other microtubule depolymerising agents on  
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the  distribution  of  annexin  A11,  such  as  colchicine  which  acts  in  a  similar  manner  to 
nocodazole  [270].  Furthermore  one  could  also  determine  the  effect  of  hyper-  or  de-
acetylation  of  tubulin  on  the  localisation  of  annexin  A11  to  microtubules,  through  the 
inhibition or overexpression of known tubulin deacetylases such as SIRT2 [287,288] and 
HDAC6 [289].  
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6. Results: Study of Annexin A11 and the Centrosome 
 
The centrosome is also known as the primary microtubule organising centre (MTOC) in 
animal cells, and as the name suggests it coordinates microtubule nucleation throughout 
the cell. It comprises two centrioles, arranged at right angles to each other, surrounded by 
electron dense pericentriolar material (PCM). This structure was initially discovered over 
130  years  ago  by  Flemming  [290]  and  later  named  by  Boveri  [291].  Since  then  the 
centrosome has been implicated in a wide range of processes during both interphase and 
mitosis; including cell motility, cytokinesis and vesicle trafficking [292].  
 
At interphase the centrosome is in close apposition to the nucleus, where it serves as the 
MTOC.  Core  centrosomal  components  particularly  required  for  this  function,  include  γ 
tubulin,  γTuRC  (γ  tubulin  ring  complex)  and  pericentrin.  γ  tubulin  is  a  member  of  the 
tubulin family present at far lower levels than α and β, which make up the microtubule 
filaments, but with a vital role in the assembly of these filaments. Purification of γ tubulin 
from Xenopus egg extracts  showed it to be part of a large complex of at  least  seven 
different proteins [293]. Electron micrography showed this complex to have a ring structure 
and it was accordingly coined the γ tubulin ring complex (γTuRC). In vitro experiments 
went  on  to  show  that  this  complex  could  nucleate  microtubules  from  one  end  of  the 
filament, namely the minus end where it was shown to bind. 
 
Pericentrin is known to form a complex with γ tubulin [294] and has also been shown to 
anchor γTuRC to the centrosome via its interaction with γ tubulin complex proteins 2 and 3 
(GCP2/3) [295]. It is believed that there may be up to ten different isoforms of this coiled-
coil  domain  protein,  however  the  two  major  isoforms  are  pericentrin  A  and  pericentrin 
B/kendrin [296]. Depletion of both isoforms resulted in defects in mitotic cells, including the 
loss  of  γ  tubulin  at  the  centrosome  and  the  formation  of  monopolar  spindles.  This 
highlights the importance of the centrosome, not just as an MTOC in interphase cells, but 
as a regulator of the cell cycle. 
 
During mitosis, chromosome duplication is tightly coupled to the centrosome cycle (Figure 
41). At G1 the two parent centrioles separate slightly and lose their orthogonal orientation, 
before  budding  off  a  daughter  centriole  each.  During  S  phase  centrosome  duplication  
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completes, as each daughter centriole has grown to full length, and DNA replication ends. 
By G2 the cell now contains two parent centrioles and two full length daughter centrioles, 
bound  within  the  same  PCM.  At  the  onset  of  mitosis,  as  the  chromosomes  begin  to 
condense,  the  new  centrosomes,  consisting  of  one  parent  centriole  and  one  daughter 
centriole, migrate to opposite poles of the cell [236].  
 
 
 
Figure 41 The Centrosome Cycle in Relation to the Stages of the Cell Cycle 
The centrosome cell cycle progresses in line with the cell cycle. At G1 (growth phase 1) the parent centrioles 
separate just enough to allow for their duplication during S phase. At S phase as the DNA replicates the parent 
centrioles each bud off a daughter centriole. At G2 (growth phase 2) the two new centrosomes separate and 
during the beginning of mitosis migrate to opposite poles of the dividing cell. 
 
During prometaphase the centrosomes organise three distinct sets of microtubules, all of 
which serve different purposes during the cell cycle (Figure 42). Polar microtubules radiate 
out from the centrosome towards the cell equator where they overlap with each other and 
define the spindle midzone. Astral microtubules radiate out towards the cell cortex, where 
some will attach to help position the mitotic spindle. Kinetochore microtubules attach to 
kinetochores at centromeres on the sister chromatids and are responsible for physically 
pulling apart the chromatids to form their respective chromosomes. This organisation of 
microtubules  allows  alignment  of  the  chromatids  along  the  cell  equator  at  metaphase, 
separation of the chromatids at anaphase and ultimately cell cleavage at the furrow at 
telophase  and  cytokinesis.  This  results  in  two  daughter  cells,  each  containing  a 
centrosome of two centrioles encased in PCM [236]. 
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Figure 42 The Three Groups of Microtubules That Comprise The Mitotic Spindle 
During mitosis the microtubule network undergoes massive changes in structure in order to accommodate the 
new functions it must perform. The production of the mitotic spindle results in the formation of three distinct 
groups of microtubules called kinetochore, astral and polar microtubules. Kinetochore microtubules bind to the 
chromatids  at  their  centromeres.  Astral  microtubules  extend  cortically  to  anchor  the  mitotic  spindle.  Polar 
microtubules extend towards the cell equator and set the location of the spindle midzone. 
  
It  should  be  noted  that  during  the  centrosome  cycle,  mitotic  centrosomes  mature  and 
accumulate  an  array  of  different  centrosome  associated  proteins  that  interphase 
centrosomes lack. Maturation begins at prometaphase when, for example NuMA (Nuclear 
Mitotic  Apparatus  Protein)  is  acquired,  as  it  translocates  from  the  nucleus  to  the 
centrosome.  Other  cell  cycle  dependent  centrosome  associated  proteins  include  Plk1 
[297], Cdk1 (Cyclin dependent kinase 1) [298] and AurA (Aurora A kinase) [263]. These 
proteins have also been implicated in cascades controlling cytokinesis [299-301]. The link 
between the centrosome and cytokinesis has been further strengthened by the discovery 
of a centriole protein, centriolin, which also localises to the midbody – a protein dense 
structure  at  the  cleavage  furrow  crucial  for  cytokinesis  [302].  The  knock  down  of  this 
protein  resulted  in  the failure  of cytokinesis,  with  cells  remaining  connected  by  a  long 
intracellular  bridge  of  membrane.  This  phenotype  is  also  seen  with  the  knockdown  of 
annexin A11 [146]. Further investigation has shown centriolin to interact with exocyst and 
SNARE  complex  proteins  and  to  recruit  these  to  the  midbody  [303],  therefore 
strengthening  ideas  of  the  centrosome  influencing  cytokinesis,  perhaps  via  membrane 
trafficking. 
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6.1 Annexin A11 Localises to the Centrosome 
The  distribution  of  annexin  A11  in  PFA  fixed  cells  is  both  nuclear  and  cytoplasmic  in 
several cultured lines, including HeLa and A431 [146,147,150]. Methanol fixation retains 
the nuclear and cytoplasmic distribution of annexin A11 (Figure 43A), however the signal 
is diminished and exposes more distinct puncta within the cytoplasm that would otherwise 
be  obscured.  It  is  in  this  manner  that  the  co-localisation  of  annexin  A11  with  the 
centrosome can be observed. HeLa cells were fixed in methanol and stained for annexin 
A11  using  a  polyclonal  goat  antibody  against  annexin  A11,  and  pericentrin,  a  known 
component  of  the  centrosome  [294,304],  using  a  polyclonal  rabbit  antibody  against 
pericentrin. The cells were then imaged on an inverted confocal microscope. Annexin A11 
and pericentrin co-localised at the centrosome (Figure 43A).  
 
In order to confirm that this co-localisation was not due to cross talk between the two 
fluorescent  channels  used  to  visualise  annexin  A11  and  pericentrin  (FITC  and  Cy5 
respectively), secondary antibody controls were carried out. Cells were stained with both 
primary  antibodies  and  then  incubated  with  either  FITC  conjugated  donkey  anti-goat 
antibody or Cy5 conjugated donkey anti-rabbit antibody. Images were taken in both FITC 
and Cy5 channels. No bleed through between the channels was detected (Figure 43B). 
Primary antibody controls were also carried out to confirm that the staining was not due to 
non-specific binding to the centrosome. Normal immunoglobulin G (IgG) corresponding to 
the  species  in  which  the  primary  antibodies  were  raised  in,  was  used  instead  of  the 
antigen  specific  primary  antibodies.  Cells  were  then  incubated  with  the  appropriate 
secondary antibody. No non-specific staining was seen for the rabbit IgG. Although there 
was  some  faint  background  in  the  goat  IgG  contol,  there  were  no  discrete  puncta  as 
detected when the polyclonal goat anti-annexin A11 antibody was used.  
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Figure 43 Annexin A11 Colocalises with Pericentrin 
 (A) HeLa cells were fixed in methanol and stained for annexin A11 using a polyclonal goat anti annexin A11 
antibody (1/50 dilution), pericentrin using a polyclonal rabbit anti pericentrin antibody (1/1000 dilution) and DNA 
using DAPI (1/500 dilution). (B) HeLa cells were fixed in methanol and subjected to primary and secondary 
antibody controls. Centrosomes (arrowheads) (Scale Bar 10μm)  
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The co-localisation of pericentrin and annexin A11 was quantified in 20 cells using line 
scan analysis (Figure 44A). Line scans were taken across the cells and passed through 
the centrosome, as determined by pericentrin staining. The signals for both annexin A11 
and  pericentrin  were  plotted  against  the  position  along  the  line  scan.  Pericentrin  is 
represented by a singular, sharp peak. Annexin A11 is represented by several small peaks 
corresponding to the diffuse, cytoplasmic distribution. In addition, there is a large, sharp 
peak which overlaps with the peak in pericentrin staining – this overlap corresponds to the 
co-localisation  of  these  two  proteins  (Figure  44A,  Graph  (a)).  An  average  graph  was 
plotted from  20 such  line  scans,  where  the  maximal  pericentrin  signal  was  used  as a 
standard point against which all the line scans were set. The signals for annexin A11 and 
pericentrin  were  therefore  plotted  against  the  position  relative  to  the  peak  pericentrin 
signal. Pericentrin is represented by a singular peak, slightly broader than that seen in 
individual traces due to the variation in the length of the pericentrin signal between cells. 
Annexin A11 is also represented by a singular, broad peak. The smaller peaks seen in 
individual traces representing the diffuse, cytoplasmic staining are no longer visible due to 
averaging. The broad annexin A11 and pericentrin peaks clearly overlap, again illustrating 
the co-localisation of these two proteins (Figure 44A, Graph (b)). Pericentrin however does 
not co-localise with annexin A2 or annexin A7, which has the highest degree of homology 
with annexin A11 (Figure 44B). The co-localisation between annexin A11 and pericentrin 
occurs  throughout  the  cell  cycle  (Figure  45)  at  metaphase,  anaphase,  telophase  and 
cytokinesis.  At metaphase and anaphase  pericentrin and annexin A11 are localised at 
both centrosomes of the dividing cell at opposite poles. At telophase and cytokinesis the 
extreme, polarised localisation of the centrosomes is lost and the two centrosomes are 
each clearly localised within each of the two prospective daughter cells. In both instances 
pericentrin and annexin A11 co-localise. 
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Figure 44 Annexin A11, but not A2 or A7, Colocalises with Pericentrin 
HeLa cells were fixed in methanol and stained for pericentrin using a polyclonal rabbit anti-pericentrin antibody 
(1/1000 dilution), DNA using DAPI (1/500 dilution) and either annexin A11 using a polyclonal goat anti-annexin 
A11 antibody (1/50 dilution) or annexin A7 using a polyclonal goat anti-annexin A11 antibody (1/50 dilution) or 
annexin A2 using a polyclonal rabbit anti-annexin A2 antibody (1/60 dilution). (A) Line scan through the point of 
co-localisation (line in merge) between annexin A11 and pericentrin plotted in graph (a). Average of 20 such 
line scans shown in graph (b). Gray scale normalised to the maximal pericentrin value. Position denoted as 
plus  or  minus  pixels  from  the  pericentrin  peak.  (B)  Absence  of  co-localisation  between  pericentrin  and 
annexins A2 and A7. Centrosomes (arrowheads) (Scale Bar 10μm)  
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Figure 45 Annexin A11 Co-localises with Pericentrin During the Cell Cycle 
HeLa  cells  were  fixed  in methanol  and  stained  for  annexin  A11 using a  polyclonal goat-anti  annexin  A11 
antibody  (1/50  dilution), pericentrin  using a  polyclonal  rabbit  anti-pericentrin  antibody  (1/1000  dilution)  and 
tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution). At anaphase and telophase two 
focal planes (1, 2) are depicted per cell in order to show both centrosomes. At telophase each daughter cell is 
shown in a zoom (A, B). Centrosomes (arrowheads) (Scale Bar 10μm)  
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The  co-localisation  of  annexin  A11  and  the  centrosome  was  confirmed  with  a  second 
centrosomal  marker,  γ  tubulin  (Figure  46A).  Primary  and  secondary  antibody  controls 
again  showed  that  this  co-localisation  was  not  due  to  either  non-specific  centrosomal 
binding or cross talk between the fluorescent channels, respectively (Figure  46B). Line 
scans were taken across cells passing through the centrosome, in this case as defined by 
γ  tubulin  staining  (Figure  47A).  Individual  line  scans  showed  a  singular,  sharp  peak 
representing  γ  tubulin  and  a  series  of  smaller  peaks  as  well  as  a  large,  sharp  peak 
representing annexin A11. The two large, sharp peaks overlapped (Figure  47A, Graph 
(a)). This  was  recapitulated  in  an  average  of 20  such  line  scans,  which  show  a  clear 
overlap between the peak in annexin A11 signal and the peak in γ tubulin signal (Figure 
47A, Graph (b)), indicating the co-localisation of these two proteins. However γ tubulin did 
not co-localise with annexin A2 or annexin A7 (Figure 47B), demonstrating that this is not 
simply a generic property of annexins. The co-localisation between annexin A11 and γ 
tubulin also occurs throughout the cell cycle, from metaphase through to cytokinesis in the 
same manner as pericentrin and annexin A11 (Figure 48A).   
 
The centrosome is known to expand at metaphase due to an increase in the distribution of 
the pericentriolar matrix. The distribution of annexin A11 at the centrosome also appears 
to expand at metaphase. The increase in size of the centrosome between interphase and 
metaphase was quantified using Image J, as determined by the area of γ tubulin staining 
(Figure 48B). The area of γ tubulin at the centrosome increased from 0.63 µm
2 (+/- 0.18 
µm
2) at interphase to 1.29 µm
2 (+/- 0.15 µm
2) at metaphase i.e. the centrosome roughly 
doubles in size (P=0.00052, two tailed student t-test). The area of annexin A11 at the 
centrosome was also measured and increased from 0.45 µm
2 (+/- 0.18 µm
2) at interphase 
to 0.86 µm
2 (+/- 0.15 µm
2) at metaphase – again showing an approximate doubling in size 
(P=0.0015, two tailed students t-test), though remaining smaller than the total area of the 
centrosome itself.   
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Figure 46 Annexin A11 Colocalises with γ Tubulin 
(A) HeLa cells were fixed in methanol and stained for annexin A11 using a polyclonal goat anti-annexin A11 
antibody (1/50 dilution), γ tubulin using a polyclonal rabbit anti-γ tubulin antibody (1/1000 dilution) and DNA 
using DAPI (1/500 dilution). (B) HeLa cells were fixed in methanol and subjected to primary and secondary 
antibody controls. Centrosomes (arrowheads) (Scale Bar 10μm)  
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Figure 47 Annexin A11, but not A2 or A7, Colocalises with γ Tubulin 
HeLa cells were fixed in methanol and stained for γ tubulin using a polyclonal rabbit anti-γ tubulin antibody 
(1/1000 dilution), DNA using DAPI (1/500 dilution) and either annexin A11 using a polyclonal goat anti-annexin 
A11 antibody (1/50 dilution) or annexin A7 using a polyclonal goat anti-annexin A11 antibody (1/50 dilution) or 
annexin A2 using a polyclonal rabbit anti-annexin A2 antibody (1/60 dilution). (A) Line scan through the point of 
co-localisation (line in merge) between annexin A11 and γ tubulin plotted in graph (a). Average of 20 such line 
scans shown in graph (b). Gray scale normalised to the maximal γ tubulin value. Position denoted as plus or 
minus pixels from the γ tubulin peak. (B) Absence of co-localisation between γ tubulin and annexins A2 and 
A7. Centrosomes (arrowheads) (Scale Bar 10μm)  
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Figure 48 Annexin A11 Co-localises with γ Tubulin During the Cell Cycle 
(A) HeLa cells were fixed in methanol and stained for annexin A11 using a polyclonal goat anti-annexin A11 
antibody (1/50 dilution), γ tubulin using a polyclonal rabbit anti-γ tubulin antibody (1/1000 dilution) and tubulin 
using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution). Centrosomes (arrowheads). A single 
focal plane is shown per cell depicting one of the two centrosomes within the dividing cell. (Scale Bar 10μm) 
(B) The area of the centrosome, as detected by γ tubulin staining was measured using Image J (1.40g) in cells 
at interphase (n=21) and metaphase (n=4). The same was done for the annexin A11 puncta that colocalised 
here with γ tubulin. Error bars are standard deviations. * P=0.00052 ** P=0.0015  
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6.2 Annexin A11 Knock Down and the Centrosome 
In order to determine whether the localisation of annexin A11 at the centrosome had an 
effect on the centrosome itself, annexin A11 was depleted using siRNA. Cells were plated 
at 30% confluency and transfected the next day with 20µM annexin A11 siRNA or 20µM 
negative control siRNA. Cells were transfected with siRNA again three days after plating. 
Cells  were  lysed  on  2,  3  and  6  days  after  plating  and  subjected  to  SDS-PAGE  and 
Western blotting. The knock down of annexin A11 was carried  out in A431, HeLa and 
CaCo-2 cells and in all three cases significant knock down of annexin A11 was achieved, 
as detected by Western blotting against annexin A11 and tubulin (Figure 35A). Annexin 
A11  proteins  levels  were  normalised  to  tubulin  in  three  independent  knock  down 
experiments for each cell line. By day 6 annexin A11 levels had decreased by 95% in 
A431 cells, 82% in HeLa cells and 89% in CaCo-2 cells (Figure 35B).  
 
The knockdown of annexin A11 was confirmed by immunofluorescence of annexin A11 in 
A431 cells. Cells were methanol fixed on day 6, following two rounds of transfection with 
siRNA, and stained for annexin A11, alpha tubulin, DNA and γ tubulin. Cells were imaged 
at different stages of the cell cycle on an inverted confocal microscope. At metaphase 
(Figure 49) and anaphase (Figure 50) in both control and annexin A11 depleted cells, γ 
tubulin is located at both the poles of the mitotic spindle marking out each of the two 
centrosomes. At telophase, following mitotic spindle disassembly, the centrosomes are no 
longer  localised  at  the  extreme  opposite  ends  of  the  cell.  The  two  centrosomes,  as 
detected  by  γ  tubulin  staining,  can  clearly  be  seen  to  localise  within  each  of  the  two 
prospective daughter cells in both control and annexin A11 depleted cells  (Figure  51). 
Therefore the centrosome is present in annexin A11 depleted cells and its localisation 
throughout the cell cycle appears unchanged relative to control cells.  
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Figure  49  Annexin  A11  Knock  Down  Does  Not  Affect  the  Distribution  of  γ  Tubulin  at 
Metaphase 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then methanol fixed on day 6 and stained for annexin 
A11 using a polyclonal goat anti-annexin A11 antibody (1/50 dilution), γ tubulin using a polyclonal rabbit anti-γ 
tubulin antibody (1/1000 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution) 
and DNA using DAPI (1/500 dilution). In instances where the two centosomes of a dividing cell could not be 
seen in one focal plane, two focal planes (A, B) are shown at the level of each centrosome. Centrosomes 
(arrowheads) (Scale bars 10μm)  
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Figure  49  Annexin  A11  Knock  Down  Does  Not  Affect  the  Distribution  of  γ  Tubulin  at 
Anaphase 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then methanol fixed on day 6 and stained for annexin 
A11 using a polyclonal goat anti-annexin A11 antibody (1/50 dilution), γ tubulin using a polyclonal rabbit anti-γ 
tubulin antibody (1/1000 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution) 
and DNA using DAPI (1/500 dilution). In instances where the two centosomes of a dividing cell could not be 
seen in one focal plane, two focal planes (A, B) are shown at the level of each centrosome. Centrosomes 
(arrowheads) (Scale bars 10μm)  
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Figure  50  Annexin  A11  Knock  Down  Does  Not  Affect  the  Distribution  of  γ  Tubulin  at 
Telophase 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then methanol fixed on day 6 and stained for annexin 
A11 using a polyclonal goat anti-annexin A11 antibody (1/50 dilution), γ tubulin using a polyclonal rabbit anti-γ 
tubulin antibody (1/1000 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution) 
and DNA using DAPI (1/500 dilution). In instances where the two centosomes of a dividing cell could not be 
seen in one focal plane, two focal planes (A, B) are shown at the level of each centrosome. Centrosomes 
(arrowheads) (Scale bars 10μm)  
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6.3 Annexin A11 Knock Down and Cell Cycle Markers 
The  depletion  of  annexin  A11  had  no  detectable  effect  on  the  localisation  of  the 
centrosome, as detected by γ tubulin staining. In order to determine whether there were 
effects on other proteins involved in the cell cycle, several cell cycle markers were stained 
for in A431 cells depleted of annexin A11 for 6 days. Cells were PFA fixed and stained for 
annexin A11, alpha tubulin, DNA and either Plk1 (polo-like kinase 1), aurora B (aurora B 
kinase) or INCENP (Inner Centromere protein). Cells were then imaged on an inverted 
confocal microscope at different stages of the cell cycle. 
 
In  control  cells  Plk1  localised  to  the  centrosomes  at  the  spindle  poles  at  metaphase 
(Figure  52).  At  anaphase  Plk1  localised  to  the  spindle  midzone  (Figure  53)  and  at 
telophase  to  the  cleavage  furrow,  either  side  of  the  midbody  (Figure  53).    These 
localisations were unchanged in annexin A11 depleted cells. In control cells at metaphase 
aurora  B  was  localised  to  puncta  on  the  condensed  chromosomes  (Figure  54).  At 
anaphase aurora B localised to the spindle midzone (Figure 54) and at telophase to the 
cleavage furrow, either side of the midbody (Figure 55). These localisations were also 
unchanged  in  annexin  A11  depleted  cells.  INCENP  also  localised  to  the  condensed 
chromosomes as metaphase (Figure 56), the spindle midzone at anaphase (Figure 56) 
and  the  cleavage  furrow,  either  side  of  the  midbody,  at  telophase  (Figure  57).  These 
localisations  were  the  same  in  both  control  and  annexin  A11  depleted  cells.  The 
knockdown of annexin A11 therefore does not alter the distribution of a range of cell cycle 
markers.  
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Figure 51 Annexin A11 Knock Down Does Not Affect the Distribution of Polo-like Kinase 1 at 
Metaphase 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then PFA fixed on day 6 and stained for annexin A11 
using  a  polyclonal  goat  anti-annexin  A11  antibody  (1/50  dilution),  Plk1  using  a  polyclonal  rabbit  anti-Plk1 
antibody (1/1000 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution) and 
DNA using DAPI (1/500 dilution). In instances where the localisations of Plk1 cannot be seen in one focal 
plane, two focal planes (A, B) within the same cell are shown. Centrosomes (arrowheads) (Scale bars 10μm)  
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Figure 52 Annexin A11 Knock Down Does Not Affect the Distribution of Polo-like Kinase 1 at 
Anaphase or Telophase 
 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then PFA fixed on day 6 and stained for annexin A11 
using  a  polyclonal  goat  anti-annexin  A11  antibody  (1/50  dilution),  Plk1  using  a  polyclonal  rabbit  anti-Plk1 
antibody (1/1000 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody (1/100 dilution) and 
DNA using DAPI (1/500 dilution). (Scale bars 10μm)  
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Figure 53 Annexin A11 Knock Down Does Not Affect the Distribution of Aurora B Kinase at 
Metaphase or Anaphase 
 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then PFA fixed on day 6 and stained for annexin A11 
using a polyclonal goat anti-annexin A11 antibody (1/50 dilution), Aurora B kinase using a polyclonal rabbit 
anti-Aurora B kinase antibody (1/1000 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody 
(1/100 dilution) and DNA using DAPI (1/500 dilution). (Scale bars 10μm)  
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Figure 54 Annexin A11 Knock Down Does Not Affect the Distribution of Aurora B Kinase at 
Telophase 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then PFA fixed on day 6 and stained for annexin A11 
using a polyclonal goat anti-annexin A11 antibody (1/50 dilution), Aurora B kinase using a polyclonal rabbit 
anti-Aurora B kinase antibody (1/1000 dilution), tubulin using a monoclonal mouse anti-alpha tubulin antibody 
(1/100 dilution) and DNA using DAPI (1/500 dilution). (Scale bars 10μm)   
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Figure  55  Annexin  A11  Knock  Down  Does  Not  Affect  the  Distribution  of  INCENP  at 
Metaphase or Anaphase 
 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then PFA fixed on day 6 and stained for annexin A11 
using  a  polyclonal  goat  anti-annexin  A11  antibody  (1/50  dilution),  INCENP  using  a  polyclonal  rabbit  anti-
INCENP  antibody  (1/1000  dilution),  tubulin  using  a  monoclonal  mouse  anti-alpha  tubulin  antibody  (1/100 
dilution) and DNA using DAPI (1/500 dilution). (Scale bars 10μm)  
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Figure  56  Annexin  A11  Knock  Down  Does  Not  Affect  the  Distribution  of  INCENP  at 
Telophase 
A431 cells were treated with 20µM annexin A11 siRNA or 20µM scrambled control siRNA for 6 days, with two 
treatments administered on day 1 and day 3. Cells were then PFA fixed on day 6 and stained for annexin A11 
using  a  polyclonal  goat  anti-annexin  A11  antibody  (1/50  dilution),  INCENP  using  a  polyclonal  rabbit  anti-
INCENP  antibody  (1/1000  dilution),  tubulin  using  a  monoclonal  mouse  anti-alpha  tubulin  antibody  (1/100 
dilution) and DNA using DAPI (1/500 dilution). (Scale bars 10μm)  
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In accordance with the normal distribution of cell cycle markers in the annexin A11 knock 
down cells, as well as the detection of these cells throughout the different stages of the cell 
cycle, cell proliferation also appeared unchanged from that of control cells. A431 cells 
were treated with either annexin A11 siRNA or control siRNA four times over the course of 
two weeks. At the end of two weeks, strong knock down of annexin A11 was achieved with 
a decrease of 90% on average when compared to control cells, from three independent 
experiments (Figure 58A). The cells were counted on days 1, 3, 7, 9 and 14 and a graph 
plotted of their growth over time. No difference can be seen between the control and knock 
down  cells  (Figure  58B).  In  addition  the  distribution  of  cells  within  mitosis  was  also 
investigated. A431 cells were treated with control or annexin A11 siRNA for six days prior 
to fixation in PFA. The cells were then stained for annexin A11, tubulin and DNA. For each 
dish of treated cells, five fields of view were randomly chosen and the number of cells in 
mitosis  counted,  including  the  phase  of  the  cell  cycle  they  were  in  (Figure  58C).  No 
significant difference in the proportion of cells in each phase of mitosis was seen between 
control  and  knock  down  cells  (Prophase  P=0.68,  metaphase  P=1,  anaphase  P=1, 
telophase P=0.30, cytokinesis P=0.15). 
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Figure 57 Annexin A11 Knock Down Does Not Affect Proliferation or Cell Cycle Distribution 
(A)  Western  blot  of  whole  cell  lysates  from  A431  cells  treated  with  20µM  annexin  A11  siRNA  or  20µM 
scrambled control siRNA for two weeks, in three independent experiments. Four treatments were administered 
on days 2, 4, 8 and 10. Cell lysates were then collected on day 14. Annexin A11 was blotted for using a 
polyclonal goat anti-annexin A11 antibody (1/200 dilution) and tubulin using a monoclonal mouse anti-alpha 
tubulin antibody (1/1000 dilution) (B) A graph of the number of A431 cells counted on days 1, 3, 7, 9, 11 and 
14 in annexin A11 siRNA treated samples and control samples. Cells were treated with 20µM annexin A11 
siRNA or 20µM scrambled control siRNA for two weeks. Four treatments were administered on days 2, 4, 8 
and 10. (C) Bar chart of the cell cycle distribution of A431 cells treated with 20µM annexin A11 siRNA or 20µM 
scrambled control siRNA for six days, with two treatments administered on days 1 and 3. n = 3 experiments, 
with five fields of view for each experiment. Error bars are standard errors of the mean. Prophase P=0.68, 
metaphase P=1, anaphase P=1, telophase P=0.30, cytokinesis P=0.15.   
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6.4 Discussion 
Work in this study has revealed a novel localisation of annexin A11 to the centrosome, 
through the application of immunostaining against annexin A11 alongside pericentrin or γ 
tubulin  –  two  markers  of  the  centrosome.  The  localisation  of  annexin  A11  to  the 
centrosome appears to be specific to this particular annexin, as this was not observed for 
annexin A2 or annexin A7, with annexin A7 sharing the highest degree of homology to 
annexin A11. Annexin A11 is therefore likely to be unique amongst the annexins in its 
ability to target to both the centrosome and the midbody. Annexin A11 has previously been 
shown to have a role at cytokinesis, such that the loss of annexin A11 results in the loss of 
the  midbody  and  the  failure  of  daughter  cells  to  abscise  from  each  other  [150]. 
Interestingly a strong link has emerged for the role of the centrosome in cytokinesis.   
 
Initial  studies  demonstrated  that  the  centrosome  was  not  essential  for  mitotic  spindle 
formation. This was shown through both laser ablation [305] and micro-surgical removal 
[306] of the centrosome. The subsequent recruitment of centrosomal-associated proteins, 
such as γ tubulin and pericentrin, to mitotic spindle poles varied between these studies. 
However the acentrosomal cells consistently entered metaphase and progressed through 
to anaphase, demonstrating the ability of cells to form a mitotic spindle and initiate mitosis 
in a centrosome-independent manner. In a significant proportion of acentrosomal cells, 
although the cells were able to initiate cytokinesis, the cleavage furrows regressed [306]. 
This is suggested to be due to the inability of these cells to re-position the mitotic spindle 
along the appropriate axis for division [305], as this process requires astral microtubules 
which ordinarily extend towards the cell cortex from the centrosome [307]. This highlights 
the essential role of the centrosome in the later stages of mitosis. 
 
Further studies uncovered the localisation of known centrosome proteins, such as γ tubulin 
and centriolin, targeting to the midbody [302]. Interestingly the knock down of centriolin 
resulted  in  a  cytokinesis  defect  [302]  similar  to  that  described  for  the  knock  down  of 
annexin A11 [150], whereby the daughter cells remain connected by a long, intercellular 
bridge of membrane and the midbody is lost. It is therefore not wholly surprising that a 
protein such as annexin A11, which localises to the midbody and is implicated in the final 
stages of cytokinesis, should also localise to the centrosome.  
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The  localisation  of  annexin  A11  to  the  centrosome  was  shown  in  this  study  to  be 
consistent  throughout  the  life  cycle  of  a  cell  i.e.  from  interphase  through  to  mitosis. 
Although annexin A11 appears to be intimately involved in the cell cycle, the knock down 
of annexin A11 did not perturb the centrosome or present any other obvious cell cycle 
phenotype.  Previous  studies  however  have  shown  the  knock  down  of  annexin  A11  to 
cause either a complete failure in the completion of cytokinesis leading to apoptosis [150] 
or a general decrease in cell proliferation though the population is still maintained [196]. It 
is therefore likely that although the knock down achieved in this study is considerable, a 
small but significant amount of annexin A11 is still translated. This appears to be enough 
for the cells to remain viable and continue through the cell cycle without any detectable 
defects. Therefore one cannot rule out an essential role for annexin A11 at the centrosome 
during either interphase or mitosis.  
 
Interestingly during mitosis, the distribution of annexin A11 at metaphase centrosomes in 
particular appears to change, such that it expands in area. The centrosome is known to 
expand  in  area  at  metaphase  during  a  process  called  centrosome  maturation.  This 
process of maturation is said to represent an increase in the ability of the centrosome to 
nucleate microtubules, but is increasingly thought to also involve the gain of other non-
nucleating abilities [308]. Maturation during mitosis involves the loss of certain proteins 
such as C-Nap1 and Nlp, and the gain of others such as Plk1 and NuMA [292]. Annexin 
A11 however is present on both interphase and mitotic centrosomes, but appears to be 
additionally recruited during maturation. This mimics more the behaviour of γ tubulin [309] 
which is present on interphase centrosomes but has also been shown to accumulate at the 
centrosome during mitosis. This accumulation was shown to be microtubule independent. 
The function of γ tubulin here revolves around its ability to nucleate microtubules [294], 
enhancing  the  most  noted  function  of  the  centrosome.  Other  proteins,  including  the 
centrosomal  marker  pericentrin,  are  known  to  be  trafficked  to  the  centrosome  in  a 
microtubule-dependent manner involving the movement of granules along microtubules via 
dynactin, an accessory protein of the motor protein dynein [310]. This is perhaps a more 
likely pathway for the transport of annexin A11 to the centrosome, given its previously 
noted localisation along microtubules. 
 
The role of pericentrin at the centrosome is to anchor the γ TuRC (γ  tubulin ring complex), 
which is responsible for microtubule nucleation at this site [294]. More recent studies of the  
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centrosome have extended its founding function as a nucleating site, to that of a docking 
station for a range of protein complexes involved in different cell signalling pathways [292]. 
This  emphasises  the  new  functions  being  uncovered  for  the  centrosome,  such  as  its 
involvement  in  nuclear  envelope  breakdown  through  the  release  of  a  diffusible  factor, 
speculated to be Aurora A kinase, which like Plk1 and NuMA also accumulates at the 
centrosome during mitosis [311]. Therefore annexin A11 may also be involved in a more 
unconventional centrosomal function. 
 
Defects in the centrosome cycle, such as centriole separation, duplication and migration 
can  result  in  unequal  segregation  of  chromosomes  and  therefore  poly-  or  aneuploidy. 
Such  an  unstable  situation  is  often  present  in  malignant  tumours  and  it  is  suggested 
therefore that centrosomal defects may be important in oncogenesis [312]. Annexin A11 
has  recently  been  identified  as  being  down-regulated  in  a  range  of  cancers,  including 
kidney, colon, lung and ovarian cancer [194]. Further investigation into the role of annexin 
A11  in  ovarian  cancer  demonstrated  that  knock  down  of  annexin  A11  decreased  cell 
proliferation, colony formation and increased resistance to the anti-cancer drug cisplatin 
[196]. The increase in non-proliferating, quiescent cells was suggested to be a mechanism 
by  which  cells  may  become  more  resistant  to  drug  treatment  and  apoptosis.  The 
mechanism by which annexin A11 mediates this change in cell cycling is as yet unclear. 
Although  it  is  unlikely  that  annexin  A11  is  capable  of  nucleating  microtubules  at  the 
centrosome, its localisation to this organelle may still be of some significance, particularly 
during cell cycle regulation (Figure 59). 
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Figure 59 Model of Annexin A11 Redistribution During the Cell Cycle 
Annexin A11 may accumulate at the centrosome in order to more easily facilitate its dynamic redistribution 
during  the  cell  cycle,  exemplified  here  at  metaphase.  Annexin  A11  vesicles  could  be  transported  along 
microtubules emanating from the centrosome, which form the mitotic spindle. This would allow annexin A11 to 
target to the spindle midzone at anaphase and the midbody at telophase and cytokinesis, where it can then 
carry out its function.  
 
It  is  plausible  that  annexin  A11  may  utilise  the  centrosome  as  a  docking  station  for 
accumulation,  before  redistribution  along  the  mitotic  spindle  where  it  carries  out  its 
designated function – perhaps in regulating the cell cycle (Figure 59). Further investigation 
of annexin A11 trafficking during the cell cycle, both to and from the centrosome, would 
therefore be of great interest. 
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7. Conclusions and Summary 
 
Annexin A11 is the common ancestor  of nine of the eleven vertebrate annexins [144]. 
Although it is one of the oldest vertebrate annexins in terms of evolution, far less is known 
about its physiological functions compared to the other annexins.  However it has been 
strongly implicated in the cell cycle [150]. Work carried out in this study confirms the highly 
dynamic  localisation  of  annexin  A11  during  the  cell  cycle  and  further  elucidates  this 
through different fixation methods. The use of methanol fixation has uncovered several 
novel localisations of  this protein, all of which point  towards annexin A11 being tightly 
coupled to the cell cycle in a microtubule dependent manner.  
 
In this study puncta of annexin A11 were observed along microtubules in interphase cells, 
and  upon  depolymerisation  of  the  microtubule  network  annexin  A11  appeared  to 
accumulate  perinuclearly  on  more  stable  microtubule  structures.  The  perinuclear 
localisation of annexin A11 has been further characterised in both interphase and mitotic 
cells  and  been  shown  to  specifically  localise  to  the  centrosome.  Taken  together,  it  is 
plausible that annexin A11 is trafficked to and from the centrosome via microtubules, a 
process  which  when  interrupted  through  microtubule  depolymerisation  results  in  the 
accumulation  of  annexin  A11  in  this  region.  During  the  cell  cycle,  at  the  onset  of 
metaphase,  annexin  A11  further  accumulates  at  the  centrosome  during  centrosome 
maturation. Annexin A11 is also seen along the length of metaphase and anaphase mitotic 
spindles.  It  is  therefore  possible  that  the  accumulation  of  annexin  A11  at  mitotic 
centrosomes  primes  the  cell  for  the  redistribution  of  annexin  A11  along  the  mitotic 
apparatus.  Live  imaging  of  GFP-tagged  annexin  A11  would  help  uncover  the  dynamic 
trafficking of this protein during the cell cycle. However careful attention would need to be 
paid to the GFP controls, as GFP alone targets to both the centrosome and midbody, 
though the same trafficking pathway may not be utilised. 
 
The  trafficking  of  annexin  A11  positive  vesicles  from  the  centrosome  (as  modelled  in 
Figure  59)  would  require  the  involvement  of  a  protein  complex  which  directly  binds 
microtubules. A potential protein complex was previously suggested (see Figure 40) in the 
context of ER to Golgi trafficking of COPII positive vesicles. This involved dynein, a minus 
end directed motor protein. However trafficking away from the centrosome, towards the  
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spindle midzone or midbody, would require the use of a plus end directed motor protein. 
Annexin A11 has been shown to interact with the plus end directed motor protein CHO1 at 
cytokinesis [146]. CHO1 belongs to the kinesin-6 family of kinesins - a superfamily of plus 
end directed motor proteins, that provide potential candidates for the transport of annexin 
A11 away from the centrosome. The kinesin-6 family currently comprises two members; 
KIF20 and KIF23, also known as Rab6-KIFL (Rab6 binding kinesin) and MKLP1/CHO1, 
respectively. MKLP1/CHO1 has been shown in this study to co-localise with annexin A11 
during the cell cycle. Rab6-KIFL has also been shown to localise to similar domains during 
the cell cycle, specifically the spindle midzone at anaphase and the midbody at telophase 
and cytokinesis [313]. The knock down of CHO1 [238], MKLP1 [176] or Rab6-KIFL [313], 
all cause defects in cytokinesis resulting in the formation of binucleate cells. These motor 
proteins therefore all appear to have crucial roles in regulating the cell cycle, perhaps in 
part due to their role in delivering cargo to target destinations such as the midbody. For 
example MKLP1 is known to be required for the targeting of centriolin to the midbody 
[303].  Therefore  it  would  be  of  interest  to  investigate  the  targeting  of  annexin  A11 
throughout the cell cycle in cells depleted of MKLP1/CHO1 and Rab6-KIFL. 
 
The potential delivery of annexin A11 positive vesicles to the midbody, via the microtubule 
network, is supported by the observation that under methanol fixation conditions annexin 
A11 strongly co-localises with the densely packed microtubules of the cleavage furrow. 
Membrane delivery to the cleavage furrow is now well-established to be required for the 
completion of abscission (reviewed in [314]). A substantial body of evidence exists for the 
involvement  of  exocyst  components  in  cytokinesis,  specifically  the  ESCRT  machinery 
(Endosomal Sorting Complex Required for Transport). Cep55, a centrosomal and midbody 
protein,  has  been  shown  to  recruit  the  ESCRTI  component,  Tsg101  and  the  ESCRT 
associated protein, Alix (ALG2 Interacting Protein X) to the midbody [157-159]. The knock 
down of either Alix or Tsg101 resulted in cytokinesis defects and multinucleated cells. It 
has  been  suggested  that  midbody  targeted  ESCRTI  machinery  goes  on  to  recruit 
ESCRTIII, which is thought to be able to mediate abscission and sever the link between 
the two daughter cells [158].  
 
Targeted membrane delivery to the cleavage furrow is also believed to involve the SNARE 
complexes  (SNAP  (Soluble  NSF  Attachment  Protein)  Receptors). The midbody  protein 
centriolin has been shown to interact with exocyst proteins Sec5, Sec8 and Sec15 and to  
-168- 
directly bind the SNARE associated protein snapin [303]. The knock down of centriolin, 
which  results  in  cytokinesis  defects  and  subsequent  multicellular  syncitia  [302],  also 
caused the loss of exocyst and SNARE proteins from the midbody [303]. Furthermore the 
knock down of the SNARE component snapin also resulted in cytokinesis defects and 
multicellular syncitia. Interestingly the knock down of the exocyst component Sec5 resulted 
in the accumulation of v-SNARE positive secretory vesicles at the midbody, suggesting 
that vesicle fusion was delayed or inhibited.  
 
Studies carried out into both the SNARE and ESCRT complexes clearly demonstrate the 
involvement of post-Golgi secretory vesicle trafficking in cytokinesis. In accordance with 
this the inhibition of post-Golgi trafficking, through the use of Brefeldin A (BFA), has been 
demonstrated to delay the completion of cytokinesis [150,303]. Under these circumstances 
however, annexin A11 was still shown to target to the midbody [150]. It is important to note 
that  while  cytokinesis  is  delayed  upon  BFA  treatment,  it  is  not  completely  blocked, 
suggesting  the  presence  of  alternative  membrane  delivery  pathways  which  allow 
cytokinesis  to  complete  even  when  one  pathway  is  disrupted.  Given  the  persistent 
targeting of annexin A11 to the midbody upon BFA treatment, it is likely that annexin A11 
is  involved  in  these  alternative  pathways,  which  include  the  trafficking  of  recycling 
endosomes.   
 
Rab11  GTPase-positive  recycling  endosomes  have  been  shown  to  accumulate  in  the 
cleavage furrow. Over-expression of a Rab11 dominant negative mutant or knock down of 
Rab11 resulted in increased numbers of binucleate cells. The Rab11 interacting proteins, 
FIP3 and FIP4 (Family of Rab11 Interacting Proteins 3 and 4), both target to the cleavage 
furrow and midbody. The interaction between FIP3 and Rab11 was shown to be necessary 
for the completion of cytokinesis, as the over-expression of a Rab11 binding deficient FIP3 
resulted  in  binucleate  cells.  This  study  [315]  illustrates  the  possible  contribution  of 
recycling endosomes to the cleavage furrow. An interesting point to note is the cell cycle 
dependent localisations of FIP3. During interphase, metaphase and early anaphase FIP3 
localises  to  endosomes.  However  as  anaphase  proceeds  FIP3  translocates  to  the 
centrosome, then during cytokinesis it is trafficked to the cleavage furrow and midbody 
[315].  It is proposed that the Rab11-FIP3 complex may regulate this dynamic distribution, 
through the trafficking of endosomes from the centrosome to the cleavage furrow. It is 
further speculated that this pathway may utilise the midzone microtubules. A similar route  
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may be taken by annexin A11 which also localises to the centrosome and cleavage furrow 
and in addition is present along the length of the midzone microtubules. The link between 
recycling  endosomes,  the  centrosome  and  the  microtubule  network  was  further 
strengthened through experiments on the Rab11 effector Nuf (Nuclear-fallout protein) in 
Drosophila [316]. Nuf and Rab11 both localise to the centrosome, but Nuf only does so 
during  cleavage  furrow  formation.  Depolymerisation  of  the  microtubule  network,  using 
colchicine, prevents Nuf accumulation at the centrosome in the following round of the cell 
cycle.  Similarly  Rab11  was  diminished  at  the  centrosome  following  treatment  with 
colchicine. Nuf was shown to interact with the motor protein dynein and its localisation to 
the  centrosome  to  be  dependent  on  this  interaction.  This  supports  the  role  of  the 
microtubule  network  in  the  delivery  of  recycling  endosome-derived  vesicles  to  the 
centrosome. 
 
Several of the annexins have previously been associated with endosomal trafficking. Most 
notably annexin  A1,  which regulates  EGF-stimulated multivesicular  body (MVB) inward 
vesiculation [24] and annexin A2, which regulates early to late endosome trafficking [89]. 
More recently annexin A8 has been shown to regulate the late endocytic pathway. The 
knock down of annexin A8 resulted in a delay in the transport of late endosome cargo, 
thought to be due to the dispersal of these endosomes and their diminished association to 
the actin network [317]. It is clear from these studies that the loss of annexins can impair 
endosomal  trafficking.  It  would  be  interesting  to  investigate  the  kinetics  of  endosomal 
trafficking upon knock down of annexin A11 and to investigate the kinetics of the cell cycle 
in cells where annexins known to regulate endosomal trafficking have been knocked down.  
 
Beyond the role of annexin A11 in the cell cycle, this study has also focused on the affect 
of a recently identified single nucleotide polymorphism (SNP) [193] within annexin A11 in 
the context of sarcoidosis. This SNP, namely the R230C mutation, was identified as the 
most  highly  associated  SNP  with  a  subpopulation  of  German  sarcoidosis  patients. 
Although  no  difference was  detected  between  annexin  A11
WT  and annexin  A11
R230C  in 
response to calcium, much is still left to be investigated. Most importantly it would be of 
interest to investigate annexin A11
R230C in more disease relevant cells such as T cells. This 
is  of  particular  note  given  the  high  expression  of  annexin  A11  in  T  cells  [148]  which 
contribute greatly to the hyper-inflammatory environment present in sarcoidosis.  
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Annexin A11 is notably down-regulated in CD8 and CD19 positive lymphocytes [193], with 
the greatest decrease in mRNA expression in CD8 positive T cells. It is not yet known if 
this drop is also seen at the protein level and whether it also occurs in sarcoidosis patients 
expressing  annexin  A11
R230C.  It  has  however  been  shown  that  CD8  positive  T  cells, 
harvested from a population of American sarcoidosis patients, behave normally. This is in 
regards to their ability to suppress the proliferation of activated CD4 positive T cells, which 
are expanded in sarcoidosis patients, and to proliferate normally [318]. It is not known 
whether annexin A11 in this subpopulation of patients also contains the R230C mutation. 
Given the association between annexin A11 and the cell cycle, it would be important to 
determine  whether  the  CD8  positive  T  cells  in  the  German  population  expressing  the 
R230C mutation also proliferate normally, as in the American population.  In addition it 
would be interesting to examine the protein expression of annexin A11 in CD4 positive T 
cells  from  control  and  sarcoidosis  patients,  in  order  to  determine  whether  there  is  a 
correlation between annexin A11 expression and cell proliferation, particularly as activated 
CD4 positive T cells are significantly increased in number in sarcoidosis patients [231].  
 
A role for annexin A11 in sarcoidosis, separate to its function during mitosis, may focus on 
its  effect  extracellularly  especially  given  that  autoantibodies  against  annexin  A11  have 
been detected in a range of autoimmune diseases, including rheumatoid arthritis, systemic 
lupus erythrematosus and Raynauds disease [319]. A number of the annexins are known 
to be secreted [228,229], including annexin A11 [227] which was shown to be secreted by 
activated neutrophils. Annexin A1, which is also secreted [228,229], has been shown to 
exert extracellular affects through binding members of the formyl peptide receptor family 
on neutrophils [320]. This results in the inhibition of neutrophil transendothelial migration 
and  desensitisation  to  chemoattractant.  It  would  therefore  be  interesting  to  investigate 
whether extracellular annexin A11 exerts similar effects on leukocytes.  
 
7.1 Future Perspectives 
In summary, this study supports a role for annexin A11 in the cell cycle, potentially through 
an association with the microtubule network. In order to further elucidate the role of 
annexin A11 during mitosis, live imaging of GFP tagged annexin A11 in conjunction with 
RFP tagged tubulin would be useful in determining how annexin A11 is trafficked to the 
discrete localisations observed in this study. Furthermore the use of GFP tagged tyrosine 
phosphorylation mutants of annexin A11 would be of interest, given the cytokinesis- 
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specific tyrosine phosphorylation of annexin A11 [146]. In more general terms, the 
trafficking of annexin A11 in interphase cells could also be investigated, initially through 
the knock down of ALG-2 and COPII components speculated to be part of the protein 
complex required for its transport.  
 
Future studies of the role of annexin A11 in interphase cells would also involve further 
work on the sarcoidosis-associated variant of annexin A11, annexin A11
R230C. Although the 
calcium-dependent translocations of this variant were shown in this study to not differ 
spatially or temporally from wild type annexin A11, the extracellular role of this protein has 
yet to be investigated. Initial studies would require the determination of secretion of 
endogenous annexin A11 from disease-relevant cell types, such as macrophages and 
monocytes [206], as well as subsets of B and T cells [193]. It would be particularly 
interesting to determine whether the role of annexin A11 in sarcoidosis relates to its 
function in the cell cycle, and as such an initial characterisation of the cell cycle distribution 
of annexin A11 in these cells would be important, particularly in cells harbouring the 
R230C mutation.   
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